{"id": 920, "name": "Molecular Neurodegeneration Journal", "domain": "molecularneurodegeneration.biomedcentral.com", "bias": "pro-science", "credibility": "high-credibility", "reporting": "high", "questionable": null, "url": "https://molecularneurodegeneration.biomedcentral.com/articles/10.1186/s13024-023-00600-z", "title": null, "content": "Advertisement Explore journals Get published About BMC My account Home About Articles Submission Guidelines Submit manuscript Review Open access Published:10 February 2023 **Translational molecular imaging and drug development in Parkinson\u2019s disease** Achi Haider1,2, Nehal H. Elghazawy3,4, Alyaa DawoudORCID:orcid.org/0000-0002-8140-10703,4, Catherine Gebhard5,6, Thomas Wichmann7, Wolfgang Sippl8, Marius Hoener9, Ernest Arenas10& \u2026 Steven H. LiangORCID:orcid.org/0000-0003-1413-63151,2 Molecular Neurodegenerationvolume18, Article number:11(2023)Cite this article 15kAccesses 15kAccesses 15kAccesses 27Citations 27Citations 27Citations 15Altmetric 15Altmetric 15Altmetric Metricsdetails Metricsdetails Metricsdetails **Abstract** Parkinson\u2019s disease (PD) is a progressive neurodegenerative disorder that primarily affects elderly people and constitutes a major source of disability worldwide. Notably, the neuropathological hallmarks of PD include nigrostriatal loss and the formation of intracellular inclusion bodies containing misfolded \u03b1-synuclein protein aggregates. Cardinal motor symptoms, which include tremor, rigidity and bradykinesia, can effectively be managed with dopaminergic therapy for years following symptom onset. Nonetheless, patients ultimately develop symptoms that no longer fully respond to dopaminergic treatment. Attempts to discover disease-modifying agents have increasingly been supported by translational molecular imaging concepts, targeting the most prominent pathological hallmark of PD, \u03b1-synuclein accumulation, as well as other molecular pathways that contribute to the pathophysiology of PD. Indeed, molecular imaging modalities such as positron emission tomography (PET) and single-photon emission computed tomography (SPECT) can be leveraged to study parkinsonism not only in animal models but also in living patients. For instance, mitochondrial dysfunction can be assessed with probes that target the mitochondrial complex I (MC-I), while nigrostriatal degeneration is typically evaluated with probes designed to non-invasively quantify dopaminergic nerve loss. In addition to dopaminergic imaging, serotonin transporter andN-methyl-D-aspartate (NMDA) receptor probes are increasingly used as research tools to better understand the complexity of neurotransmitter dysregulation in PD. Non-invasive quantification of neuroinflammatory processes is mainly conducted by targeting the translocator protein 18 kDa (TSPO) on activated microglia using established imaging agents. Despite the overwhelming involvement of the brain and brainstem, the pathophysiology of PD is not restricted to the central nervous system (CNS). In fact, PD also affects various peripheral organs such as the heart and gastrointestinal tract \u2013 primarily via autonomic dysfunction. As such, research into peripheral biomarkers has taken advantage of cardiac autonomic denervation in PD, allowing the differential diagnosis between PD and multiple system atrophy with probes that visualize sympathetic nerve terminals in the myocardium. Further, \u03b1-synuclein has recently gained attention as a potential peripheral biomarker in PD. This review discusses breakthrough discoveries that have led to the contemporary molecular concepts of PD pathophysiology and how they can be harnessed to develop effective imaging probes and therapeutic agents. Further, we will shed light on potential future trends, thereby focusing on potential novel diagnostic tracers and disease-modifying therapeutic interventions. **Background** Parkinson\u2019s disease (PD) is a progressive neurodegenerative disorder that mainly affects elderly people [1]. The clinical diagnosis of PD is based on the presence of a constellation of movement abnormalities, including the presence of slowness of movement (bradykinesia), poverty of movement (akinesia), tremor at rest, and muscle stiffness (rigidity). Although the history of parkinsonism dates back to the ancient Indian medical literature [2], the first coherent description of PD-related clinical symptoms was reported in 1817 by James Parkinson in his seminal work \u2018An essay on the shaking palsy\u2019 [3,4]. Notably, the incidence and prevalence of PD have risen rapidly in the past two decades, contributing to a mounting socioeconomic burden [5]. Along this line, epidemiological studies unveiled that the age-standardized global prevalence of PD has more than doubled from 1990\u20132016, thereby exhibiting the highest growth rate among all major neurological disorders [6]. While underlying causes for this disproportionate growth are not fully understood, the alerting development calls for improved diagnostic and therapeutic measures. PD has traditionally been classified into two distinct forms, namely, the hereditary form with genetic mutations known to contribute to the pathophysiology of PD and the idiopathic form, which is essentially of unknown origin [7]. In 2004, Braak et. al. introduced a PD staging metric comprising six neuropathological phenotypes that included both, presymptomatic and symptomatic disease stages [8]. Of note, while initial pathological stages included the formation of intracellular inclusion bodies (mainly aggregates of misfolded \u03b1-synuclein) in neurons of asymptomatic individuals, more advanced disease stages were characterized by degeneration of dopaminergic neurons in the substantia nigra pars compacta. Many of the prototypical parkinsonian motor signs (see above) are due to the loss of dopamine in the striatum, the primary recipient of nigral efferents. The brain has a remarkable ability to compensate for the loss of nigrostriatal fibers: It is estimated that up to 50\u201380% of dopaminergic cells in the nigrostriatal system can be lost before motor symptoms manifest [9,10,11]. In later stages, neurodegeneration is observed in the neocortex and other brain regions, leading to additional (non-dopaminergic) symptoms [8,12]. Although the clinical presentation of PD is dominated by motor symptoms (Fig.1A), it has become apparent that the majority of patients also display a multitude of non-motor features [13]. Indeed, individuals with prodromal disease may first experience one or several of the following symptoms, including autonomic dysfunction, cognitive impairments, depression, sleep disorders, hyposmia and pain [10,14,15,16]. Accordingly, PD constitutes a clinical syndrome that affects multiple organs. Clinical presentation, pathophysiology and diagnostic imaging in Parkinson\u2019s disease (PD).ACardinal motor symptoms and non-motor features of PD.BPathological hallmarks of PD include aggregates of misfolded \u03b1-synuclein (Lewy bodies), mitochondrial dysfunction & oxidative stress, infiltration of immune cells and persistent activation of microglia, as well as an increased release of cytokines. The pathophysiology of PD prompts neurodegeneration and dopamine deficiency, which is particularly pronounced in the mammalian striatum.CTranslational molecular imaging with positron emission tomography (PET) and single-photon emission computed tomography (SPECT), visualizing striatal degeneration in PD non-invasively. DAT, dopamine transporter.; DDC, DOPA decarboxylase; VMAT2, vesicular monoamine transporter 2. Figure 1C reprinted by permission from the Royal College of Physicians (RCP): Pagano et al., [17] copyright (2016) Molecular imaging has contributed to a better understanding of a variety of molecular and cellular concepts that have been linked to PD onset and progression, including mitochondrial dysfunction [18,19], oxidative stress [20,21], neuroinflammation [22,23], excitotoxicity [24], genetic mutations [25,26], failure of protein clearance pathways and abnormal protein aggregation (Fig.1B) [27]. Amyloid-based imaging has been suggested to aid the clinical evaluation of PD-associated forms of dementia, in particular, to assess whether cognitive decline is occurring in the setting of abnormal A\u03b2 accumulation [28]. With the development of improved sensitivity of detection modalities, PET now allows the assessment of reactive oxygen species (ROS) in vivo [29], however, this application is still in its infancy and future studies will reveal whether ROS-targeted PET is useful in PD patients. Advanced molecular imaging applications have led to considerable progress in our understanding of non-dopaminergic receptor systems, including glutamatergic, cholinergic, serotonergic and adrenergic signaling in PD [10,30,31]. PD can be successfully managed for many years following disease onset. Nonetheless, while the oral administration of L-dopa is still considered the cornerstone of PD therapy, chronic L-dopa treatment is associated with several limitations, including drug-induced dyskinesia, motor fluctuations, and hallucinations [32,33]. Further, PD remains a progressive disease with no curative treatment to date, which ultimately leads to severe disability. Accordingly, the development of improved PD therapy constitutes an unmet medical need and various therapy concepts have been suggested in addition to dopamine substitution. Contemporary efforts aim at introducing novel disease-modifying drugs that harbor potential to delay disease progression. Innovative concepts involving translational molecular imaging have proven particularly useful for the early detection of PD and can facilitate the identification of pre-symptomatic individuals at risk. Similarly, strenuous efforts have been devoted to the development of molecular probes that would facilitate drug discovery and development by enabling the non-invasive assessment of molecular processes, which may include alterations in receptor expression for target validation and therapy monitoring, drug biodistribution and pharmacokinetics, target engagement experiments, and micro-dosing studies [34,35,36]. Molecular imaging tools have proven valuable, from bench-to-bedside, and may effectively reduce late-stage failures in drug development. Imaging modalities such as positron emission tomography (PET) and single photon-emission tomography (SPECT) can provide real-time information on drug distribution in patients as well as the assessment of target protein abundancy in different organs without physiological disturbance of the tissue microenvironment [37]. Indeed, PET and SPECT have been applied to study PD and were established as reliable clinical tools that provide information on PD onset and progression (Fig.1C) [38,39]. In most cases, targeted PET probes can be used for multiple purposes, including pharmacological assessment by means of target engagement studies, as well as for diagnostic purposes when alterations in target abundancy are anticipated. Another key advantage of molecular imaging-guided drug development is the ability to provide effective patient stratification during clinical PD trials [40,41,42,43]. In this review, we discuss key concepts that led to the discovery of translational molecular imaging probes and therapeutic agents for PD. Further, this review sheds light on current developments, thereby discussing potential novel diagnostic tracers and experimental disease-modifying drug candidates. **Targeting \u03b1-synuclein** As PD progresses, protein pathology spreads from the brainstem to the substantia nigra pars compacta (SNpc) and then to the forebrain [13]. Although a variety of molecular mechanisms are believed to contribute to PD onset and its irreversible progression, the most extensively studied pathological hallmark of PD is the accumulation of intracellular inclusion bodies (Lewy bodies), that consist of misfolded \u03b1-synuclein (\u03b1S). Of note, \u03b1S is a 140 amino acid long native presynaptic neuronal protein that is encoded by theSNCAgene [44] and is abundantly expressed in the healthy CNS, where it regulates vesicle fusion and neurotransmitter release via molecular interactions with presynaptic solubleN-ethylmaleimide-sensitive attachment protein receptors (SNAREs) [45]. Misfolding of \u03b1S leads to the formation of aggregates of the protein, and such aggregates are implicated in a group of overlapping neurodegenerative disorders, designated \u03b1-synucleinopathies, which include PD, dementia with Lewy bodies (DLB) and multiple system atrophy (MSA) [46,47,48,49]. Genetic mutations, post-translational modifications (PTMs), and increased \u03b1S protein concentrations have been linked to the formation of insoluble \u03b1S aggregates [50]. One of the earliest PD-related mutations discovered were within theSNCAgene, which was found to initiate early-onset PD with an autosomal dominant inheritance pattern [51]. Some advances have been made since then by the identification of a series of mutations in the \u03b1S gene that were linked to hereditary PD.A30P, E46K, H50Q, G51D, A53E, A53VandA53Tare mutations in the \u03b1S gene that were linked to hereditary PD [52,53,54,55,56,57,58,59,60]. Similarly, several PTMs, such as phosphorylation, ubiquitination and nitration, have emerged as valuable markers of \u03b1S pathology [61,62,63]. Even though today's medications against PD provide symptomatic relief at early disease stages, there is a need to develop drugs that instead target the underlying disease process and thereby can delay or halt disease progression. There is much interest in non-invasive molecular imaging of \u03b1S, with the hope that \u03b1S detection could serve as a biomarker for presymptomatic detection of PD, or for monitoring of disease progression. Although the development of \u03b1S-targeted probes is still in its infancy, there have been attempts to develop high-affinity ligands with appropriate tracer pharmacokinetics. An overview of selected \u03b1S-targeted translational molecular imaging probes is provided in Fig.2. Initially, probes that were known for their use in Alzheimer\u2019s disease were tested in PD patients. Indeed, amyloid-beta (A\u03b2)-targeted probes, such as the thioflavin-T derivative,11C-Pittsburgh compound-B (11C-PIB), and benzoxazole BF227 (18F-BF227), have been suggested to also be useful for the early diagnosis of PD since they not only bind to A\u03b2, but also to the beta-sheet structures of \u03b1S-aggregates [64]. However, recent studies with brain homogenates revealed that11C-PIB binding was not associated with the presence of Lewy bodies [65,66]. Similarly, the radiofluorinated amyloid PET ligand,18F-BF227, did not show meaningful binding to brain homogenates enriched with Lewy bodies [67,68]. These findings encouraged the development of novel \u03b1S-selective PET tracers beyond repurposed A\u03b2-targeted probes. Along this line, Yu et al. synthesized a series of phenothiazine derivatives and reported the discovery of SIL5, SIL23, and SIL26 as high-affinity ligands for \u03b1S fibrils [69]. The same group subsequently reported the synthesis of the125I-labeled analogue of SIL23,125I-SIL23, which exhibited specific binding to \u03b1S fibrils in postmortem PD brain tissue as well as on brain slices of \u03b1S transgenic mice [70]. Despite these encouragingin vitrofindings, the further development of125I-SIL23 was plagued by a high degree of non-specific bindingin vivo[70]. Structural derivatization of125I-SIL23 yielded11C-SIL5 and18F-SIL26 with improved selectivity, however, their pharmacokinetic properties suggested the need for further optimization to achieve successful \u03b1S imagingin vivo[71]. The development of novel PET imaging agents for PD has been increasingly focusing on the discovery of high-affinity \u03b1S-targeted probes with suitablein vivokinetics and biodistribution, which led to the design of novel scaffolds via high throughput screening [72,73]. Among these scaffolds,N, N-dibenzyl-cinnamamide [74] and bisquinoline derivatives such as18F-BQ2 [75] and11C-MODAG-001 [76] proved to be promising lead candidates with moderate-to-high brain uptake, laying the foundation for the development of suitable clinical candidates. Matsuoka et al., recently reported on the clinical translation of an \u03b1S-targeted PET ligand codenamed18F-SPAL-T-06, which was co-localized with regions known to accumulate glial cytoplasmic inclusion bodies in multiple system atrophy (MSA) patients [77]. Similarly, the biotech company AC Immune has recently announced that their lead \u03b1S-targeted PET ligand,18F-ACI-12589, revealed excellentin vivoperformance characteristics, supporting its translation into humans [78]. Future studies will examine the suitability of18F-ACI-12589 to image \u03b1S aggregates in patients with PD or MSA. Targeting \u03b1S with radiolabeled antibodies constitutes a challenge due to the low penetration of antibodies across the blood\u2013brain barrier. To overcome this limitation, more recent examples of \u03b1S-targeted PET imaging involve the use of bispecific antibodies that carry a transferrin binding domain, to support blood\u2013brain barrier penetration via receptor-mediated transcytosis, as well as a high-affinity \u03b1S binding domain [79]. Probing \u03b1S is further complicated by posttranslational modifications, which may affect protein folding and capacity to induce neuronal damage. Indeed, it was found that the serine residue at position 129 (Ser 129) of \u03b1S is selectively and extensively phosphorylated in synucleinopathy lesions. Phosphorylation of \u03b1S at Ser 129 promoted fibril formation in vitro, pointing towards a key role of this particular modification in the pathogenesis of \u03b1- synuclopathies [80], and prompting calls to carefully consider the impact of posttranslational modifications on the pharmacodynamic properties of PET and SPECT imaging probes. It should be noted that dementia is increasingly recognized as a common consequence of PD and around 50% of PD dementia cases develop significant amounts of A\u03b2 plaques or p-tau containing neurofibrillary tangles [81]. As such, the specificity and selectivity of \u03b1S-targeted probes over these other proteinopathies is of paramount importance to decrease the likelihood for false positive scans, which constitutes an ongoing challenge for contemporary probe development. Other challenges in tracer development include the notion that \u03b1S is not abundantly expressed at early PD stages, requiring a highly sensitive detection tool and hampering the development of a suitable \u03b1S-targeted imaging probe for early PD diagnosis. Notably, \u03b1S aggregate structure, as well as spatial brain distribution and abundance of \u03b1S can vary depending on the underlying \u03b1-synucleinopathy, adding more layers of complexity, but concurrently providing an opportunity to harness these differences for differential diagnosis. A recent study concluded that the intrinsic structure of \u03b1S fibrils determines the characteristics of synucleinopathies [82]. For instance, fibrillar \u03b1S assemblies derived from patients with MSA exhibited strong similarities with PD-derived \u03b1S fibrils, but were significantly more potent in prompting nigrostriatal neurodegeneration, spread of \u03b1S pathology, inflammation and motor deficits, reflecting the aggressive nature of this disease [82]. In sharp contrast, strains from DLB cases displayed very modest neuropathological features. DLB is clinically distinguished from PD dementia by the timing of dementia onset \u2013 with individuals that develop dementia up to one year after the onset of motor symptoms considered to suffer from DLB, and individuals developing dementia later than one year following the onset of motor symptoms being assigned to the PD dementia group [83,84]. Despite these various challenges in the development of \u03b1S-targeted PET ligands, a clinically validated probe could be used as a biomarker for disease progression, as well as to monitor therapy response in future trials. Further, other approaches such as real-time quaking-induced conversion (RT-QuIC) have enabled the identification of misfolded \u03b1S in the cerebrospinal fluid (CSF) of patients with prodromal and manifest \u03b1-synuclopathies with a sensitivity of 90\u201395% and a specificity of 80\u2013100% [85,86]. While the latter diagnostic performance is intriguing, limitations of current RT-QuIC applications for the detection of misfolded \u03b1S include the invasive nature of lumbar puncturing as well as the lack of information on spatial distribution of Lewy bodies across different brain regions. Finally, given the involvement of peripheral organs in PD, more recent findings indicated that colon, skin, gastrointestinal and submandibular gland biopsies may constitute valid alternatives to the brain as a source of pathological \u03b1S for diagnostic purposes [87,88,89,90,91,92]. A recent study by Wang et al. concluded that \u03b1S seeding activity from skin samples can serve as a novel biomarker for antemortem diagnoses of synucleinopathies [93]. Employing RT-QuIC analysis to assess 41 antemortem skin biopsies from patients with PD and controls, the authors found that posterior cervical and leg skin biopsy tissues provided a diagnostic sensitivity and specificity for the detection synucleinopathies in PD patients of 95% (95% CI, 77\u2013100) and 100% (95% CI, 84\u2013100), respectively. Along this line, phosphorylated \u03b1S depositions within autonomic nerve terminals of biopsied skin samples have been detected by immunohistochemistry (IHC) and immunofluorescence (IF) microscopy in living PD patients. Although a variety of immunohistochemical assays have been reported, the majority of studies were conducted at single centers without blinded and independent replication. However, in a recent study by Donadio et al., skin biopsies have been validated across laboratories, showing a high degree of reproducibility [94]. In most reported cases, peripheral biopsies were successfully used to discriminate PD patients from healthy subjects. Larger multicenter trials are warranted to unleash the full diagnostic potential of peripheral PD biopsies. Further, molecular imaging probes with tailored pharmacokinetic properties may facilitate the non-invasive assessment of pathological \u03b1S in peripheral organs such as the colon or submandibular gland. Molecular imaging in Parkinson\u2019s disease (PD). Selected biological targets that have been harnessed for positron emission tomography (PET) and single photon-emission tomography (SPECT) imaging in PD. These targets have been used to allow diagnostic imaging as well as to facilitate drug discovery & development and include the translocator protein 18 kDa (TSPO), which is upregulated in activated microglia, mitochondrial complex I (MC-I) to assess mitochondrial function, various \u03b1-synuclein and amyloid-\u03b2 (A\u03b2)-targeted probes, radiolabeled dopamine & serotonin transporter substrates & ligands of dopamine receptors, probes targeting the vesicular monoamine transporter 2 (VMAT2) and attempts to visualize autophagy as well as cytokines such as the tumor necrosis factor \u03b1 (TNF-\u03b1). Given that these molecular variables are critical to the pathophysiology of PD, most of them have been suggested as therapeutic targets The availability of molecular imaging tools to visualize \u03b1S has the potential to support emerging therapeutic concepts that are focused on attenuating the formation of misfolded \u03b1S aggregates, through reduction of \u03b1S production, inhibition of \u03b1S aggregation, increased \u03b1S degradation, or inhibition of uptake of extracellular \u03b1S into neurons [95]. For instance, reduced \u03b1S expression can be achieved by the silencing of theSNCAgene via small interfering RNA (siRNA). Studies have established the potential neuroprotective effects of siRNAs in rodent models of \u03b1-synucleinopathies, particularly upon intracranial administration in hippocampal and cortical regions of the rodent brain [96,97,98]. In a recent study by Mittal et al., \u03b22-adrenoreceptors were found to regulateSNCAtranscription via histone 3 lysine 27 acetylation of its promoter and enhancers [99]. Along this line, individuals treated with \u03b22-adrenoreceptor agonists had a significantly reduced risk of developing PD (OR = 0.66, 95% CI, 0.58 to 0.76) [99]. Further, studies have highlighted the potential of heat shock proteins (HSPs) [100,101]. Of note, HSPs serve as molecular chaperons, capable of preventing the aggregation of misfolded proteins such as pathological \u03b1S. It was found that the small heat-shock proteins, \u03b1B-crystallin and Hsp27, prevent \u03b1S aggregation in vitro via transient molecular interactions that were dependent on the kinetics of \u03b1S aggregation [101]. Similarly, Hsp70 was found to reduce the amount of aggregated \u03b1S in vitro and in vivo, in an \u03b1-synucleopathy mouse model overexpressing Hsp70, protecting it from \u03b1S-dependent neurotoxicity. Further, first-generation epitope vaccines that were generated against B cell antigenic determinants of human \u03b1S and produced high titers of anti-human \u03b1S antibodies attenuated Lewy bodies pathology in brain specimens from DLB cases [102]. Active and passive immunization against \u03b1-syn have shown neuroprotective activity via attenuation of \u03b1S aggregation in transgenic mouse models of PD [103,104,105]. In an initial clinical trial, the humanized IgG1 monoclonal antibody, prasinezumab, prompted a 96.5% reduction of soluble serum \u03b1S with good tolerability and favorable safety profile in patients [106]. However, results of a phase 2 clinical trial (NCT03100149) showed that the drug has limited effects on disease progression [107]. To date, interesting exploratory concepts of \u03b1S-targeted therapy involve the development of monoclonal antibodies against \u03b1S, which promote its degradation [105]. Further, the anti-\u03b1S antibody, Lu-AF82422, has proven to inhibit seeding of \u03b1S in preclinical studies [108] and may constitute a promising candidate for the treatment of \u03b1-synucleinopathies in future clinical trials. Of note, drug development efforts in Alzheimer\u2019s disease revealed that immunotherapies directed at aggregated forms of A\u03b2, with the particular aim not to target monomeric A\u03b2, proved to be highly promising [109,110]. Similar attempts to design and develop antibodies that specifically target aggregated oligomeric forms of \u03b1S are currently emerging [111,112,113], and future studies will reveal their therapeutic potential. Given their neurotoxic properties, oligomeric \u03b1S forms are considered a particularly attractive target for passive immunization strategies in PD [114]. As such, several examples have been reported in which antibodies against oligomeric \u03b1S triggered a reduction in \u03b1S accumulation in studies with transgenic murine models of synucleinopathies, as recently reviewed by Vaikath et al. [115]. Similar to the examples from PET ligand development, bispecific antibodies that undergo transferrin receptor-mediated transcytosis have also been developed for therapeutic purposes [116]. This concept has been leveraged to advance A\u03b2-targeted antibodies to AD patients and has found application in preclinical PD studies, as evidenced by the reduction of \u03b1S pathology in transgenic L61 mice following treatment with the bispecific antibody, RmAbSynO2-scFv8D3 [117]. It is anticipated that similar efforts will be used in clinical trials with PD patients in the near future. Overall, \u03b1S-targeted therapy in PD has been extensively investigated in preclinical models and a steadily accumulating body of clinical evidence seems to underscore the potential value of development of \u03b1S-targeted therapy. **Mitochondrial and lysosomal dysfunction** The link between parkinsonism and mitochondrial dysfunction was initially established when the neurotoxin,N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), was reported to trigger acute parkinsonism in humans [118], with similar observations in rodents and non-human primates [119,120,121,122]. These observations gave rise to concerted research into the role of mitochondrial dysfunction in PD. Of note, MPTP is a pro-drug that rapidly passes through the blood\u2013brain barrier. Once in the brain, it is oxidized to the active compound, 1-methyl-4-pyridinium (MPP +). MPP + is a substrate of the dopamine transporter, thus leading to MPP + accumulation in dopaminergic cells, where the compound inhibits respiration at mitochondrial complex I (MC-I) of the electron transport chain [123,124,125]. Abnormal mitochondrial dynamics, including fission and fusion, was found to prompt dopaminergic nerve loss, thus providing a potential mechanism of MPTP-induced parkinsonism [126]. Later studies showed that many PD-associated gene mutations directly or indirectly lead to mitochondrial dysfunction, [127,128,129] which leads to the formation of reactive oxygen species (ROS), exposing the respective neurons to persistent oxidative stress [47,57,58]. Although MC-I deficiencies are the primary source of ROS in PD [125], other factors including auto-oxidation of dopamine [130] and neuroinflammation also contribute to oxidative stress [21]. Given (1) the implications of mitochondrial dysfunction and oxidative stress in PD and (2) the critical role of MC-I in maintaining redox homeostasis, targeting MC-I may constitute a promising diagnostic and therapeutic approach in PD. Indeed, MC-I selective PET ligands such as18F-BCPP-EF and18F-flurpiridaz have been developed and validated in humans [131,132]. These tools can be readily harnessed to facilitate the discovery of MC-I-targeted therapeutic agents, thereby harboring the potential to provide a novel disease-modifying concept in PD. It should be mentioned, however, that18F-flurpiridaz is mainly used for myocardial perfusion imaging due to the perfusion-dependent tracer kinetics in the myocardium [133,134]. It is currently unclear whether18F-flurpiridaz can be leveraged for mapping MC-1 in the mammalian brain. Beyond the role of MC-I in mitochondrial dysfunction, mutations inPINK1, the gene encoding for PTEN-induced putative kinase 1 (PINK1), are associated with mitochondrial dysfunction in PD, whereas patients who are heterozygous for mutations inPINK1present with reduced intensity on18F-fluoro-levodopa PET compared with controls [135]. Lysosomal dysfunction has been increasingly recognized as another key determinant in the pathophysiology of PD. Along this line, the lysosomal hydroxylase glucocerebrosidase (GCase), encoded by the GBA gene, is known to exhibit pathogenic mutations that can cause hereditary PD [136]. GCase and \u03b1S form a bidirectional pathologic loop where GCase deficiency leads to a decline of lysosomal proteolysis that affects \u03b1S, while increased levels of \u03b1S attenuate the function of GCase in neuronal lysosomes [137,138]. Targeting GCase as a therapeutic strategy for PD has been suggested. Ambroxol is considered a potentially disease-modifying agent that proved to increase brain GCase activity and decrease \u03b1S in experimental parkinsonism, prompting its clinical translation. Indeed, ambroxol has recently been advanced to clinical trials for the treatment of PD (NCT02941822) and PD-associated dementia (NCT02914366) [136,139]. Similar to GCase, leucine-rich repeat kinase 2 (LRRK2) is involved in hereditary PD [140]. Genetic and biochemical data unveiled that hyperactivity of LRRK2 is linked to PD progression and thus it has been hypothesized that lowering its activity may exhibit disease-modifying effects in PD [141]. While attempts to develop LRRK2-targeted molecular imaging probes have been reported, a clinically validated PET or SPECT tracer is currently lacking [142,143,144]. Nonetheless, the recently reported radiofluorinated probe,18F-PF-06455943, exhibited favorable performance characteristics in rodents and non-human primates, rendering it a promising candidate for clinical translation [145]. The availability of such a tool would facilitate the development of LRRK2-targeted therapeutics in the pipeline. Although LRRK2 kinase inhibitors have proven protective in experimental parkinsonism and have been suggested for clinical translation [146], the mechanisms by which mutant LRRK2 contributes to PD pathophysiology are not fully understood. LRRK2 does not form aggregates in the affected PD brain, however, the pathological function of mutated LRRK2 may involve common pathways with \u03b1S. For instance, mice that were transgenic for mutant human LRRK2 and overexpressed mutant humanSNCAexhibited an enhanced deposition of \u03b1-synuclein, as compared with control mice that overexpressed mutant humanSNCAalone [147]. In contrast, removal of the endogenousLrrk2gene limited the detrimental effects of mutant \u03b1-synuclein, reducing protein deposition and neuronal loss in experimental parkinsonism [148]. Studies assessing PD-related changes in LRRK2 levels are limited. Nonetheless, a study that used laser microdissection to isolate dopaminergic neurons from the substantia nigra pars compacta of subjects with idiopathic PD and controls suggested that LRRK2 mRNA levels were attenuated in PD patients [149]. These results warrant confirmation in larger trials and may support the notion that LRRK2 could serve as a disease biomarker that can be targeted with molecular imaging probes. While the molecular mechanism underlying a beneficial effect of LRRK2 inhibitors in PD are not entirely understood, an LRRK2-induced attenuation of autophagy has recently been proposed [150]. Among the LRRK2 inhibitors in clinical development, DNL201 and DNL151 were well tolerated in a phase I study in healthy volunteers [146]. Further, DNL201 was evaluated in a phase Ib trial assessing drug safety and pharmacokinetics in 28 patients with early PD. DNL201 was generally well tolerated and demonstrated a robust cerebrospinal fluid penetration [151]. Other LRRK2 inhibitors such as MLi-2 and PF-06685360 have shown encouraging preclinical efficacy, however, there are no reports on human use of these agents to date [152]. Another approach to suppress LRRK2 activity is through the use of anti-sense oligonucleotides (ASOs) that can decrease LRRK2 expression. Indeed, the recently reported ASO, BIIB094, prompted a decrease of \u03b1S inclusions in mice, and its safety, tolerability and pharmacokinetic profile are currently being evaluated in humans (NCT03976349) [153,154]. While PD has been linked to dysfunctional autophagy, attempts to target autophagy by translational molecular imaging probes have been scarce. The histone deacetylase 6 (HDAC6) constitutes a potential biological target to non-invasively assess autophagy. Indeed, HDAC6 was found to orchestrate autophagosome maturation [155] and prevent neurodegeneration by enhancing autophagy when the ubiquitin\u2013proteasome system is impaired [156]. HDAC6 was further found to participate in PD pathophysiology [157], and can be targeted using18F-EKZ-001 PET, as recently shown in a first-in-human study [158]. Indeed,18F-EKZ-001 was well tolerated and exhibited favorable tracer pharmacokinetics, including rapid brain uptake and retention in cortical regions with high HDAC6 abundancy [158]. This imaging tool can be harnessed for clinical target engagement studies, facilitating the development of HDAC6 modulators in the pipeline. Moreover, future studies will reveal whether HDAC6-based molecular imaging is useful to assess the integrity of the autophagy machinery in PD. **Neuroinflammation in Parkinson\u2019s disease** Neuroinflammatory mechanisms that contribute to the neuronal degeneration in PD include, but are not limited to, microglial activation [159], excessive cytokine release, and lymphocytic CNS infiltration (Fig.3) [160]. The latter triggers deleterious events that ultimately result in cytokine receptor-mediated apoptosis, which, in turn, may contribute to the dopaminergic cell death and PD progression [22]. Microglia represent 10\u201320% of all glial cells in the brain and act as a natural defense mechanism against pathogens and as key mediators of immune response in the brain [161,162]. However, excessive microglial activation following mitochondrial dysfunction and oxidative stress can ultimately result in neuronal cell death. Upon activation, microglial cells upregulate the peripheral benzodiazepine receptor (translocator protein 18 kDa, TSPO) \u2013 an essential component of the mitochondrial membrane that mediates functions such as cholesterol transport, mitochondrial respiration, apoptosis, and cell proliferation [163]. Although the underlying trigger of increased TSPO expression in activated microglia is not fully understood, TSPO is believed to be a key modulator of microglial activity [164]. TSPO has been used as a biomarker for neuroinflammation and a variety of clinically validated imaging probes for TSPO have been developed (Fig.2). The isoquinoline derivative,11C-PK11195, was the first TSPO PET ligand that proved to be clinically useful for imaging neuroinflammation [165,166]. PET studies indicated that there is pronounced microglial activation in various regions of the PD brain, as evidenced by studies with11C-PK11195 [167,168]. However, due to the limitations of11C-PK11195, which include high non-specific binding, low brain penetration, and high plasma protein binding, the clinical use of11C-PK11195 is hampered [169,170]. Second generation radiotracers with superior imaging characteristics have subsequently been developed, including several probes with variable chemical structures, such as11C-PBR28,18F-FEPPA,11C-DAA1106 [171,172,173,174,175,176,177,178,179]. One critical drawback of these tracers is their sensitivity to polymorphism in the TSPO gene, thus affecting their binding properties and leading to increased inter-individual variability. The latter shortcoming prompted the development of third generation TSPO-targeted probes such as the tricyclic indole,18F-GE180 [180]. The ability of18F-GE180 to bind selectively and with high affinity to TSPO is critical for the assessment of neuroinflammation in disease states, providing significantly better TSPO imaging signal to noise ratios and lower nonspecific binding, as compared to11C-PK11195 [181,182]. Notably, it was recently suggested that substantial discrepancies between in vitro and in vivo sensitivity to TSPO gene polymorphism might further complicate TSPO PET ligand development, as evidenced by studies involving the translational work on quinazoline-2-carboxamide derivative,11C-ER176 [183], of which a radiofluorinated analogue (18F-3b) has been reported. [184] Future clinical trials are warranted to assess the utility of18F-3band18F-GE180 to visualize neuroinflammatory processes in PD. Established vs. experimental therapies in Parkinson\u2019s disease (PD). While current drug PD therapy is primarily symptomatic and attempts to restore dopaminergic function, many lines of experimental research focus currently on the development of potentially disease-modifying concepts. The latter involve various targets that can be visualized using translational molecular imaging probes, thus providing the opportunity to conduct imaging-guided preclinical and clinical studies in PD. Among the promising concepts, preventing the formation of inclusion bodies by targeting misfolded \u03b1-synuclein, attenuating neuroinflammation via anti-tumor necrosis factor \u03b1 (TNF-\u03b1) antibodies and glucagon-like peptide 1 (GLP-1) activation, as well as stimulation of autophagy with leucine-rich repeat kinase 2 (LRRK2) inhibitors have been suggested Other mechanisms by which microglial function can be attenuated include the activation of glucagon-like peptide-1 (GLP-1) receptor and the inhibition of inflammatory cytokines such as the tumor necrosis factor \u03b1 (TNF\u03b1) [185,186]. In a recent single-center, randomized, double-blind and placebo-controlled trial, patients with moderate idiopathic PD received the GLP-1 receptor agonist, exenatide, once weekly for 48 weeks in addition to their regular medication, prompting a significant improvement of their clinical scores, as compared to the placebo group [185]. These results not only suggested that exenatide may warrant further study as a therapy, but also provided the opportunity to pursue imaging-guided clinical trials with radiolabeled exenatide analogs, which have recently entered the clinical arena [187,188,189]. While anti-TNF\u03b1 antibody therapy with agents such as with infliximab or adalimumab has been established for peripheral inflammatory diseases [190], these agents have not yet been extensively studied as potential therapeutics in PD. In the wake of previous examples of bispecific anti-TNF\u03b1 antibodies, it is conceivable that a bispecific anti-TNF\u03b1 antibody, that allows receptor-mediated transcytosis, may be of particular interest for therapy studies in PD patients. Further, the notion that64Cu-etanercept was shown to rapidly accumulate in the choroid plexus and the CSF within the cerebral ventricles of a living rat after peripheral administration [191] points towards a potential utility of the probe to visualize TNF\u03b1 in the central nervous system. The latter may lay the foundation for the assessment of TNF\u03b1 abundancy in live PD patients in the near future, as well as for the potential assessment of target engagement by anti-TNF\u03b1 drugs in the PD brain. Triggering receptor expressed on myeloid cells 2 (TREM2) is heavily implicated in glial function and axonal myelination [192]. Genetic variants of TREM2 were linked to PD, however, the potential role of TREM2 on the formation and aggregation of pathological \u03b1S is poorly understood. In a recent study involving BV2 microglial cells and TREM2 knock-out mice, it was demonstrated that TREM2 deficiency aggravates \u03b1S-related neuropathology [193]. Further, soluble TREM2 levels were found to be elevated in PD subgroups presenting with increased levels of tau in the CSF [194]. Further studies to identify molecular pathways linking TREM2 with \u03b1S are required to pave the way for TREM2-targeted novel therapeutic concepts in PD. Similarly, molecular imaging probes directed at TREM2 [195] hold promise to serve as research tools, thereby shedding light on the role of TREM2 in PD pathophysiology. **Dysregulation of neuroreceptor systems** To date, most of the routinely used antiparkinsonian medications target dopamine deficiency. While dopaminergic pharmacological treatment is presumed not to considerably affect disease progression, it has enabled sustained symptom control and ground-breaking improvements in the quality of life for PD patients [13]. An overview of the contemporary arsenal of validated and selected experimental PD drugs is provided in Fig.3. While progressive degeneration of dopaminergic neurons is evident in PD, experimental and clinical studies have highlighted the involvement of other neuroreceptor systems, including the glutamatergic, serotonergic, adrenergic and cholinergic system [10,196]. For instance, it has been suggested that a well-defined balance between central dopaminergic and cholinergic signaling is required for movement control and that efforts to restore that balance, with anticholinergic agents, would result in improvement of motor symptoms in PD patients [197,198]. Approved anticholinergics provide symptomatic relief for tremor and to some extent for rigidity, however, they exhibit significant side effects (such as memory disturbances or somnolence), which makes them unusable in most elderly parkinsonian patients. Although dopaminergic therapy has largely supplanted the use of anticholinergic drugs, they are still used in clinical practice, particularly in younger PD patients with prominent tremor [199,200,201,202]. Aside from the CNS implications of the cholinergic system in PD, there is a solid body of evidence supporting its role in autonomic dysfunction in peripheral organs, which is observed in most PD patients and substantially affects their quality of life. Peripheral PD symptoms (cholinergic or non-cholinergic) include gastrointestinal dysfunction, cardiovascular dysregulation, urinary disturbances, sexual dysfunction, and thermoregulatory changes [203,204]. Intriguingly, \u03b1S pathology has recently been linked to autonomic denervation [205,206,207,208]. Cardiac autonomic denervation has the potential to allow differential diagnosis between PD and other forms of parkinsonism, thus rendering it a useful biomarker for diagnostic imaging [209]. A summary of contemporary molecular imaging concepts involving dysregulated neuroreceptor systems in PD is provided in Fig.2. **Dopamine receptors** Postsynaptic dopamine receptors are divided into five subtypes, namely, dopamine receptors 1\u20135 (D1-D5). While D1 and D5 are coupled to G stimulatory sites and activate adenylyl cyclase, D2-D4 couple to G inhibitory sites, thereby inhibiting adenylyl cyclase [210]. Dopamine receptors are typically upregulated in early PD, which can be quantified by dopamine receptor PET [211,212]. A major obstacle of D1-targeted PET imaging has been the challenging development of selective probes. While11C-SCH23390 was initially identified as D1 PET ligand and was advanced to humans [213], the broad use of this tracer was hampered due to the limited subtype-selectivity. A close derivative,11C-SCH39166 exhibited improved selectivity, however, at the expense of reduced binding affinity towards D1 [214]. Further, another PET ligand code-named,11C-NNC112, was suggested for quantitative assessment of dopamine receptors, [215] but was demonstrated to have off-target binding at 5-HT2A receptors in humans [216]. Tamagnan et al. reported on the development of a potentially promising D1-targeted probe codenamed18F-MNI-968, which was administered to non-human primates and humans [217]. Although preliminary data was deemed promising, further studies are currently ongoing to elucidate the potential of18F-MNI-968 for subtype-selective imaging of D1 receptors. With regard to D2 receptor imaging,11C-raclopride has been widely used. This agent competes with endogenous dopamine, thereby proving to be a useful tool for qualitative assessment of D2 receptor density [213]. Alternative D2-targeted PET probes such as18F-fallypride are considered valid alternatives with improved binding affinities at D2 receptors [218]. These dopamine receptor-targeted probes are not currently in routine use for the diagnosis of PD because of potential interactions of dopamine replacement therapy with tracer-receptor binding, and the complexity of such analyses related to the dopamine receptor autoregulation in response to the loss of dopaminergic neurons. However, the imaging tools are valuable to facilitate the development of improved dopamine receptor agonists. Indeed, these tools have been harnessed to assess target occupancy by endogenous dopamine, or dopamine released in response to levodopa therapy, and various synthetic agonists across different species, thereby advancing our understanding of the biologic effects of dopaminergic therapy [219,220,221,222,223]. Various dopamine receptor agonists have been developed and shown to attenuate PD motor symptoms. Dopamine receptor agonists can be divided in two major classes, namely, ergot- and non-ergot derivatives. Because the use of ergot derivatives has been associated with pleuropulmonary and cardiac valvular fibrosis [13], currently used dopamine receptor agonists belong to the non-ergot family [224]. Examples include pramipexole, ropinirole, rotigotine, apomorphine and piribedil [225]. Although, they were initially licensed for synergistic administration with levodopa at advanced PD stages, their application as monotherapy has also proven useful in PD [224,226]. In conclusion, targeting dopamine receptors constitutes a compelling example of how translational molecular imaging probes can be exploited to provide imaging-supported PD therapy. **DOPA decarboxylase and dopamine transporters** In the mammalian brain, DOPA decarboxylase (DDC) facilitates the transformation of levodopa to dopamine [227]. Levodopa is the L-isomer of the naturally occurring amino acid, D,L-dihydroxy-phenylalanine [228]. Unlike dopamine, levodopa crosses the blood\u2013brain barrier, thus allowing peripheral administration of the drug. The paramount therapeutic value of levodopa in PD was recognized when the enzyme that converts levodopa to dopamine, DDC, was found to be present in high amounts in the mammalian brain [229,230]. For more than half a century, levodopa has been the first-line treatment for PD [231,232,233]. Indeed, levodopa therapy is remarkably effective in attenuating primary motor symptoms of PD patients. Upon oral administration of levodopa, it undergoes an extensive first-pass metabolism and rapid plasma clearance, allowing for only 1% of the administered dose to enter the brain [234]. This limitation can be overcome by co-administration of peripheral DDC inhibitors that do not enter the central nervous system (CNS). In fact, the latter was shown to substantially increase CNS availability of levodopa, thus reducing the substantial peripheral side effects of levodopa treatment, and improving its central efficacy [234,235,236,237,238]. Moreover, administration of levodopa via inhalation (CVT-301) [239] or continuous subcutaneous infusion [240,241,242] \u2013 mainly to circumvent the first-pass effect \u2013 have been suggested to maintain a steady prodrug supply to the brain. Contemporary levodopa treatment regimens include the co-administration of a peripheral DDC inhibitor, carbidopa or benserazide, which inhibits the peripheral decarboxylation of levodopa, thus reducing peripheral toxicity (nausea) and allowing greater CNS bioavailability of levodopa [13]. To further improve the availability of dopamine in the brain of parkinsonian patients, inhibitors of levodopa (and dopamine) metabolism via catechol-ortho-methyl-transferase (COMT) can be used. COMT inhibitors such as entacapone, tolcapone and opicapone have been introduced as an adjunct to levodopa-based combination therapies [243,244]. As opposed to DDC and COMT inhibitors, which primarily lead to inhibition of peripheral levodopa metabolism, monoamine oxidase B (MAO-B) inhibitors prevent the degradation of dopamine in the CNS [245]. As such, synaptically released dopamine can be cleared by oxidation via MAO-B, and pharmacological modulation of MAO-B with rasagiline, selegiline or safinamide has been shown to increase synaptic dopamine concentrations, thus rendering them useful as an adjunct to levodopa therapy, and also as early-stage monotherapies in PD [246,247,248,249]. Chronic levodopa therapy can be associated with the development of troublesome motor complications, specifically levodopa-induced dyskinesias (LID) and motor response fluctuations, including sudden wearing-off effects [250,251]. The underlying mechanisms for the development of dyskinesias with chronic levodopa replacement therapy are not yet fully understood, however, non-physiological pulsatile dopamine receptor stimulation in the striatum is considered to be an important factor [13,252]. Based on this concept, drug delivery approaches that are less encumbered by pulsatile changes in brain dopamine levels, including sustained-release formulations and continuous levodopa release through implanted pumps or intestinal gels have been used effectively to prevent or ameliorate the development levodopa-induced dyskinesias [253,254]. Translational molecular imaging offers an effective way to evaluate the biodistribution of levodopa when administered via different application routes, such as those mentioned above. Similar to levodopa, the radiofluorinated analog, 6-18F-fluoro-levodopa (18F-FDOPA), is trapped in the brain by DDC-mediated biotransformation, rendering18F-FDOPA a suitable tool to study drug biodistribution, dopamine storage capacity, as well as DDC activity and the loss of dopaminergic neurons in living subjects [255,256,257,258]. Similar to levodopa,18F-FDOPA readily crosses the blood brain barrier through neuronal amino acid transporters and is taken up by presynaptic terminals of dopaminergic neurons via the dopamine transporter (DAT), where it is metabolized to18F-dopamine by DDC and stored in synaptic vesicles (Fig.2). [257,259]18F-FDOPA PET has been used to assess the degree of nigrostriatal dopaminergic nerve loss in PD patients [260,261]. In combination with a clinical history,18F-FDOPA is considered a reliable diagnostic tool for the early diagnosis of PD. In a recent clinical trial encompassing 56 patients with suspected PD,18F-FDOPA was found to be highly specific and sensitive for the diagnosis of PD, which led to approval of its use for this purpose by the US Food and Drug Administration (FDA) in 2019 [262]. Other PET tracers that are considered substrates of DAT are typically employed for the assessment of presynaptic dopaminergic neurons in the nigrostriatal system [38]. In line with histopathological evidence, it was found that the uptake of DAT-targeted probes in the striatum is substantially reduced in PD patients, as compared to controls. Selected examples of reported DAT PET radioligands include11C-WIN 35,428 (11C-CFT) [263],18F-CFT [264],11C-PE2I [265] and11C-altropane [266]. All of these PET probes are highly sensitive to striatal dopaminergic denervation in PD. Similarly, DAT-targeted SPECT radioligands have proven useful for PD diagnosis. Particularly,123I-ioflupane (the ligand used commercially for DaTscans) and123I-\u03b2-CIT have been broadly used to support the assessment of parkinsonism [267]. While carbon-11 and fluorine-18 labeled DAT-targeted PET ligands typically provide higher image resolution than iodine-123 labeled SPECT tracer, the latter exhibit a longer physical half-life, which facilitates the logistics and distribution to facilities without on-site tracer production. In conclusion, DAT imaging with either PET or SPECT is the most widely applied functional imaging tool for the diagnostic work-up and can be considered a valuable tool for PD diagnosis in clinical routine [268,269,270]. **Vesicular monoamine transporter 2** While vesicular monoamine transporter 1 (VMAT1) is mainly expressed in the periphery, the central nervous system is endowed with a high abundancy of vesicular monoamine transporter 2 (VMAT2) [271]. There are several PET tracers available to image the distribution of VMAT2. The potentially most prominent VMAT2-targeted probes belong to the class of tetrabenazines and include tritium-labeled methoxytetrabenazine for preclinical applications, as well as11C-dihydrotetrabenazine (11C-DTBZ) for preclinical and clinical PET imaging.3H-methoxytetrabenazine was successfully used to map VMAT2 density in rodents [272]. Similarly,11C-DTBZ has been used in humans to monitor the integrity of striatal monoaminergic nerve terminals [273]. To improve the half-live of11C-DTBZ, a radiofluorinated analog,18F-DTBZ (18F-AV-133), was developed and tested in PD patients [274]. VMAT2 binding, as determined by18F-DTBZ PET, correlated significantly with clinical disease severity and duration [274,275]. Collectively, these results suggested that18F-DTBZ PET is a powerful tool to measure dopaminergic degeneration and monitor disease progression in PD patients. **Serotonergic and glutamatergic system** Although most reported PET and SPECT tracers for use in PD are geared towards evaluating the function or integrity of the dopaminergic system, several non-dopaminergic targets have recently been suggested as molecular biomarkers in PD. While dopaminergic markers allow for the diagnosis of PD at intermediate disease stages (Braak stages \u2265 3), it is possible that non-dopaminergic biomarkers could identify PD-related pathophysiological changes prior to the onset of clinical symptoms (Braak stages 1\u20132). The serotonergic system has been implicated in PD-associated depression, which typically develops early in the course of disease. Nonetheless, given the relatively high prevalence of depression in the general population, it remains to be seen whether serotonergic changes in PD-related depression can be distinguished from those in non-PD-related depression. Early observations included the low levels of 5-hydroxyindolacetic acid, a serotonin metabolite, in the cerebrospinal fluid, as well as the reduced cortical 5-HT1A receptors, in (symptomatic) PD patients suffering from depression [276]. Investigating the serotonergic system in PD patients was facilitated by the availability of serotonin transporter (SERT) PET ligands such as11C-DASB [277] and11C-WAY100635 [165,278,279]. Recently, serotonergic brain imaging with11C-DASB has proven effective in identifying individuals at risk to develop PD, prior to the development of dopaminergic pathology and motor symptoms, which highlights the potential of imaging the serotonergic system for risk-stratification [280]. To date, pimavanserin, a serotonin 5-HT2A and 5-HT2C receptor ligand with antipsychotic effects, is approved by the FDA for the treatment of hallucinations and delusions associated with PD psychosis [281]. Further, conventional antidepressant therapy with selective serotonin reuptake inhibitors (SSRIs) and selective noradrenaline reuptake inhibitors (SNRI) are commonly used in PD patients suffering from depression. Glutamate receptors (GluRs) are multimeric ligand-gated cation channels that mediate excitatory neurotransmission in the CNS. Given the role of glutamate receptors in modulating neurotransmission in the basal ganglia, it was suggested that drugs acting at these receptors may have antiparkinsonian effects [282]. GluRs are classified into ionotropic (iGluRs) and metabotropic glutamate receptors (mGluRs). IGluRs can be further subdivided into N-methyl-d-aspartate (NMDA), amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) and kainate (KA) receptors, and the family of mGluRs constitutes 8 different subtypes, mGluR1-8 [279,283]. Several NMDA antagonists, including competitive antagonists, noncompetitive antagonists, and glycine site antagonists were found to reverse muscle rigidity in rodent models of PD [282,284]. Anti-parkinsonism effects of NMDA antagonists were also observed in other animal models of PD, including MPTP-treated non-human primates [285,286]. Along this line, co-administration of NMDA antagonists with levodopa was found to potentiate the levodopa effect and decrease LID [282,287]. Similarly, amantadine, a drug with non-competitive NMDA receptor antagonist properties, ameliorates LID [288]. Due to the possible side effects that arise from global inhibition of NMDA receptors, recent drug discovery efforts are focused on the identification of subtype-selective NMDA antagonists, for instance by targeting the GluN2B subunit of the NMDA receptor, which is believed to be a key contributor to excitotoxicity-induced neuronal cell death [289,290,291]. The recent breakthroughs in translational molecular imaging of GluN2B-containing NMDA receptors may help with the development of subtype-selective NMDA antagonists for the treatment of PD [292,293,294,295,296,297,298,299,300]. The most advanced class of GluN2B-targeted PET probes is based on a benzazepine scaffold and includes the carbon-11 derivative,(R)-11C-Me-NB1 [295,300], which has recently been translated to humans, as well as the radiofluorinated analogs,(R)-18F-OF-Me-NB1 [292,298], and(R)/(S)-18F-OF-NB1 [293,296], which have recently been advanced to non-human primate studies and exhibited favorable performance characteristics, providing effective tools for the non-invasive quantification of GluN2B-carrying NMDA receptors. **Cardiac sympathetic denervation** Cardiac sympathetic denervation in PD patients was first observed more than two decades ago, when Goldstein et al. used PET imaging to visualize the significant loss of adrenergic nerve terminals in the left ventricle [301]. Since then, numerous studies have corroborated the loss of adrenergic neurons in the myocardium of PD patients. Although autonomic function is impaired in various organs, adrenergic denervation is particularly pronounced in the heart [207]. Indeed, some PD patients present with evidence of cardiac adrenergic denervation early in the disease course. Thus, in a review by Sakakibara et al., the authors concluded that cardiac sympathetic imaging with123I-metaiodobenzylguanidine (MIBG) could harbor potential for the diagnosis of pre-motor PD, in patients presenting with (non-specific) symptoms such as autonomic dysfunction, mild memory impairments, sleep disorder, visual hallucinations and depression/anxiety [302]. In addition to this potential diagnostic use, the detection of autonomic dysfunction may also have prognostic value: Autonomic dysfunction early in the course of symptomatic PD may presage a fast rate of progression [303,304]. Mechanistic studies to explain these findings are needed. Of note, the norepinephrine derivative, droxidopa, constitutes a prodrug for the management of neurogenic orthostatic hypotension in PD patients, indicating that adrenergic signaling is a valid target for the treatment of peripheral symptoms in PD [305]. Cardiac imaging with123I-MIBG can also be used to discriminate PD from MSA and progressive supranuclear palsy because the latter two conditions show only modest reduction in cardiac123I-MIBG uptake, and greater sympathetic ganglion dysfunction [306,307]. Prospective clinical trials that are adequately powered are warranted to accurately assess the diagnostic and prognostic value of cardiac sympathetic imaging in early PD as well as to identify ideal subpopulations for cardiac123I-MIBG-based differential diagnosis of parkinsonism. **Concluding remarks** Notwithstanding the significant progress in disease management, PD remains a major source of global disability, with no current cure. The main challenge in contemporary drug discovery is the identification of disease-modifying agents. Attempts to target \u03b1S are particularly promising, given the established role of \u03b1S across all stages of disease pathology. Therapeutic efficacy of \u03b1S-directed antibodies in the pipeline could potentially be monitored with a clinically validated \u03b1S-targeted probe, which holds promise to deliver an improved disease prognosis, however, their clinical development is still at an early stage and larger clinical trials that are supported by \u03b1S-specific and selective PET ligands with appropriate in vivo performance characteristics are currently pending. Beyond \u03b1S, molecular imaging with PET and SPECT has been established for the assessment of nigrostriatal loss, particularly with probes that are substrates of the dopamine transporter and serve to quantify dopaminergic nerve loss in clinical routine. More exploratory imaging approaches, that are currently mainly applied for research purposes in PD, include the assessment mitochondrial dysfunction, as well as dysregulation of the serotonergic and glutamatergic systems. To assess the role of neuroinflammation in PD patients, validated TSPO-targeted probes are employed due to their capacity to detect activated microglia. While the availability of a diverse arsenal of selective imaging probes is undoubtedly helpful as a research toolbox, further studies are required to determine the true potential of these exploratory imaging approaches to support drug discovery and improve the current standard of care for PD patients. There is an urgent need for early biomarkers that support diagnosis and patient recruitment. Further, disease progression markers are needed to facilitate the evaluation of therapeutic efficacy to improve the contemporary management of PD. Translational molecular imaging holds promise to advance the diagnostic landscape and contribute to an improved clinical decision-making. Tailored therapeutic strategies, based on individual patient scans, may help to define optimal management concepts and lead to the best possible treatment for every PD patient in the future. **Availability of data and materials** Not applicable. **Abbreviations** 11C-Dihydrotetrabenazine 11C-Pittsburgh compound-B 11C-WIN 35,428 123I-Metaiodobenzylguanidine 1-Methyl-4-pyridinium 6-18F-fluoro-levodopa \u03b1-Synuclein Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid Benzoxazole BF227 Catechol ortho methyl transferase Central nervous system Dementia with Lewy bodies DOPA decarboxylase Dopamine receptor type I Dopamine receptor type II Dopamine transporter Glucagon-like peptide-1 Glucocerebrosidase Glutamate receptors Histone deacetylase 6 Kainate receptors Leucine-rich repeat kinase 2 Mitochondrial complex I Monoamine oxidase B inhibitors Multiple system atrophy N-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine N-methyl-d-aspartate Parkinson\u2019s disease Peripheral benzodiazepine receptor Positron emission tomography Post-translational modifications Single-photon emission computed tomography SolubleN-ethylmaleimide-sensitive attachment protein receptors Substantia nigra pars compacta Tumor necrosis factor US Food and Drug Administration Vesicular monoamine transporter 1 Vesicular monoamine transporter 2 **References** Bloem BR, Okun MS, Klein C. Parkinson\u2019s disease. The Lancet. 2021;397:2284\u2013303.ArticleCASGoogle Scholar Bloem BR, Okun MS, Klein C. Parkinson\u2019s disease. The Lancet. 2021;397:2284\u2013303. ArticleCASGoogle Scholar Bloem BR, Okun MS, Klein C. Parkinson\u2019s disease. The Lancet. 2021;397:2284\u2013303. ArticleCASGoogle Scholar Ovallath S, Deepa P. The history of parkinsonism: descriptions in ancient Indian medical literature. Mov Disord. 2013;28:566\u20138.ArticlePubMedGoogle Scholar Ovallath S, Deepa P. The history of parkinsonism: descriptions in ancient Indian medical literature. Mov Disord. 2013;28:566\u20138. ArticlePubMedGoogle Scholar Ovallath S, Deepa P. The history of parkinsonism: descriptions in ancient Indian medical literature. Mov Disord. 2013;28:566\u20138. ArticlePubMedGoogle Scholar Parkinson J. An Essay on the Shaking Palsy. 1817. J Neuropsychiatry Clin Neurosci. 2002;14:223\u201336.ArticlePubMedGoogle Scholar Parkinson J. An Essay on the Shaking Palsy. 1817. J Neuropsychiatry Clin Neurosci. 2002;14:223\u201336. ArticlePubMedGoogle Scholar Parkinson J. An Essay on the Shaking Palsy. 1817. J Neuropsychiatry Clin Neurosci. 2002;14:223\u201336. ArticlePubMedGoogle Scholar Goetz CG. The history of Parkinson\u2019s disease: early clinical descriptions and neurological therapies. Cold Spring Harb Perspect Med. 2011;1:a008862\u2013a008862.ArticlePubMedPubMed CentralGoogle Scholar Goetz CG. The history of Parkinson\u2019s disease: early clinical descriptions and neurological therapies. Cold Spring Harb Perspect Med. 2011;1:a008862\u2013a008862. ArticlePubMedPubMed CentralGoogle Scholar Goetz CG. The history of Parkinson\u2019s disease: early clinical descriptions and neurological therapies. Cold Spring Harb Perspect Med. 2011;1:a008862\u2013a008862. ArticlePubMedPubMed CentralGoogle Scholar Nussbaum RL, Ellis CE. Alzheimer\u2019s disease and Parkinson\u2019s disease. N Engl J Med. 2003;348:1356\u201364.ArticleCASPubMedGoogle Scholar Nussbaum RL, Ellis CE. Alzheimer\u2019s disease and Parkinson\u2019s disease. N Engl J Med. 2003;348:1356\u201364. ArticleCASPubMedGoogle Scholar Nussbaum RL, Ellis CE. Alzheimer\u2019s disease and Parkinson\u2019s disease. N Engl J Med. 2003;348:1356\u201364. ArticleCASPubMedGoogle Scholar Collaborators GN. Global, regional, and national burden of neurological disorders, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019;18:459\u201380.ArticleGoogle Scholar Collaborators GN. Global, regional, and national burden of neurological disorders, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019;18:459\u201380. ArticleGoogle Scholar Collaborators GN. Global, regional, and national burden of neurological disorders, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019;18:459\u201380. ArticleGoogle Scholar Papapetropoulos S, Adi N, Ellul J, Argyriou AA, Chroni E. A prospective study of familial versus sporadic Parkinson\u2019s disease. Neurodegener Dis. 2007;4:424\u20137.ArticlePubMedGoogle Scholar Papapetropoulos S, Adi N, Ellul J, Argyriou AA, Chroni E. A prospective study of familial versus sporadic Parkinson\u2019s disease. Neurodegener Dis. 2007;4:424\u20137. ArticlePubMedGoogle Scholar Papapetropoulos S, Adi N, Ellul J, Argyriou AA, Chroni E. A prospective study of familial versus sporadic Parkinson\u2019s disease. Neurodegener Dis. 2007;4:424\u20137. ArticlePubMedGoogle Scholar Braak H, Ghebremedhin E, R\u00fcb U, Bratzke H, Del Tredici K. Stages in the development of Parkinson\u2019s disease-related pathology. Cell Tissue Res. 2004;318:121\u201334.ArticlePubMedGoogle Scholar Braak H, Ghebremedhin E, R\u00fcb U, Bratzke H, Del Tredici K. Stages in the development of Parkinson\u2019s disease-related pathology. Cell Tissue Res. 2004;318:121\u201334. ArticlePubMedGoogle Scholar Braak H, Ghebremedhin E, R\u00fcb U, Bratzke H, Del Tredici K. Stages in the development of Parkinson\u2019s disease-related pathology. Cell Tissue Res. 2004;318:121\u201334. ArticlePubMedGoogle Scholar Masato A, Plotegher N, Boassa D, Bubacco L. Impaired dopamine metabolism in Parkinson\u2019s disease pathogenesis. Mol Neurodegener. 2019;14:35.ArticlePubMedPubMed CentralGoogle Scholar Masato A, Plotegher N, Boassa D, Bubacco L. Impaired dopamine metabolism in Parkinson\u2019s disease pathogenesis. Mol Neurodegener. 2019;14:35. ArticlePubMedPubMed CentralGoogle Scholar Masato A, Plotegher N, Boassa D, Bubacco L. Impaired dopamine metabolism in Parkinson\u2019s disease pathogenesis. Mol Neurodegener. 2019;14:35. ArticlePubMedPubMed CentralGoogle Scholar Sveinbjornsdottir S. The clinical symptoms of Parkinson\u2019s disease. J Neurochem. 2016;139:318\u201324.ArticleCASPubMedGoogle Scholar Sveinbjornsdottir S. The clinical symptoms of Parkinson\u2019s disease. J Neurochem. 2016;139:318\u201324. ArticleCASPubMedGoogle Scholar Sveinbjornsdottir S. The clinical symptoms of Parkinson\u2019s disease. J Neurochem. 2016;139:318\u201324. ArticleCASPubMedGoogle Scholar Cheng HC, Ulane CM, Burke RE. Clinical progression in Parkinson disease and the neurobiology of axons. Ann Neurol. 2010;67:715\u201325.ArticlePubMedPubMed CentralGoogle Scholar Cheng HC, Ulane CM, Burke RE. Clinical progression in Parkinson disease and the neurobiology of axons. Ann Neurol. 2010;67:715\u201325. ArticlePubMedPubMed CentralGoogle Scholar Cheng HC, Ulane CM, Burke RE. Clinical progression in Parkinson disease and the neurobiology of axons. Ann Neurol. 2010;67:715\u201325. ArticlePubMedPubMed CentralGoogle Scholar Braak H, Bohl JR, M\u00fcller CM, R\u00fcb U, de Vos RAI, Del Tredici K. Stanley Fahn Lecture 2005: The staging procedure for the inclusion body pathology associated with sporadic Parkinson\u2019s disease reconsidered. Mov Disord. 2006;21:2042\u201351.ArticlePubMedGoogle Scholar Braak H, Bohl JR, M\u00fcller CM, R\u00fcb U, de Vos RAI, Del Tredici K. Stanley Fahn Lecture 2005: The staging procedure for the inclusion body pathology associated with sporadic Parkinson\u2019s disease reconsidered. Mov Disord. 2006;21:2042\u201351. ArticlePubMedGoogle Scholar Braak H, Bohl JR, M\u00fcller CM, R\u00fcb U, de Vos RAI, Del Tredici K. Stanley Fahn Lecture 2005: The staging procedure for the inclusion body pathology associated with sporadic Parkinson\u2019s disease reconsidered. Mov Disord. 2006;21:2042\u201351. ArticlePubMedGoogle Scholar Poewe W, Seppi K, Tanner CM, Halliday GM, Brundin P, Volkmann J, Schrag A-E, Lang AE. Parkinson disease. Nat Rev Dis Primers. 2017;3:17013.ArticlePubMedGoogle Scholar Poewe W, Seppi K, Tanner CM, Halliday GM, Brundin P, Volkmann J, Schrag A-E, Lang AE. Parkinson disease. Nat Rev Dis Primers. 2017;3:17013. ArticlePubMedGoogle Scholar Poewe W, Seppi K, Tanner CM, Halliday GM, Brundin P, Volkmann J, Schrag A-E, Lang AE. Parkinson disease. Nat Rev Dis Primers. 2017;3:17013. ArticlePubMedGoogle Scholar Jankovic J. Parkinson\u2019s disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry. 2008;79:368\u201376.ArticleCASPubMedGoogle Scholar Jankovic J. Parkinson\u2019s disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry. 2008;79:368\u201376. ArticleCASPubMedGoogle Scholar Jankovic J. Parkinson\u2019s disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry. 2008;79:368\u201376. ArticleCASPubMedGoogle Scholar Solari N, Bonito-Oliva A, Fisone G, Brambilla R. Understanding cognitive deficits in Parkinson\u2019s disease: lessons from preclinical animal models. Learn Mem. 2013;20:592\u2013600.ArticlePubMedGoogle Scholar Solari N, Bonito-Oliva A, Fisone G, Brambilla R. Understanding cognitive deficits in Parkinson\u2019s disease: lessons from preclinical animal models. Learn Mem. 2013;20:592\u2013600. ArticlePubMedGoogle Scholar Solari N, Bonito-Oliva A, Fisone G, Brambilla R. Understanding cognitive deficits in Parkinson\u2019s disease: lessons from preclinical animal models. Learn Mem. 2013;20:592\u2013600. ArticlePubMedGoogle Scholar Schneider F, Althaus A, Backes V, Dodel R. Psychiatric symptoms in Parkinson\u2019s disease. Eur Arch Psychiatry Clin Neurosci. 2008;258:55\u20139.ArticlePubMedGoogle Scholar Schneider F, Althaus A, Backes V, Dodel R. Psychiatric symptoms in Parkinson\u2019s disease. Eur Arch Psychiatry Clin Neurosci. 2008;258:55\u20139. ArticlePubMedGoogle Scholar Schneider F, Althaus A, Backes V, Dodel R. Psychiatric symptoms in Parkinson\u2019s disease. Eur Arch Psychiatry Clin Neurosci. 2008;258:55\u20139. ArticlePubMedGoogle Scholar Pagano G, Niccolini F, Politis M. Imaging in Parkinson\u2019s disease Clin Med (Lond). 2016;16:371\u20135.PubMedGoogle Scholar Pagano G, Niccolini F, Politis M. Imaging in Parkinson\u2019s disease Clin Med (Lond). 2016;16:371\u20135. PubMedGoogle Scholar Pagano G, Niccolini F, Politis M. Imaging in Parkinson\u2019s disease Clin Med (Lond). 2016;16:371\u20135. PubMedGoogle Scholar Schapira AHV, Gu M, Taanman JW, Tabrizi SJ, Seaton T, Cleeter M, Cooper JM. Mitochondria in the etiology and pathogenesis of parkinson\u2019s disease. Ann Neurol. 1998;44:S89\u201398.ArticleCASPubMedGoogle Scholar Schapira AHV, Gu M, Taanman JW, Tabrizi SJ, Seaton T, Cleeter M, Cooper JM. Mitochondria in the etiology and pathogenesis of parkinson\u2019s disease. Ann Neurol. 1998;44:S89\u201398. ArticleCASPubMedGoogle Scholar Schapira AHV, Gu M, Taanman JW, Tabrizi SJ, Seaton T, Cleeter M, Cooper JM. Mitochondria in the etiology and pathogenesis of parkinson\u2019s disease. Ann Neurol. 1998;44:S89\u201398. ArticleCASPubMedGoogle Scholar Park J-S, Davis RL, Sue CM. Mitochondrial Dysfunction in Parkinson\u2019s Disease: New Mechanistic Insights and Therapeutic Perspectives. Curr Neurol Neurosci Rep. 2018;18(5):21.ArticlePubMedPubMed CentralGoogle Scholar Park J-S, Davis RL, Sue CM. Mitochondrial Dysfunction in Parkinson\u2019s Disease: New Mechanistic Insights and Therapeutic Perspectives. Curr Neurol Neurosci Rep. 2018;18(5):21. ArticlePubMedPubMed CentralGoogle Scholar Park J-S, Davis RL, Sue CM. Mitochondrial Dysfunction in Parkinson\u2019s Disease: New Mechanistic Insights and Therapeutic Perspectives. Curr Neurol Neurosci Rep. 2018;18(5):21. ArticlePubMedPubMed CentralGoogle Scholar Jenner P, Olanow CW. Oxidative stress and the pathogenesis of Parkinson\u2019s disease. Neurology. 1996;47:161S.ArticleGoogle Scholar Jenner P, Olanow CW. Oxidative stress and the pathogenesis of Parkinson\u2019s disease. Neurology. 1996;47:161S. ArticleGoogle Scholar Jenner P, Olanow CW. Oxidative stress and the pathogenesis of Parkinson\u2019s disease. Neurology. 1996;47:161S. ArticleGoogle Scholar Blesa J, Trigo-Damas I, Quiroga-Varela A, Jackson-Lewis VR. Oxidative stress and Parkinson\u2019s disease. Front Neuroanatomy. 2015;9:91.ArticleGoogle Scholar Blesa J, Trigo-Damas I, Quiroga-Varela A, Jackson-Lewis VR. Oxidative stress and Parkinson\u2019s disease. Front Neuroanatomy. 2015;9:91. ArticleGoogle Scholar Blesa J, Trigo-Damas I, Quiroga-Varela A, Jackson-Lewis VR. Oxidative stress and Parkinson\u2019s disease. Front Neuroanatomy. 2015;9:91. ArticleGoogle Scholar Hirsch EC, Hunot S. Neuroinflammation in Parkinson\u2019s disease: a target for neuroprotection? The Lancet Neurology. 2009;8:382\u201397.ArticleCASPubMedGoogle Scholar Hirsch EC, Hunot S. Neuroinflammation in Parkinson\u2019s disease: a target for neuroprotection? The Lancet Neurology. 2009;8:382\u201397. ArticleCASPubMedGoogle Scholar Hirsch EC, Hunot S. Neuroinflammation in Parkinson\u2019s disease: a target for neuroprotection? The Lancet Neurology. 2009;8:382\u201397. ArticleCASPubMedGoogle Scholar Wang Q, Liu Y, Zhou J. Neuroinflammation in Parkinson\u2019s disease and its potential as therapeutic target. Transl Neurodegener. 2015;4:19.ArticlePubMedPubMed CentralGoogle Scholar Wang Q, Liu Y, Zhou J. Neuroinflammation in Parkinson\u2019s disease and its potential as therapeutic target. Transl Neurodegener. 2015;4:19. ArticlePubMedPubMed CentralGoogle Scholar Wang Q, Liu Y, Zhou J. Neuroinflammation in Parkinson\u2019s disease and its potential as therapeutic target. Transl Neurodegener. 2015;4:19. ArticlePubMedPubMed CentralGoogle Scholar Ambrosi G, Cerri S, Blandini F. A further update on the role of excitotoxicity in the pathogenesis of Parkinson\u2019s disease. J Neural Transm (Vienna, Austria : 1996). 2014;121:849\u201359.ArticleCASGoogle Scholar Ambrosi G, Cerri S, Blandini F. A further update on the role of excitotoxicity in the pathogenesis of Parkinson\u2019s disease. J Neural Transm (Vienna, Austria : 1996). 2014;121:849\u201359. ArticleCASGoogle Scholar Ambrosi G, Cerri S, Blandini F. A further update on the role of excitotoxicity in the pathogenesis of Parkinson\u2019s disease. J Neural Transm (Vienna, Austria : 1996). 2014;121:849\u201359. ArticleCASGoogle Scholar van der Brug MP, Singleton A, Gasser T, Lewis PA. Parkinson\u2019s disease: From human genetics to clinical trials. Sci Transl Med. 2015;7:205ps220.Google Scholar van der Brug MP, Singleton A, Gasser T, Lewis PA. Parkinson\u2019s disease: From human genetics to clinical trials. Sci Transl Med. 2015;7:205ps220. Google Scholar van der Brug MP, Singleton A, Gasser T, Lewis PA. Parkinson\u2019s disease: From human genetics to clinical trials. Sci Transl Med. 2015;7:205ps220. Google Scholar Funayama M, Nishioka K, Li Y, Hattori N. Molecular genetics of Parkinson's disease: Contributions and global trends. J Hum Genet. 2022.https://doi.org/10.1038/s10038-022-01058-5. Funayama M, Nishioka K, Li Y, Hattori N. Molecular genetics of Parkinson's disease: Contributions and global trends. J Hum Genet. 2022.https://doi.org/10.1038/s10038-022-01058-5. Funayama M, Nishioka K, Li Y, Hattori N. Molecular genetics of Parkinson's disease: Contributions and global trends. J Hum Genet. 2022.https://doi.org/10.1038/s10038-022-01058-5. McNaught KS, Olanow CW. Protein aggregation in the pathogenesis of familial and sporadic Parkinson\u2019s disease. Neurobiol Aging. 2006;27:530\u201345.ArticleCASPubMedGoogle Scholar McNaught KS, Olanow CW. Protein aggregation in the pathogenesis of familial and sporadic Parkinson\u2019s disease. Neurobiol Aging. 2006;27:530\u201345. ArticleCASPubMedGoogle Scholar McNaught KS, Olanow CW. Protein aggregation in the pathogenesis of familial and sporadic Parkinson\u2019s disease. Neurobiol Aging. 2006;27:530\u201345. ArticleCASPubMedGoogle Scholar Akhtar RS, Xie SX, Brennan L, Pontecorvo MJ, Hurtig HI, Trojanowski JQ, Weintraub D, Siderowf AD. Amyloid-Beta Positron Emission Tomography Imaging of Alzheimer\u2019s Pathology in Parkinson\u2019s Disease Dementia. Mov Disord Clin Pract. 2016;3:367\u201375.ArticlePubMedPubMed CentralGoogle Scholar Akhtar RS, Xie SX, Brennan L, Pontecorvo MJ, Hurtig HI, Trojanowski JQ, Weintraub D, Siderowf AD. Amyloid-Beta Positron Emission Tomography Imaging of Alzheimer\u2019s Pathology in Parkinson\u2019s Disease Dementia. Mov Disord Clin Pract. 2016;3:367\u201375. ArticlePubMedPubMed CentralGoogle Scholar Akhtar RS, Xie SX, Brennan L, Pontecorvo MJ, Hurtig HI, Trojanowski JQ, Weintraub D, Siderowf AD. Amyloid-Beta Positron Emission Tomography Imaging of Alzheimer\u2019s Pathology in Parkinson\u2019s Disease Dementia. Mov Disord Clin Pract. 2016;3:367\u201375. ArticlePubMedPubMed CentralGoogle Scholar Murphy MP, Bayir H, Belousov V, Chang CJ, Davies KJA, Davies MJ, Dick TP, Finkel T, Forman HJ, Janssen-Heininger Y, et al. Guidelines for measuring reactive oxygen species and oxidative damage in cells and in vivo. Nat Metab. 2022;4:651\u201362.ArticlePubMedPubMed CentralGoogle Scholar Murphy MP, Bayir H, Belousov V, Chang CJ, Davies KJA, Davies MJ, Dick TP, Finkel T, Forman HJ, Janssen-Heininger Y, et al. Guidelines for measuring reactive oxygen species and oxidative damage in cells and in vivo. Nat Metab. 2022;4:651\u201362. ArticlePubMedPubMed CentralGoogle Scholar Murphy MP, Bayir H, Belousov V, Chang CJ, Davies KJA, Davies MJ, Dick TP, Finkel T, Forman HJ, Janssen-Heininger Y, et al. Guidelines for measuring reactive oxygen species and oxidative damage in cells and in vivo. Nat Metab. 2022;4:651\u201362. ArticlePubMedPubMed CentralGoogle Scholar Chaudhuri KR, Schapira AH. Non-motor symptoms of Parkinson\u2019s disease: dopaminergic pathophysiology and treatment. Lancet Neurol. 2009;8:464\u201374.ArticleCASPubMedGoogle Scholar Chaudhuri KR, Schapira AH. Non-motor symptoms of Parkinson\u2019s disease: dopaminergic pathophysiology and treatment. Lancet Neurol. 2009;8:464\u201374. ArticleCASPubMedGoogle Scholar Chaudhuri KR, Schapira AH. Non-motor symptoms of Parkinson\u2019s disease: dopaminergic pathophysiology and treatment. Lancet Neurol. 2009;8:464\u201374. ArticleCASPubMedGoogle Scholar Braak H, Braak E. Pathoanatomy of Parkinson\u2019s disease. J Neurol. 2000;247:II3\u201310.ArticlePubMedGoogle Scholar Braak H, Braak E. Pathoanatomy of Parkinson\u2019s disease. J Neurol. 2000;247:II3\u201310. ArticlePubMedGoogle Scholar Braak H, Braak E. Pathoanatomy of Parkinson\u2019s disease. J Neurol. 2000;247:II3\u201310. ArticlePubMedGoogle Scholar Rascol O, Payoux P, Ory F, Ferreira JJ, Brefel-Courbon C, Montastruc JL. Limitations of current Parkinson\u2019s disease therapy. Ann Neurol. 2003;53(Suppl 3):S3-12; discussion S12-5.ArticleCASPubMedGoogle Scholar Rascol O, Payoux P, Ory F, Ferreira JJ, Brefel-Courbon C, Montastruc JL. Limitations of current Parkinson\u2019s disease therapy. Ann Neurol. 2003;53(Suppl 3):S3-12; discussion S12-5. ArticleCASPubMedGoogle Scholar Rascol O, Payoux P, Ory F, Ferreira JJ, Brefel-Courbon C, Montastruc JL. Limitations of current Parkinson\u2019s disease therapy. Ann Neurol. 2003;53(Suppl 3):S3-12; discussion S12-5. ArticleCASPubMedGoogle Scholar Armstrong MJ, Okun MS. Diagnosis and Treatment of Parkinson Disease: A Review. JAMA. 2020;323:548\u201360.ArticlePubMedGoogle Scholar Armstrong MJ, Okun MS. Diagnosis and Treatment of Parkinson Disease: A Review. JAMA. 2020;323:548\u201360. ArticlePubMedGoogle Scholar Armstrong MJ, Okun MS. Diagnosis and Treatment of Parkinson Disease: A Review. JAMA. 2020;323:548\u201360. ArticlePubMedGoogle Scholar Verger A, Grimaldi S, Ribeiro MJ, Frismand S, Guedj E. Single Photon Emission Computed Tomography/Positron Emission Tomography Molecular Imaging for Parkinsonism: A Fast-Developing Field. Ann Neurol. 2021;90:711\u20139.ArticlePubMedPubMed CentralGoogle Scholar Verger A, Grimaldi S, Ribeiro MJ, Frismand S, Guedj E. Single Photon Emission Computed Tomography/Positron Emission Tomography Molecular Imaging for Parkinsonism: A Fast-Developing Field. Ann Neurol. 2021;90:711\u20139. ArticlePubMedPubMed CentralGoogle Scholar Verger A, Grimaldi S, Ribeiro MJ, Frismand S, Guedj E. Single Photon Emission Computed Tomography/Positron Emission Tomography Molecular Imaging for Parkinsonism: A Fast-Developing Field. Ann Neurol. 2021;90:711\u20139. ArticlePubMedPubMed CentralGoogle Scholar Nerella SG, Singh P, Sanam T, Digwal CS. PET Molecular Imaging in Drug Development: The Imaging and Chemistry Perspective. Front Med (Lausanne). 2022;9:812270.ArticlePubMedGoogle Scholar Nerella SG, Singh P, Sanam T, Digwal CS. PET Molecular Imaging in Drug Development: The Imaging and Chemistry Perspective. Front Med (Lausanne). 2022;9:812270. ArticlePubMedGoogle Scholar Nerella SG, Singh P, Sanam T, Digwal CS. PET Molecular Imaging in Drug Development: The Imaging and Chemistry Perspective. Front Med (Lausanne). 2022;9:812270. ArticlePubMedGoogle Scholar Lu FM, Yuan Z. PET/SPECT molecular imaging in clinical neuroscience: recent advances in the investigation of CNS diseases. Quant Imaging Med Surg. 2015;5:433\u201347.PubMedPubMed CentralGoogle Scholar Lu FM, Yuan Z. PET/SPECT molecular imaging in clinical neuroscience: recent advances in the investigation of CNS diseases. Quant Imaging Med Surg. 2015;5:433\u201347. PubMedPubMed CentralGoogle Scholar Lu FM, Yuan Z. PET/SPECT molecular imaging in clinical neuroscience: recent advances in the investigation of CNS diseases. Quant Imaging Med Surg. 2015;5:433\u201347. PubMedPubMed CentralGoogle Scholar Ametamey SM, Honer M, Schubiger PA. Molecular imaging with PET. Chem Rev. 2008;108:1501\u201316.ArticleCASPubMedGoogle Scholar Ametamey SM, Honer M, Schubiger PA. Molecular imaging with PET. Chem Rev. 2008;108:1501\u201316. ArticleCASPubMedGoogle Scholar Ametamey SM, Honer M, Schubiger PA. Molecular imaging with PET. Chem Rev. 2008;108:1501\u201316. ArticleCASPubMedGoogle Scholar Zhu L, Ploessl K, Kung HF. PET/SPECT imaging agents for neurodegenerative diseases. Chem Soc Rev. 2014;43:6683\u201391.ArticleCASPubMedPubMed CentralGoogle Scholar Zhu L, Ploessl K, Kung HF. PET/SPECT imaging agents for neurodegenerative diseases. Chem Soc Rev. 2014;43:6683\u201391. ArticleCASPubMedPubMed CentralGoogle Scholar Zhu L, Ploessl K, Kung HF. PET/SPECT imaging agents for neurodegenerative diseases. Chem Soc Rev. 2014;43:6683\u201391. ArticleCASPubMedPubMed CentralGoogle Scholar Pavese N, Brooks DJ. Imaging neurodegeneration in Parkinson\u2019s disease. Biochem Biophys Acta. 2009;1792:722\u20139.CASPubMedGoogle Scholar Pavese N, Brooks DJ. Imaging neurodegeneration in Parkinson\u2019s disease. Biochem Biophys Acta. 2009;1792:722\u20139. CASPubMedGoogle Scholar Pavese N, Brooks DJ. Imaging neurodegeneration in Parkinson\u2019s disease. Biochem Biophys Acta. 2009;1792:722\u20139. CASPubMedGoogle Scholar Matthews DC, Lerman H, Lukic A, Andrews RD, Mirelman A, Wernick MN, Giladi N, Strother SC, Evans KC, Cedarbaum JM, Even-Sapir E. FDG PET Parkinson\u2019s disease-related pattern as a biomarker for clinical trials in early stage disease. Neuroimage Clin. 2018;20:572\u20139.ArticlePubMedPubMed CentralGoogle Scholar Matthews DC, Lerman H, Lukic A, Andrews RD, Mirelman A, Wernick MN, Giladi N, Strother SC, Evans KC, Cedarbaum JM, Even-Sapir E. FDG PET Parkinson\u2019s disease-related pattern as a biomarker for clinical trials in early stage disease. Neuroimage Clin. 2018;20:572\u20139. ArticlePubMedPubMed CentralGoogle Scholar Matthews DC, Lerman H, Lukic A, Andrews RD, Mirelman A, Wernick MN, Giladi N, Strother SC, Evans KC, Cedarbaum JM, Even-Sapir E. FDG PET Parkinson\u2019s disease-related pattern as a biomarker for clinical trials in early stage disease. Neuroimage Clin. 2018;20:572\u20139. ArticlePubMedPubMed CentralGoogle Scholar Meyer PT, Frings L, R\u00fccker G, Hellwig S. (18)F-FDG PET in Parkinsonism: Differential Diagnosis and Evaluation of Cognitive Impairment. J Nucl Med. 2017;58:1888\u201398.ArticleCASPubMedGoogle Scholar Meyer PT, Frings L, R\u00fccker G, Hellwig S. (18)F-FDG PET in Parkinsonism: Differential Diagnosis and Evaluation of Cognitive Impairment. J Nucl Med. 2017;58:1888\u201398. ArticleCASPubMedGoogle Scholar Meyer PT, Frings L, R\u00fccker G, Hellwig S. (18)F-FDG PET in Parkinsonism: Differential Diagnosis and Evaluation of Cognitive Impairment. J Nucl Med. 2017;58:1888\u201398. ArticleCASPubMedGoogle Scholar Garraux G, Phillips C, Schrouff J, Kreisler A, Lemaire C, Degueldre C, Delcour C, Hustinx R, Luxen A, Dest\u00e9e A, Salmon E. Multiclass classification of FDG PET scans for the distinction between Parkinson\u2019s disease and atypical parkinsonian syndromes. Neuroimage Clin. 2013;2:883\u201393.ArticlePubMedPubMed CentralGoogle Scholar Garraux G, Phillips C, Schrouff J, Kreisler A, Lemaire C, Degueldre C, Delcour C, Hustinx R, Luxen A, Dest\u00e9e A, Salmon E. Multiclass classification of FDG PET scans for the distinction between Parkinson\u2019s disease and atypical parkinsonian syndromes. Neuroimage Clin. 2013;2:883\u201393. ArticlePubMedPubMed CentralGoogle Scholar Garraux G, Phillips C, Schrouff J, Kreisler A, Lemaire C, Degueldre C, Delcour C, Hustinx R, Luxen A, Dest\u00e9e A, Salmon E. Multiclass classification of FDG PET scans for the distinction between Parkinson\u2019s disease and atypical parkinsonian syndromes. Neuroimage Clin. 2013;2:883\u201393. ArticlePubMedPubMed CentralGoogle Scholar Mudali D, Teune LK, Renken RJ, Leenders KL, Roerdink JB. Classification of Parkinsonian syndromes from FDG-PET brain data using decision trees with SSM/PCA features. Comput Math Methods Med. 2015;2015:136921.ArticleCASPubMedPubMed CentralGoogle Scholar Mudali D, Teune LK, Renken RJ, Leenders KL, Roerdink JB. Classification of Parkinsonian syndromes from FDG-PET brain data using decision trees with SSM/PCA features. Comput Math Methods Med. 2015;2015:136921. ArticleCASPubMedPubMed CentralGoogle Scholar Mudali D, Teune LK, Renken RJ, Leenders KL, Roerdink JB. Classification of Parkinsonian syndromes from FDG-PET brain data using decision trees with SSM/PCA features. Comput Math Methods Med. 2015;2015:136921. ArticleCASPubMedPubMed CentralGoogle Scholar Nalls MA, Pankratz N, Lill CM, Do CB, Hernandez DG, Saad M, DeStefano AL, Kara E, Bras J, Sharma M, et al. Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson\u2019s disease. Nat Genet. 2014;46:989\u201393.ArticleCASPubMedPubMed CentralGoogle Scholar Nalls MA, Pankratz N, Lill CM, Do CB, Hernandez DG, Saad M, DeStefano AL, Kara E, Bras J, Sharma M, et al. Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson\u2019s disease. Nat Genet. 2014;46:989\u201393. ArticleCASPubMedPubMed CentralGoogle Scholar Nalls MA, Pankratz N, Lill CM, Do CB, Hernandez DG, Saad M, DeStefano AL, Kara E, Bras J, Sharma M, et al. Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson\u2019s disease. Nat Genet. 2014;46:989\u201393. ArticleCASPubMedPubMed CentralGoogle Scholar Wassouf Z, Schulze-Hentrich JM. Alpha-synuclein at the nexus of genes and environment: the impact of environmental enrichment and stress on brain health and disease. J Neurochem. 2019;150:591\u2013604.ArticleCASPubMedPubMed CentralGoogle Scholar Wassouf Z, Schulze-Hentrich JM. Alpha-synuclein at the nexus of genes and environment: the impact of environmental enrichment and stress on brain health and disease. J Neurochem. 2019;150:591\u2013604. ArticleCASPubMedPubMed CentralGoogle Scholar Wassouf Z, Schulze-Hentrich JM. Alpha-synuclein at the nexus of genes and environment: the impact of environmental enrichment and stress on brain health and disease. J Neurochem. 2019;150:591\u2013604. ArticleCASPubMedPubMed CentralGoogle Scholar Goedert M. Alpha-synuclein and neurodegenerative diseases. Nat Rev Neurosci. 2001;2:492\u2013501.ArticleCASPubMedGoogle Scholar Goedert M. Alpha-synuclein and neurodegenerative diseases. Nat Rev Neurosci. 2001;2:492\u2013501. ArticleCASPubMedGoogle Scholar Goedert M. Alpha-synuclein and neurodegenerative diseases. Nat Rev Neurosci. 2001;2:492\u2013501. ArticleCASPubMedGoogle Scholar Vekrellis K, Xilouri M, Emmanouilidou E, Rideout HJ, Stefanis L. Pathological roles of \u03b1-synuclein in neurological disorders. Lancet Neurol. 2011;10:1015\u201325.ArticleCASPubMedGoogle Scholar Vekrellis K, Xilouri M, Emmanouilidou E, Rideout HJ, Stefanis L. Pathological roles of \u03b1-synuclein in neurological disorders. Lancet Neurol. 2011;10:1015\u201325. ArticleCASPubMedGoogle Scholar Vekrellis K, Xilouri M, Emmanouilidou E, Rideout HJ, Stefanis L. Pathological roles of \u03b1-synuclein in neurological disorders. Lancet Neurol. 2011;10:1015\u201325. ArticleCASPubMedGoogle Scholar Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. Alpha-synuclein in Lewy bodies. Nature. 1997;388:839\u201340.ArticleCASPubMedGoogle Scholar Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. Alpha-synuclein in Lewy bodies. Nature. 1997;388:839\u201340. ArticleCASPubMedGoogle Scholar Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. Alpha-synuclein in Lewy bodies. Nature. 1997;388:839\u201340. ArticleCASPubMedGoogle Scholar Wakabayashi K, Tanji K, Odagiri S, Miki Y, Mori F, Takahashi H. The Lewy Body in Parkinson\u2019s Disease and Related Neurodegenerative Disorders. Mol Neurobiol. 2013;47:495\u2013508.ArticleCASPubMedGoogle Scholar Wakabayashi K, Tanji K, Odagiri S, Miki Y, Mori F, Takahashi H. The Lewy Body in Parkinson\u2019s Disease and Related Neurodegenerative Disorders. Mol Neurobiol. 2013;47:495\u2013508. ArticleCASPubMedGoogle Scholar Wakabayashi K, Tanji K, Odagiri S, Miki Y, Mori F, Takahashi H. The Lewy Body in Parkinson\u2019s Disease and Related Neurodegenerative Disorders. Mol Neurobiol. 2013;47:495\u2013508. ArticleCASPubMedGoogle Scholar Benskey MJ, Perez RG, Manfredsson FP. The contribution of alpha synuclein to neuronal survival and function - Implications for Parkinson\u2019s disease. J Neurochem. 2016;137:331\u201359.ArticleCASPubMedPubMed CentralGoogle Scholar Benskey MJ, Perez RG, Manfredsson FP. The contribution of alpha synuclein to neuronal survival and function - Implications for Parkinson\u2019s disease. J Neurochem. 2016;137:331\u201359. ArticleCASPubMedPubMed CentralGoogle Scholar Benskey MJ, Perez RG, Manfredsson FP. The contribution of alpha synuclein to neuronal survival and function - Implications for Parkinson\u2019s disease. J Neurochem. 2016;137:331\u201359. ArticleCASPubMedPubMed CentralGoogle Scholar Polymeropoulos MH. Mutation in the -Synuclein Gene Identified in Families with Parkinson\u2019s Disease. Science. 1997;276:2045\u20137.ArticleCASPubMedGoogle Scholar Polymeropoulos MH. Mutation in the -Synuclein Gene Identified in Families with Parkinson\u2019s Disease. Science. 1997;276:2045\u20137. ArticleCASPubMedGoogle Scholar Polymeropoulos MH. Mutation in the -Synuclein Gene Identified in Families with Parkinson\u2019s Disease. Science. 1997;276:2045\u20137. ArticleCASPubMedGoogle Scholar Kruger R, Kuhn W, Muller T, Woitalla D, Graeber M, Kosel S, Przuntek H, Epplen JT, Schols L, Riess O. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson\u2019s disease. Nat Genet. 1998;18:106\u20138.ArticleCASPubMedGoogle Scholar Kruger R, Kuhn W, Muller T, Woitalla D, Graeber M, Kosel S, Przuntek H, Epplen JT, Schols L, Riess O. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson\u2019s disease. Nat Genet. 1998;18:106\u20138. ArticleCASPubMedGoogle Scholar Kruger R, Kuhn W, Muller T, Woitalla D, Graeber M, Kosel S, Przuntek H, Epplen JT, Schols L, Riess O. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson\u2019s disease. Nat Genet. 1998;18:106\u20138. ArticleCASPubMedGoogle Scholar Zarranz JJ, Alegre J, G\u00f3mez-Esteban JC, Lezcano E, Ros R, Ampuero I, Vidal L, Hoenicka J, Rodriguez O, Atar\u00e9s B, et al. The new mutation, E46K, of \u03b1-synuclein causes parkinson and Lewy body dementia. Ann Neurol. 2004;55:164\u201373.ArticleCASPubMedGoogle Scholar Zarranz JJ, Alegre J, G\u00f3mez-Esteban JC, Lezcano E, Ros R, Ampuero I, Vidal L, Hoenicka J, Rodriguez O, Atar\u00e9s B, et al. The new mutation, E46K, of \u03b1-synuclein causes parkinson and Lewy body dementia. Ann Neurol. 2004;55:164\u201373. ArticleCASPubMedGoogle Scholar Zarranz JJ, Alegre J, G\u00f3mez-Esteban JC, Lezcano E, Ros R, Ampuero I, Vidal L, Hoenicka J, Rodriguez O, Atar\u00e9s B, et al. The new mutation, E46K, of \u03b1-synuclein causes parkinson and Lewy body dementia. Ann Neurol. 2004;55:164\u201373. ArticleCASPubMedGoogle Scholar Appel-Cresswell S, Vilarino-Guell C, Encarnacion M, Sherman H, Yu I, Shah B, Weir D, Thompson C, Szu-Tu C, Trinh J, et al. Alpha-synuclein p.H50Q, a novel pathogenic mutation for Parkinson\u2019s disease. Mov Disord. 2013;28:811\u20133.ArticleCASPubMedGoogle Scholar Appel-Cresswell S, Vilarino-Guell C, Encarnacion M, Sherman H, Yu I, Shah B, Weir D, Thompson C, Szu-Tu C, Trinh J, et al. Alpha-synuclein p.H50Q, a novel pathogenic mutation for Parkinson\u2019s disease. Mov Disord. 2013;28:811\u20133. ArticleCASPubMedGoogle Scholar Appel-Cresswell S, Vilarino-Guell C, Encarnacion M, Sherman H, Yu I, Shah B, Weir D, Thompson C, Szu-Tu C, Trinh J, et al. Alpha-synuclein p.H50Q, a novel pathogenic mutation for Parkinson\u2019s disease. Mov Disord. 2013;28:811\u20133. ArticleCASPubMedGoogle Scholar Kiely AP, Asi YT, Kara E, Limousin P, Ling H, Lewis P, Proukakis C, Quinn N, Lees AJ, Hardy J, et al. \u03b1-Synucleinopathy associated with G51D SNCA mutation: a link between Parkinson\u2019s disease and multiple system atrophy? Acta Neuropathol. 2013;125:753\u201369.ArticleCASPubMedPubMed CentralGoogle Scholar Kiely AP, Asi YT, Kara E, Limousin P, Ling H, Lewis P, Proukakis C, Quinn N, Lees AJ, Hardy J, et al. \u03b1-Synucleinopathy associated with G51D SNCA mutation: a link between Parkinson\u2019s disease and multiple system atrophy? Acta Neuropathol. 2013;125:753\u201369. ArticleCASPubMedPubMed CentralGoogle Scholar Kiely AP, Asi YT, Kara E, Limousin P, Ling H, Lewis P, Proukakis C, Quinn N, Lees AJ, Hardy J, et al. \u03b1-Synucleinopathy associated with G51D SNCA mutation: a link between Parkinson\u2019s disease and multiple system atrophy? Acta Neuropathol. 2013;125:753\u201369. ArticleCASPubMedPubMed CentralGoogle Scholar Pasanen P, Myllykangas L, Siitonen M, Raunio A, Kaakkola S, Lyytinen J, Tienari PJ, P\u00f6yh\u00f6nen M, Paetau A. A novel \u03b1-synuclein mutation A53E associated with atypical multiple system atrophy and Parkinson\u2019s disease-type pathology. Neurobiol Aging. 2014;35:2180.e2181-2180.e2185.ArticleGoogle Scholar Pasanen P, Myllykangas L, Siitonen M, Raunio A, Kaakkola S, Lyytinen J, Tienari PJ, P\u00f6yh\u00f6nen M, Paetau A. A novel \u03b1-synuclein mutation A53E associated with atypical multiple system atrophy and Parkinson\u2019s disease-type pathology. Neurobiol Aging. 2014;35:2180.e2181-2180.e2185. ArticleGoogle Scholar Pasanen P, Myllykangas L, Siitonen M, Raunio A, Kaakkola S, Lyytinen J, Tienari PJ, P\u00f6yh\u00f6nen M, Paetau A. A novel \u03b1-synuclein mutation A53E associated with atypical multiple system atrophy and Parkinson\u2019s disease-type pathology. Neurobiol Aging. 2014;35:2180.e2181-2180.e2185. ArticleGoogle Scholar Lesage S, Anheim M, Letournel F, Bousset L, Honor\u00e9 A, Rozas N, Pieri L, Madiona K, D\u00fcrr A, Melki R, et al. G51D \u03b1-synuclein mutation causes a novel Parkinsonian-pyramidal syndrome. Ann Neurol. 2013;73:459\u201371.ArticleCASPubMedGoogle Scholar Lesage S, Anheim M, Letournel F, Bousset L, Honor\u00e9 A, Rozas N, Pieri L, Madiona K, D\u00fcrr A, Melki R, et al. G51D \u03b1-synuclein mutation causes a novel Parkinsonian-pyramidal syndrome. Ann Neurol. 2013;73:459\u201371. ArticleCASPubMedGoogle Scholar Lesage S, Anheim M, Letournel F, Bousset L, Honor\u00e9 A, Rozas N, Pieri L, Madiona K, D\u00fcrr A, Melki R, et al. G51D \u03b1-synuclein mutation causes a novel Parkinsonian-pyramidal syndrome. Ann Neurol. 2013;73:459\u201371. ArticleCASPubMedGoogle Scholar Proukakis C, Dudzik CG, Brier T, MacKay DS, Cooper JM, Millhauser GL, Houlden H, Schapira AH. A novel \u03b1-synuclein missense mutation in Parkinson disease. Neurology. 2013;80:1062.ArticlePubMedPubMed CentralGoogle Scholar Proukakis C, Dudzik CG, Brier T, MacKay DS, Cooper JM, Millhauser GL, Houlden H, Schapira AH. A novel \u03b1-synuclein missense mutation in Parkinson disease. Neurology. 2013;80:1062. ArticlePubMedPubMed CentralGoogle Scholar Proukakis C, Dudzik CG, Brier T, MacKay DS, Cooper JM, Millhauser GL, Houlden H, Schapira AH. A novel \u03b1-synuclein missense mutation in Parkinson disease. Neurology. 2013;80:1062. ArticlePubMedPubMed CentralGoogle Scholar Phillipson OT. Alpha-synuclein, epigenetics, mitochondria, metabolism, calcium traffic, & circadian dysfunction in Parkinson\u2019s disease. An integrated strategy for management. Ageing Res Rev. 2017;40:149\u201367.ArticleCASPubMedGoogle Scholar Phillipson OT. Alpha-synuclein, epigenetics, mitochondria, metabolism, calcium traffic, & circadian dysfunction in Parkinson\u2019s disease. An integrated strategy for management. Ageing Res Rev. 2017;40:149\u201367. ArticleCASPubMedGoogle Scholar Phillipson OT. Alpha-synuclein, epigenetics, mitochondria, metabolism, calcium traffic, & circadian dysfunction in Parkinson\u2019s disease. An integrated strategy for management. Ageing Res Rev. 2017;40:149\u201367. ArticleCASPubMedGoogle Scholar Yoshino H, Hirano M, Stoessl AJ, Imamichi Y, Ikeda A, Li Y, Funayama M, Yamada I, Nakamura Y, Sossi V, et al. Homozygous alpha-synuclein p.A53V in familial Parkinson\u2019s disease. Neurobiol Aging. 2017;57(248):e247-248 e212.Google Scholar Yoshino H, Hirano M, Stoessl AJ, Imamichi Y, Ikeda A, Li Y, Funayama M, Yamada I, Nakamura Y, Sossi V, et al. Homozygous alpha-synuclein p.A53V in familial Parkinson\u2019s disease. Neurobiol Aging. 2017;57(248):e247-248 e212. Google Scholar Yoshino H, Hirano M, Stoessl AJ, Imamichi Y, Ikeda A, Li Y, Funayama M, Yamada I, Nakamura Y, Sossi V, et al. Homozygous alpha-synuclein p.A53V in familial Parkinson\u2019s disease. Neurobiol Aging. 2017;57(248):e247-248 e212. Google Scholar Chavarr\u00eda C, Souza JM. Oxidation and nitration of \u03b1-synuclein and their implications in neurodegenerative diseases. Arch Biochem Biophys. 2013;533:25\u201332.ArticlePubMedGoogle Scholar Chavarr\u00eda C, Souza JM. Oxidation and nitration of \u03b1-synuclein and their implications in neurodegenerative diseases. Arch Biochem Biophys. 2013;533:25\u201332. ArticlePubMedGoogle Scholar Chavarr\u00eda C, Souza JM. Oxidation and nitration of \u03b1-synuclein and their implications in neurodegenerative diseases. Arch Biochem Biophys. 2013;533:25\u201332. ArticlePubMedGoogle Scholar Shimura H, Schlossmacher MG, Hattori N, Frosch MP, Trockenbacher A, Schneider R, Mizuno Y, Kosik KS, Selkoe DJ. Ubiquitination of a new form of alpha-synuclein by parkin from human brain: implications for Parkinson\u2019s disease. Science. 2001;293:263\u20139.ArticleCASPubMedGoogle Scholar Shimura H, Schlossmacher MG, Hattori N, Frosch MP, Trockenbacher A, Schneider R, Mizuno Y, Kosik KS, Selkoe DJ. Ubiquitination of a new form of alpha-synuclein by parkin from human brain: implications for Parkinson\u2019s disease. Science. 2001;293:263\u20139. ArticleCASPubMedGoogle Scholar Shimura H, Schlossmacher MG, Hattori N, Frosch MP, Trockenbacher A, Schneider R, Mizuno Y, Kosik KS, Selkoe DJ. Ubiquitination of a new form of alpha-synuclein by parkin from human brain: implications for Parkinson\u2019s disease. Science. 2001;293:263\u20139. ArticleCASPubMedGoogle Scholar Paleologou KE, Oueslati A, Shakked G, Rospigliosi CC, Kim HY, Lamberto GR, Fernandez CO, Schmid A, Chegini F, Gai WP, et al. Phosphorylation at S87 Is Enhanced in Synucleinopathies, Inhibits -Synuclein Oligomerization, and Influences Synuclein-Membrane Interactions. J Neurosci. 2010;30:3184\u201398.ArticleCASPubMedPubMed CentralGoogle Scholar Paleologou KE, Oueslati A, Shakked G, Rospigliosi CC, Kim HY, Lamberto GR, Fernandez CO, Schmid A, Chegini F, Gai WP, et al. Phosphorylation at S87 Is Enhanced in Synucleinopathies, Inhibits -Synuclein Oligomerization, and Influences Synuclein-Membrane Interactions. J Neurosci. 2010;30:3184\u201398. ArticleCASPubMedPubMed CentralGoogle Scholar Paleologou KE, Oueslati A, Shakked G, Rospigliosi CC, Kim HY, Lamberto GR, Fernandez CO, Schmid A, Chegini F, Gai WP, et al. Phosphorylation at S87 Is Enhanced in Synucleinopathies, Inhibits -Synuclein Oligomerization, and Influences Synuclein-Membrane Interactions. J Neurosci. 2010;30:3184\u201398. ArticleCASPubMedPubMed CentralGoogle Scholar Shah M, Seibyl J, Cartier A, Bhatt R, Catafau AM. Molecular imaging insights into neurodegeneration: focus on alpha-synuclein radiotracers. J Nucl Med. 2014;55:1397\u2013400.ArticleCASPubMedGoogle Scholar Shah M, Seibyl J, Cartier A, Bhatt R, Catafau AM. Molecular imaging insights into neurodegeneration: focus on alpha-synuclein radiotracers. J Nucl Med. 2014;55:1397\u2013400. ArticleCASPubMedGoogle Scholar Shah M, Seibyl J, Cartier A, Bhatt R, Catafau AM. Molecular imaging insights into neurodegeneration: focus on alpha-synuclein radiotracers. J Nucl Med. 2014;55:1397\u2013400. ArticleCASPubMedGoogle Scholar Ye L, Velasco A, Fraser G, Beach TG, Sue L, Osredkar T, Libri V, Spillantini MG, Goedert M, Lockhart A. In vitro high affinity alpha-synuclein binding sites for the amyloid imaging agent PIB are not matched by binding to Lewy bodies in postmortem human brain. J Neurochem. 2008;105:1428\u201337.ArticleCASPubMedPubMed CentralGoogle Scholar Ye L, Velasco A, Fraser G, Beach TG, Sue L, Osredkar T, Libri V, Spillantini MG, Goedert M, Lockhart A. In vitro high affinity alpha-synuclein binding sites for the amyloid imaging agent PIB are not matched by binding to Lewy bodies in postmortem human brain. J Neurochem. 2008;105:1428\u201337. ArticleCASPubMedPubMed CentralGoogle Scholar Ye L, Velasco A, Fraser G, Beach TG, Sue L, Osredkar T, Libri V, Spillantini MG, Goedert M, Lockhart A. In vitro high affinity alpha-synuclein binding sites for the amyloid imaging agent PIB are not matched by binding to Lewy bodies in postmortem human brain. J Neurochem. 2008;105:1428\u201337. ArticleCASPubMedPubMed CentralGoogle Scholar Fodero-Tavoletti MT, Smith DP, McLean CA, Adlard PA, Barnham KJ, Foster LE, Leone L, Perez K, Cortes M, Culvenor JG, et al. In vitro characterization of Pittsburgh compound-B binding to Lewy bodies. J Neurosci. 2007;27:10365\u201371.ArticleCASPubMedPubMed CentralGoogle Scholar Fodero-Tavoletti MT, Smith DP, McLean CA, Adlard PA, Barnham KJ, Foster LE, Leone L, Perez K, Cortes M, Culvenor JG, et al. In vitro characterization of Pittsburgh compound-B binding to Lewy bodies. J Neurosci. 2007;27:10365\u201371. ArticleCASPubMedPubMed CentralGoogle Scholar Fodero-Tavoletti MT, Smith DP, McLean CA, Adlard PA, Barnham KJ, Foster LE, Leone L, Perez K, Cortes M, Culvenor JG, et al. In vitro characterization of Pittsburgh compound-B binding to Lewy bodies. J Neurosci. 2007;27:10365\u201371. ArticleCASPubMedPubMed CentralGoogle Scholar Levigoureux E, Lancelot S, Bouillot C, Chauveau F, Verdurand M, Verchere J, Billard T, Baron T, Zimmer L. Binding of the PET radiotracer [(1)(8)F]BF227 does not reflect the presence of alpha-synuclein aggregates in transgenic mice. Curr Alzheimer Res. 2014;11:955\u201360.ArticleCASPubMedGoogle Scholar Levigoureux E, Lancelot S, Bouillot C, Chauveau F, Verdurand M, Verchere J, Billard T, Baron T, Zimmer L. Binding of the PET radiotracer [(1)(8)F]BF227 does not reflect the presence of alpha-synuclein aggregates in transgenic mice. Curr Alzheimer Res. 2014;11:955\u201360. ArticleCASPubMedGoogle Scholar Levigoureux E, Lancelot S, Bouillot C, Chauveau F, Verdurand M, Verchere J, Billard T, Baron T, Zimmer L. Binding of the PET radiotracer [(1)(8)F]BF227 does not reflect the presence of alpha-synuclein aggregates in transgenic mice. Curr Alzheimer Res. 2014;11:955\u201360. ArticleCASPubMedGoogle Scholar Fodero-Tavoletti MT, Mulligan RS, Okamura N, Furumoto S, Rowe CC, Kudo Y, Masters CL, Cappai R, Yanai K, Villemagne VL. In vitro characterisation of BF227 binding to alpha-synuclein/Lewy bodies. Eur J Pharmacol. 2009;617:54\u20138.ArticleCASPubMedGoogle Scholar Fodero-Tavoletti MT, Mulligan RS, Okamura N, Furumoto S, Rowe CC, Kudo Y, Masters CL, Cappai R, Yanai K, Villemagne VL. In vitro characterisation of BF227 binding to alpha-synuclein/Lewy bodies. Eur J Pharmacol. 2009;617:54\u20138. ArticleCASPubMedGoogle Scholar Fodero-Tavoletti MT, Mulligan RS, Okamura N, Furumoto S, Rowe CC, Kudo Y, Masters CL, Cappai R, Yanai K, Villemagne VL. In vitro characterisation of BF227 binding to alpha-synuclein/Lewy bodies. Eur J Pharmacol. 2009;617:54\u20138. ArticleCASPubMedGoogle Scholar Yu L, Cui J, Padakanti PK, Engel L, Bagchi DP, Kotzbauer PT, Tu Z. Synthesis and in vitro evaluation of alpha-synuclein ligands. Bioorg Med Chem. 2012;20:4625\u201334.ArticleCASPubMedPubMed CentralGoogle Scholar Yu L, Cui J, Padakanti PK, Engel L, Bagchi DP, Kotzbauer PT, Tu Z. Synthesis and in vitro evaluation of alpha-synuclein ligands. Bioorg Med Chem. 2012;20:4625\u201334. ArticleCASPubMedPubMed CentralGoogle Scholar Yu L, Cui J, Padakanti PK, Engel L, Bagchi DP, Kotzbauer PT, Tu Z. Synthesis and in vitro evaluation of alpha-synuclein ligands. Bioorg Med Chem. 2012;20:4625\u201334. ArticleCASPubMedPubMed CentralGoogle Scholar Bagchi DP, Yu L, Perlmutter JS, Xu J, Mach RH, Tu Z, Kotzbauer PT. Binding of the Radioligand SIL23 to \u03b1-Synuclein Fibrils in Parkinson Disease Brain Tissue Establishes Feasibility and Screening Approaches for Developing a Parkinson Disease Imaging Agent. PLoS ONE. 2013;8(2):e55031.ArticleCASPubMedPubMed CentralGoogle Scholar Bagchi DP, Yu L, Perlmutter JS, Xu J, Mach RH, Tu Z, Kotzbauer PT. Binding of the Radioligand SIL23 to \u03b1-Synuclein Fibrils in Parkinson Disease Brain Tissue Establishes Feasibility and Screening Approaches for Developing a Parkinson Disease Imaging Agent. PLoS ONE. 2013;8(2):e55031. ArticleCASPubMedPubMed CentralGoogle Scholar Bagchi DP, Yu L, Perlmutter JS, Xu J, Mach RH, Tu Z, Kotzbauer PT. Binding of the Radioligand SIL23 to \u03b1-Synuclein Fibrils in Parkinson Disease Brain Tissue Establishes Feasibility and Screening Approaches for Developing a Parkinson Disease Imaging Agent. PLoS ONE. 2013;8(2):e55031. ArticleCASPubMedPubMed CentralGoogle Scholar Zhang X, Jin H, Padakanti P, Li J, Yang H, Fan J, Mach R, Kotzbauer P, Tu Z. Radiosynthesis and in Vivo Evaluation of Two PET Radioligands for Imaging \u03b1-Synuclein. Appl Sci. 2014;4(1):66\u201378.ArticlePubMedGoogle Scholar Zhang X, Jin H, Padakanti P, Li J, Yang H, Fan J, Mach R, Kotzbauer P, Tu Z. Radiosynthesis and in Vivo Evaluation of Two PET Radioligands for Imaging \u03b1-Synuclein. Appl Sci. 2014;4(1):66\u201378. ArticlePubMedGoogle Scholar Zhang X, Jin H, Padakanti P, Li J, Yang H, Fan J, Mach R, Kotzbauer P, Tu Z. Radiosynthesis and in Vivo Evaluation of Two PET Radioligands for Imaging \u03b1-Synuclein. Appl Sci. 2014;4(1):66\u201378. ArticlePubMedGoogle Scholar Ferrie JJ, Lengyel-Zhand Z, Janssen B, Lougee MG, Giannakoulias S, Hsieh CJ, Pagar VV, Weng CC, Xu H, Graham TJA, et al. Identification of a nanomolar affinity alpha-synuclein fibril imaging probe by ultra-high throughput in silico screening. Chem Sci. 2020;11:12746\u201354.ArticleCASPubMedPubMed CentralGoogle Scholar Ferrie JJ, Lengyel-Zhand Z, Janssen B, Lougee MG, Giannakoulias S, Hsieh CJ, Pagar VV, Weng CC, Xu H, Graham TJA, et al. Identification of a nanomolar affinity alpha-synuclein fibril imaging probe by ultra-high throughput in silico screening. Chem Sci. 2020;11:12746\u201354. ArticleCASPubMedPubMed CentralGoogle Scholar Ferrie JJ, Lengyel-Zhand Z, Janssen B, Lougee MG, Giannakoulias S, Hsieh CJ, Pagar VV, Weng CC, Xu H, Graham TJA, et al. Identification of a nanomolar affinity alpha-synuclein fibril imaging probe by ultra-high throughput in silico screening. Chem Sci. 2020;11:12746\u201354. ArticleCASPubMedPubMed CentralGoogle Scholar Miranda-Azpiazu P, Svedberg M, Higuchi M, Ono M, Jia Z, Sunnemark D, Elmore CS, Schou M, Varrone A. Identification and in vitro characterization of C05\u201301, a PBB3 derivative with improved affinity for alpha-synuclein. Brain Res. 2020;1749:147131.ArticleCASPubMedGoogle Scholar Miranda-Azpiazu P, Svedberg M, Higuchi M, Ono M, Jia Z, Sunnemark D, Elmore CS, Schou M, Varrone A. Identification and in vitro characterization of C05\u201301, a PBB3 derivative with improved affinity for alpha-synuclein. Brain Res. 2020;1749:147131. ArticleCASPubMedGoogle Scholar Miranda-Azpiazu P, Svedberg M, Higuchi M, Ono M, Jia Z, Sunnemark D, Elmore CS, Schou M, Varrone A. Identification and in vitro characterization of C05\u201301, a PBB3 derivative with improved affinity for alpha-synuclein. Brain Res. 2020;1749:147131. ArticleCASPubMedGoogle Scholar Chen YF, Bian J, Zhang P, Bu LL, Shen Y, Yu WB, Lu XH, Lin X, Ye DY, Wang J, Chu Y. Design, synthesis and identification of N, N-dibenzylcinnamamide (DBC) derivatives as novel ligands for alpha-synuclein fibrils by SPR evaluation system. Bioorg Med Chem. 2020;28:115358.ArticleCASPubMedGoogle Scholar Chen YF, Bian J, Zhang P, Bu LL, Shen Y, Yu WB, Lu XH, Lin X, Ye DY, Wang J, Chu Y. Design, synthesis and identification of N, N-dibenzylcinnamamide (DBC) derivatives as novel ligands for alpha-synuclein fibrils by SPR evaluation system. Bioorg Med Chem. 2020;28:115358. ArticleCASPubMedGoogle Scholar Chen YF, Bian J, Zhang P, Bu LL, Shen Y, Yu WB, Lu XH, Lin X, Ye DY, Wang J, Chu Y. Design, synthesis and identification of N, N-dibenzylcinnamamide (DBC) derivatives as novel ligands for alpha-synuclein fibrils by SPR evaluation system. Bioorg Med Chem. 2020;28:115358. ArticleCASPubMedGoogle Scholar Kaide S, Watanabe H, Shimizu Y, Iikuni S, Nakamoto Y, Hasegawa M, Itoh K, Ono M. Identification and Evaluation of Bisquinoline Scaffold as a New Candidate for alpha-Synuclein-PET Imaging. ACS Chem Neurosci. 2020;11:4254\u201361.ArticleCASPubMedGoogle Scholar Kaide S, Watanabe H, Shimizu Y, Iikuni S, Nakamoto Y, Hasegawa M, Itoh K, Ono M. Identification and Evaluation of Bisquinoline Scaffold as a New Candidate for alpha-Synuclein-PET Imaging. ACS Chem Neurosci. 2020;11:4254\u201361. ArticleCASPubMedGoogle Scholar Kaide S, Watanabe H, Shimizu Y, Iikuni S, Nakamoto Y, Hasegawa M, Itoh K, Ono M. Identification and Evaluation of Bisquinoline Scaffold as a New Candidate for alpha-Synuclein-PET Imaging. ACS Chem Neurosci. 2020;11:4254\u201361. ArticleCASPubMedGoogle Scholar Kuebler L, Buss S, Leonov A, Ryazanov S, Schmidt F, Maurer A, Weckbecker D, Landau AM, Lillethorup TP, Bleher D, et al. [(11)C]MODAG-001-towards a PET tracer targeting alpha-synuclein aggregates. Eur J Nucl Med Mol Imaging. 2021;48:1759\u201372.ArticleCASPubMedGoogle Scholar Kuebler L, Buss S, Leonov A, Ryazanov S, Schmidt F, Maurer A, Weckbecker D, Landau AM, Lillethorup TP, Bleher D, et al. [(11)C]MODAG-001-towards a PET tracer targeting alpha-synuclein aggregates. Eur J Nucl Med Mol Imaging. 2021;48:1759\u201372. ArticleCASPubMedGoogle Scholar Kuebler L, Buss S, Leonov A, Ryazanov S, Schmidt F, Maurer A, Weckbecker D, Landau AM, Lillethorup TP, Bleher D, et al. [(11)C]MODAG-001-towards a PET tracer targeting alpha-synuclein aggregates. Eur J Nucl Med Mol Imaging. 2021;48:1759\u201372. ArticleCASPubMedGoogle Scholar Matsuoka K, Ono M, Takado Y, Hirata K, Endo H, Ohfusa T, Kojima T, Yamamoto T, Onishi T, Orihara A, et al. High-Contrast Imaging of \u03b1-Synuclein Pathologies in Living Patients with Multiple System Atrophy. Movement Disorders. 2022;37(10):2159\u201361.https://doi.org/10.1002/mds.29186. Matsuoka K, Ono M, Takado Y, Hirata K, Endo H, Ohfusa T, Kojima T, Yamamoto T, Onishi T, Orihara A, et al. High-Contrast Imaging of \u03b1-Synuclein Pathologies in Living Patients with Multiple System Atrophy. Movement Disorders. 2022;37(10):2159\u201361.https://doi.org/10.1002/mds.29186. Matsuoka K, Ono M, Takado Y, Hirata K, Endo H, Ohfusa T, Kojima T, Yamamoto T, Onishi T, Orihara A, et al. High-Contrast Imaging of \u03b1-Synuclein Pathologies in Living Patients with Multiple System Atrophy. Movement Disorders. 2022;37(10):2159\u201361.https://doi.org/10.1002/mds.29186. Capotosti F, Vokali E, Molette J, Ravache M, Delgado C, Kocher J, Pittet L, Dimitrakopoulos IK, Di-Bonaventura I, Touilloux T, et al. The development of [18F]ACI-12589, a high affinity and selective alpha-synuclein radiotracer, as a biomarker for Parkinson\u2019s disease and other synucleinopathies. Alzheimers Dement. 2021;17:e053943.ArticleGoogle Scholar Capotosti F, Vokali E, Molette J, Ravache M, Delgado C, Kocher J, Pittet L, Dimitrakopoulos IK, Di-Bonaventura I, Touilloux T, et al. The development of [18F]ACI-12589, a high affinity and selective alpha-synuclein radiotracer, as a biomarker for Parkinson\u2019s disease and other synucleinopathies. Alzheimers Dement. 2021;17:e053943. ArticleGoogle Scholar Capotosti F, Vokali E, Molette J, Ravache M, Delgado C, Kocher J, Pittet L, Dimitrakopoulos IK, Di-Bonaventura I, Touilloux T, et al. The development of [18F]ACI-12589, a high affinity and selective alpha-synuclein radiotracer, as a biomarker for Parkinson\u2019s disease and other synucleinopathies. Alzheimers Dement. 2021;17:e053943. ArticleGoogle Scholar Roshanbin S, Xiong M, Hultqvist G, S\u00f6derberg L, Zachrisson O, Meier S, Ekmark-Lew\u00e9n S, Bergstr\u00f6m J, Ingelsson M, Sehlin D, Syv\u00e4nen S. In vivo imaging of alpha-synuclein with antibody-based PET. Neuropharmacology. 2022;208:108985.ArticleCASPubMedGoogle Scholar Roshanbin S, Xiong M, Hultqvist G, S\u00f6derberg L, Zachrisson O, Meier S, Ekmark-Lew\u00e9n S, Bergstr\u00f6m J, Ingelsson M, Sehlin D, Syv\u00e4nen S. In vivo imaging of alpha-synuclein with antibody-based PET. Neuropharmacology. 2022;208:108985. ArticleCASPubMedGoogle Scholar Roshanbin S, Xiong M, Hultqvist G, S\u00f6derberg L, Zachrisson O, Meier S, Ekmark-Lew\u00e9n S, Bergstr\u00f6m J, Ingelsson M, Sehlin D, Syv\u00e4nen S. In vivo imaging of alpha-synuclein with antibody-based PET. Neuropharmacology. 2022;208:108985. ArticleCASPubMedGoogle Scholar Fujiwara H, Hasegawa M, Dohmae N, Kawashima A, Masliah E, Goldberg MS, Shen J, Takio K, Iwatsubo T. alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol. 2002;4:160\u20134.ArticleCASPubMedGoogle Scholar Fujiwara H, Hasegawa M, Dohmae N, Kawashima A, Masliah E, Goldberg MS, Shen J, Takio K, Iwatsubo T. alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol. 2002;4:160\u20134. ArticleCASPubMedGoogle Scholar Fujiwara H, Hasegawa M, Dohmae N, Kawashima A, Masliah E, Goldberg MS, Shen J, Takio K, Iwatsubo T. alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol. 2002;4:160\u20134. ArticleCASPubMedGoogle Scholar Irwin DJ, Lee VM, Trojanowski JQ. Parkinson\u2019s disease dementia: convergence of \u03b1-synuclein, tau and amyloid-\u03b2 pathologies. Nat Rev Neurosci. 2013;14:626\u201336.ArticleCASPubMedPubMed CentralGoogle Scholar Irwin DJ, Lee VM, Trojanowski JQ. Parkinson\u2019s disease dementia: convergence of \u03b1-synuclein, tau and amyloid-\u03b2 pathologies. Nat Rev Neurosci. 2013;14:626\u201336. ArticleCASPubMedPubMed CentralGoogle Scholar Irwin DJ, Lee VM, Trojanowski JQ. Parkinson\u2019s disease dementia: convergence of \u03b1-synuclein, tau and amyloid-\u03b2 pathologies. Nat Rev Neurosci. 2013;14:626\u201336. ArticleCASPubMedPubMed CentralGoogle Scholar Van der Perren A, Gelders G, Fenyi A, Bousset L, Brito F, Peelaerts W, Van den Haute C, Gentleman S, Melki R, Baekelandt V. The structural differences between patient-derived \u03b1-synuclein strains dictate characteristics of Parkinson\u2019s disease, multiple system atrophy and dementia with Lewy bodies. Acta Neuropathol. 2020;139:977\u20131000.ArticlePubMedPubMed CentralGoogle Scholar Van der Perren A, Gelders G, Fenyi A, Bousset L, Brito F, Peelaerts W, Van den Haute C, Gentleman S, Melki R, Baekelandt V. The structural differences between patient-derived \u03b1-synuclein strains dictate characteristics of Parkinson\u2019s disease, multiple system atrophy and dementia with Lewy bodies. Acta Neuropathol. 2020;139:977\u20131000. ArticlePubMedPubMed CentralGoogle Scholar Van der Perren A, Gelders G, Fenyi A, Bousset L, Brito F, Peelaerts W, Van den Haute C, Gentleman S, Melki R, Baekelandt V. The structural differences between patient-derived \u03b1-synuclein strains dictate characteristics of Parkinson\u2019s disease, multiple system atrophy and dementia with Lewy bodies. Acta Neuropathol. 2020;139:977\u20131000. ArticlePubMedPubMed CentralGoogle Scholar McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, Salmon DP, Lowe J, Mirra SS, Byrne EJ, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology. 1996;47:1113\u201324.ArticleCASPubMedGoogle Scholar McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, Salmon DP, Lowe J, Mirra SS, Byrne EJ, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology. 1996;47:1113\u201324. ArticleCASPubMedGoogle Scholar McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, Salmon DP, Lowe J, Mirra SS, Byrne EJ, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology. 1996;47:1113\u201324. ArticleCASPubMedGoogle Scholar Lippa CF, Duda JE, Grossman M, Hurtig HI, Aarsland D, Boeve BF, Brooks DJ, Dickson DW, Dubois B, Emre M, et al. DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology. 2007;68:812\u20139.ArticleCASPubMedGoogle Scholar Lippa CF, Duda JE, Grossman M, Hurtig HI, Aarsland D, Boeve BF, Brooks DJ, Dickson DW, Dubois B, Emre M, et al. DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology. 2007;68:812\u20139. ArticleCASPubMedGoogle Scholar Lippa CF, Duda JE, Grossman M, Hurtig HI, Aarsland D, Boeve BF, Brooks DJ, Dickson DW, Dubois B, Emre M, et al. DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology. 2007;68:812\u20139. ArticleCASPubMedGoogle Scholar van Rumund A, Green AJE, Fairfoul G, Esselink RAJ, Bloem BR, Verbeek MM. \u03b1-Synuclein real-time quaking-induced conversion in the cerebrospinal fluid of uncertain cases of parkinsonism. Ann Neurol. 2019;85:777\u201381.ArticlePubMedPubMed CentralGoogle Scholar van Rumund A, Green AJE, Fairfoul G, Esselink RAJ, Bloem BR, Verbeek MM. \u03b1-Synuclein real-time quaking-induced conversion in the cerebrospinal fluid of uncertain cases of parkinsonism. Ann Neurol. 2019;85:777\u201381. ArticlePubMedPubMed CentralGoogle Scholar van Rumund A, Green AJE, Fairfoul G, Esselink RAJ, Bloem BR, Verbeek MM. \u03b1-Synuclein real-time quaking-induced conversion in the cerebrospinal fluid of uncertain cases of parkinsonism. Ann Neurol. 2019;85:777\u201381. ArticlePubMedPubMed CentralGoogle Scholar Iranzo A, Fairfoul G, Ayudhaya ACN, Serradell M, Gelpi E, Vilaseca I, Sanchez-Valle R, Gaig C, Santamaria J, Tolosa E, et al. Detection of \u03b1-synuclein in CSF by RT-QuIC in patients with isolated rapid-eye-movement sleep behaviour disorder: a longitudinal observational study. Lancet Neurol. 2021;20:203\u201312.ArticleCASPubMedGoogle Scholar Iranzo A, Fairfoul G, Ayudhaya ACN, Serradell M, Gelpi E, Vilaseca I, Sanchez-Valle R, Gaig C, Santamaria J, Tolosa E, et al. Detection of \u03b1-synuclein in CSF by RT-QuIC in patients with isolated rapid-eye-movement sleep behaviour disorder: a longitudinal observational study. Lancet Neurol. 2021;20:203\u201312. ArticleCASPubMedGoogle Scholar Iranzo A, Fairfoul G, Ayudhaya ACN, Serradell M, Gelpi E, Vilaseca I, Sanchez-Valle R, Gaig C, Santamaria J, Tolosa E, et al. Detection of \u03b1-synuclein in CSF by RT-QuIC in patients with isolated rapid-eye-movement sleep behaviour disorder: a longitudinal observational study. Lancet Neurol. 2021;20:203\u201312. ArticleCASPubMedGoogle Scholar Lee JM, Derkinderen P, Kordower JH, Freeman R, Munoz DG, Kremer T, Zago W, Hutten SJ, Adler CH, Serrano GE, Beach TG. The Search for a Peripheral Biopsy Indicator of \u03b1-Synuclein Pathology for Parkinson Disease. J Neuropathol Exp Neurol. 2017;76:2\u201315.CASPubMedGoogle Scholar Lee JM, Derkinderen P, Kordower JH, Freeman R, Munoz DG, Kremer T, Zago W, Hutten SJ, Adler CH, Serrano GE, Beach TG. The Search for a Peripheral Biopsy Indicator of \u03b1-Synuclein Pathology for Parkinson Disease. J Neuropathol Exp Neurol. 2017;76:2\u201315. CASPubMedGoogle Scholar Lee JM, Derkinderen P, Kordower JH, Freeman R, Munoz DG, Kremer T, Zago W, Hutten SJ, Adler CH, Serrano GE, Beach TG. The Search for a Peripheral Biopsy Indicator of \u03b1-Synuclein Pathology for Parkinson Disease. J Neuropathol Exp Neurol. 2017;76:2\u201315. CASPubMedGoogle Scholar Antelmi E, Donadio V, Incensi A, Plazzi G, Liguori R. Skin nerve phosphorylated \u03b1-synuclein deposits in idiopathic REM sleep behavior disorder. Neurology. 2017;88:2128\u201331.ArticleCASPubMedGoogle Scholar Antelmi E, Donadio V, Incensi A, Plazzi G, Liguori R. Skin nerve phosphorylated \u03b1-synuclein deposits in idiopathic REM sleep behavior disorder. Neurology. 2017;88:2128\u201331. ArticleCASPubMedGoogle Scholar Antelmi E, Donadio V, Incensi A, Plazzi G, Liguori R. Skin nerve phosphorylated \u03b1-synuclein deposits in idiopathic REM sleep behavior disorder. Neurology. 2017;88:2128\u201331. ArticleCASPubMedGoogle Scholar Donadio V, Incensi A, Piccinini C, Cortelli P, Giannoccaro MP, Baruzzi A, Liguori R. Skin nerve misfolded \u03b1-synuclein in pure autonomic failure and Parkinson disease. Ann Neurol. 2016;79:306\u201316.ArticleCASPubMedGoogle Scholar Donadio V, Incensi A, Piccinini C, Cortelli P, Giannoccaro MP, Baruzzi A, Liguori R. Skin nerve misfolded \u03b1-synuclein in pure autonomic failure and Parkinson disease. Ann Neurol. 2016;79:306\u201316. ArticleCASPubMedGoogle Scholar Donadio V, Incensi A, Piccinini C, Cortelli P, Giannoccaro MP, Baruzzi A, Liguori R. Skin nerve misfolded \u03b1-synuclein in pure autonomic failure and Parkinson disease. Ann Neurol. 2016;79:306\u201316. ArticleCASPubMedGoogle Scholar Donadio V, Incensi A, Rizzo G, Capellari S, Pantieri R, Stanzani Maserati M, Devigili G, Eleopra R, Defazio G, Montini F, et al. A new potential biomarker for dementia with Lewy bodies: Skin nerve \u03b1-synuclein deposits. Neurology. 2017;89:318\u201326.ArticleCASPubMedGoogle Scholar Donadio V, Incensi A, Rizzo G, Capellari S, Pantieri R, Stanzani Maserati M, Devigili G, Eleopra R, Defazio G, Montini F, et al. A new potential biomarker for dementia with Lewy bodies: Skin nerve \u03b1-synuclein deposits. Neurology. 2017;89:318\u201326. ArticleCASPubMedGoogle Scholar Donadio V, Incensi A, Rizzo G, Capellari S, Pantieri R, Stanzani Maserati M, Devigili G, Eleopra R, Defazio G, Montini F, et al. A new potential biomarker for dementia with Lewy bodies: Skin nerve \u03b1-synuclein deposits. Neurology. 2017;89:318\u201326. ArticleCASPubMedGoogle Scholar Gibbons CH, Garcia J, Wang N, Shih LC, Freeman R. The diagnostic discrimination of cutaneous \u03b1-synuclein deposition in Parkinson disease. Neurology. 2016;87:505\u201312.ArticleCASPubMedPubMed CentralGoogle Scholar Gibbons CH, Garcia J, Wang N, Shih LC, Freeman R. The diagnostic discrimination of cutaneous \u03b1-synuclein deposition in Parkinson disease. Neurology. 2016;87:505\u201312. ArticleCASPubMedPubMed CentralGoogle Scholar Gibbons CH, Garcia J, Wang N, Shih LC, Freeman R. The diagnostic discrimination of cutaneous \u03b1-synuclein deposition in Parkinson disease. Neurology. 2016;87:505\u201312. ArticleCASPubMedPubMed CentralGoogle Scholar Visanji NP, Mollenhauer B, Beach TG, Adler CH, Coffey CS, Kopil CM, Dave KD, Foroud T, Chahine L, Jennings D. The Systemic Synuclein Sampling Study: toward a biomarker for Parkinson\u2019s disease. Biomark Med. 2017;11:359\u201368.ArticleCASPubMedGoogle Scholar Visanji NP, Mollenhauer B, Beach TG, Adler CH, Coffey CS, Kopil CM, Dave KD, Foroud T, Chahine L, Jennings D. The Systemic Synuclein Sampling Study: toward a biomarker for Parkinson\u2019s disease. Biomark Med. 2017;11:359\u201368. ArticleCASPubMedGoogle Scholar Visanji NP, Mollenhauer B, Beach TG, Adler CH, Coffey CS, Kopil CM, Dave KD, Foroud T, Chahine L, Jennings D. The Systemic Synuclein Sampling Study: toward a biomarker for Parkinson\u2019s disease. Biomark Med. 2017;11:359\u201368. ArticleCASPubMedGoogle Scholar Wang Z, Becker K, Donadio V, Siedlak S, Yuan J, Rezaee M, Incensi A, Kuzkina A, Orr\u00fa CD, Tatsuoka C, et al. Skin \u03b1-Synuclein Aggregation Seeding Activity as a Novel Biomarker for Parkinson Disease. JAMA Neurol. 2020;78:1\u201311.PubMedPubMed CentralGoogle Scholar Wang Z, Becker K, Donadio V, Siedlak S, Yuan J, Rezaee M, Incensi A, Kuzkina A, Orr\u00fa CD, Tatsuoka C, et al. Skin \u03b1-Synuclein Aggregation Seeding Activity as a Novel Biomarker for Parkinson Disease. JAMA Neurol. 2020;78:1\u201311. PubMedPubMed CentralGoogle Scholar Wang Z, Becker K, Donadio V, Siedlak S, Yuan J, Rezaee M, Incensi A, Kuzkina A, Orr\u00fa CD, Tatsuoka C, et al. Skin \u03b1-Synuclein Aggregation Seeding Activity as a Novel Biomarker for Parkinson Disease. JAMA Neurol. 2020;78:1\u201311. PubMedPubMed CentralGoogle Scholar Donadio V, Doppler K, Incensi A, Kuzkina A, Janzen A, Mayer G, Volkmann J, Rizzo G, Antelmi E, Plazzi G, et al. Abnormal \u03b1-synuclein deposits in skin nerves: intra- and inter-laboratory reproducibility. Eur J Neurol. 2019;26:1245\u201351.ArticleCASPubMedGoogle Scholar Donadio V, Doppler K, Incensi A, Kuzkina A, Janzen A, Mayer G, Volkmann J, Rizzo G, Antelmi E, Plazzi G, et al. Abnormal \u03b1-synuclein deposits in skin nerves: intra- and inter-laboratory reproducibility. Eur J Neurol. 2019;26:1245\u201351. ArticleCASPubMedGoogle Scholar Donadio V, Doppler K, Incensi A, Kuzkina A, Janzen A, Mayer G, Volkmann J, Rizzo G, Antelmi E, Plazzi G, et al. Abnormal \u03b1-synuclein deposits in skin nerves: intra- and inter-laboratory reproducibility. Eur J Neurol. 2019;26:1245\u201351. ArticleCASPubMedGoogle Scholar Fields CR, Bengoa-Vergniory N, Wade-Martins R. Targeting Alpha-Synuclein as a Therapy for Parkinson\u2019s Disease. Front Mol Neurosci. 2019;12:299\u2013299.ArticleCASPubMedPubMed CentralGoogle Scholar Fields CR, Bengoa-Vergniory N, Wade-Martins R. Targeting Alpha-Synuclein as a Therapy for Parkinson\u2019s Disease. Front Mol Neurosci. 2019;12:299\u2013299. ArticleCASPubMedPubMed CentralGoogle Scholar Fields CR, Bengoa-Vergniory N, Wade-Martins R. Targeting Alpha-Synuclein as a Therapy for Parkinson\u2019s Disease. Front Mol Neurosci. 2019;12:299\u2013299. ArticleCASPubMedPubMed CentralGoogle Scholar Sapru MK, Yates JW, Hogan S, Jiang L, Halter J, Bohn MC. Silencing of human alpha-synuclein in vitro and in rat brain using lentiviral-mediated RNAi. Exp Neurol. 2006;198:382\u201390.ArticleCASPubMedGoogle Scholar Sapru MK, Yates JW, Hogan S, Jiang L, Halter J, Bohn MC. Silencing of human alpha-synuclein in vitro and in rat brain using lentiviral-mediated RNAi. Exp Neurol. 2006;198:382\u201390. ArticleCASPubMedGoogle Scholar Sapru MK, Yates JW, Hogan S, Jiang L, Halter J, Bohn MC. Silencing of human alpha-synuclein in vitro and in rat brain using lentiviral-mediated RNAi. Exp Neurol. 2006;198:382\u201390. ArticleCASPubMedGoogle Scholar Takahashi M, Suzuki M, Fukuoka M, Fujikake N, Watanabe S, Murata M, Wada K, Nagai Y, Hohjoh H. Normalization of Overexpressed \u03b1-Synuclein Causing Parkinson\u2019s Disease By a Moderate Gene Silencing With RNA Interference. Molecular Therapy - Nucleic Acids. 2015;4:e241.ArticlePubMedGoogle Scholar Takahashi M, Suzuki M, Fukuoka M, Fujikake N, Watanabe S, Murata M, Wada K, Nagai Y, Hohjoh H. Normalization of Overexpressed \u03b1-Synuclein Causing Parkinson\u2019s Disease By a Moderate Gene Silencing With RNA Interference. Molecular Therapy - Nucleic Acids. 2015;4:e241. ArticlePubMedGoogle Scholar Takahashi M, Suzuki M, Fukuoka M, Fujikake N, Watanabe S, Murata M, Wada K, Nagai Y, Hohjoh H. Normalization of Overexpressed \u03b1-Synuclein Causing Parkinson\u2019s Disease By a Moderate Gene Silencing With RNA Interference. Molecular Therapy - Nucleic Acids. 2015;4:e241. ArticlePubMedGoogle Scholar Lewis J, Melrose H, Bumcrot D, Hope A, Zehr C, Lincoln S, Braithwaite A, He Z, Ogholikhan S, Hinkle K, et al. In vivo silencing of alpha-synuclein using naked siRNA. Mol Neurodegener. 2008;3:19.ArticlePubMedPubMed CentralGoogle Scholar Lewis J, Melrose H, Bumcrot D, Hope A, Zehr C, Lincoln S, Braithwaite A, He Z, Ogholikhan S, Hinkle K, et al. In vivo silencing of alpha-synuclein using naked siRNA. Mol Neurodegener. 2008;3:19. ArticlePubMedPubMed CentralGoogle Scholar Lewis J, Melrose H, Bumcrot D, Hope A, Zehr C, Lincoln S, Braithwaite A, He Z, Ogholikhan S, Hinkle K, et al. In vivo silencing of alpha-synuclein using naked siRNA. Mol Neurodegener. 2008;3:19. ArticlePubMedPubMed CentralGoogle Scholar Mittal S, Bj\u00f8rnevik K, Im DS, Flierl A, Dong X, Locascio JJ, Abo KM, Long E, Jin M, Xu B, et al. \u03b22-Adrenoreceptor is a regulator of the \u03b1-synuclein gene driving risk of Parkinson\u2019s disease. Science. 2017;357:891\u20138.ArticleCASPubMedPubMed CentralGoogle Scholar Mittal S, Bj\u00f8rnevik K, Im DS, Flierl A, Dong X, Locascio JJ, Abo KM, Long E, Jin M, Xu B, et al. \u03b22-Adrenoreceptor is a regulator of the \u03b1-synuclein gene driving risk of Parkinson\u2019s disease. Science. 2017;357:891\u20138. ArticleCASPubMedPubMed CentralGoogle Scholar Mittal S, Bj\u00f8rnevik K, Im DS, Flierl A, Dong X, Locascio JJ, Abo KM, Long E, Jin M, Xu B, et al. \u03b22-Adrenoreceptor is a regulator of the \u03b1-synuclein gene driving risk of Parkinson\u2019s disease. Science. 2017;357:891\u20138. ArticleCASPubMedPubMed CentralGoogle Scholar Klucken J, Shin Y, Masliah E, Hyman BT, McLean PJ. Hsp70 Reduces alpha-Synuclein Aggregation and Toxicity. J Biol Chem. 2004;279:25497\u2013502.ArticleCASPubMedGoogle Scholar Klucken J, Shin Y, Masliah E, Hyman BT, McLean PJ. Hsp70 Reduces alpha-Synuclein Aggregation and Toxicity. J Biol Chem. 2004;279:25497\u2013502. ArticleCASPubMedGoogle Scholar Klucken J, Shin Y, Masliah E, Hyman BT, McLean PJ. Hsp70 Reduces alpha-Synuclein Aggregation and Toxicity. J Biol Chem. 2004;279:25497\u2013502. ArticleCASPubMedGoogle Scholar Cox D, Selig E, Griffin MDW, Carver JA, Ecroyd H. Small Heat-shock Proteins Prevent \u03b1-Synuclein Aggregation via Transient Interactions and Their Efficacy Is Affected by the Rate of Aggregation. J Biol Chem. 2016;291:22618\u201329.ArticleCASPubMedPubMed CentralGoogle Scholar Cox D, Selig E, Griffin MDW, Carver JA, Ecroyd H. Small Heat-shock Proteins Prevent \u03b1-Synuclein Aggregation via Transient Interactions and Their Efficacy Is Affected by the Rate of Aggregation. J Biol Chem. 2016;291:22618\u201329. ArticleCASPubMedPubMed CentralGoogle Scholar Cox D, Selig E, Griffin MDW, Carver JA, Ecroyd H. Small Heat-shock Proteins Prevent \u03b1-Synuclein Aggregation via Transient Interactions and Their Efficacy Is Affected by the Rate of Aggregation. J Biol Chem. 2016;291:22618\u201329. ArticleCASPubMedPubMed CentralGoogle Scholar Ghochikyan A, Petrushina I, Davtyan H, Hovakimyan A, Saing T, Davtyan A, Cribbs DH, Agadjanyan MG. Immunogenicity of epitope vaccines targeting different B cell antigenic determinants of human \u03b1-synuclein: Feasibility study. Neurosci Lett. 2014;560:86\u201391.ArticleCASPubMedGoogle Scholar Ghochikyan A, Petrushina I, Davtyan H, Hovakimyan A, Saing T, Davtyan A, Cribbs DH, Agadjanyan MG. Immunogenicity of epitope vaccines targeting different B cell antigenic determinants of human \u03b1-synuclein: Feasibility study. Neurosci Lett. 2014;560:86\u201391. ArticleCASPubMedGoogle Scholar Ghochikyan A, Petrushina I, Davtyan H, Hovakimyan A, Saing T, Davtyan A, Cribbs DH, Agadjanyan MG. Immunogenicity of epitope vaccines targeting different B cell antigenic determinants of human \u03b1-synuclein: Feasibility study. Neurosci Lett. 2014;560:86\u201391. ArticleCASPubMedGoogle Scholar Masliah E, Rockenstein E, Adame A, Alford M, Crews L, Hashimoto M, Seubert P, Lee M, Goldstein J, Chilcote T, et al. Effects of alpha-synuclein immunization in a mouse model of Parkinson\u2019s disease. Neuron. 2005;46:857\u201368.ArticleCASPubMedGoogle Scholar Masliah E, Rockenstein E, Adame A, Alford M, Crews L, Hashimoto M, Seubert P, Lee M, Goldstein J, Chilcote T, et al. Effects of alpha-synuclein immunization in a mouse model of Parkinson\u2019s disease. Neuron. 2005;46:857\u201368. ArticleCASPubMedGoogle Scholar Masliah E, Rockenstein E, Adame A, Alford M, Crews L, Hashimoto M, Seubert P, Lee M, Goldstein J, Chilcote T, et al. Effects of alpha-synuclein immunization in a mouse model of Parkinson\u2019s disease. Neuron. 2005;46:857\u201368. ArticleCASPubMedGoogle Scholar Sanchez-Guajardo V, Annibali A, Jensen PH, Romero-Ramos M. alpha-Synuclein vaccination prevents the accumulation of parkinson disease-like pathologic inclusions in striatum in association with regulatory T cell recruitment in a rat model. J Neuropathol Exp Neurol. 2013;72:624\u201345.ArticleCASPubMedGoogle Scholar Sanchez-Guajardo V, Annibali A, Jensen PH, Romero-Ramos M. alpha-Synuclein vaccination prevents the accumulation of parkinson disease-like pathologic inclusions in striatum in association with regulatory T cell recruitment in a rat model. J Neuropathol Exp Neurol. 2013;72:624\u201345. ArticleCASPubMedGoogle Scholar Sanchez-Guajardo V, Annibali A, Jensen PH, Romero-Ramos M. alpha-Synuclein vaccination prevents the accumulation of parkinson disease-like pathologic inclusions in striatum in association with regulatory T cell recruitment in a rat model. J Neuropathol Exp Neurol. 2013;72:624\u201345. ArticleCASPubMedGoogle Scholar Masliah E, Rockenstein E, Mante M, Crews L, Spencer B, Adame A, Patrick C, Trejo M, Ubhi K, Rohn TT, et al. Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease. PLoS ONE. 2011;6:e19338.ArticleCASPubMedPubMed CentralGoogle Scholar Masliah E, Rockenstein E, Mante M, Crews L, Spencer B, Adame A, Patrick C, Trejo M, Ubhi K, Rohn TT, et al. Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease. PLoS ONE. 2011;6:e19338. ArticleCASPubMedPubMed CentralGoogle Scholar Masliah E, Rockenstein E, Mante M, Crews L, Spencer B, Adame A, Patrick C, Trejo M, Ubhi K, Rohn TT, et al. Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease. PLoS ONE. 2011;6:e19338. ArticleCASPubMedPubMed CentralGoogle Scholar Schenk DB, Koller M, Ness DK, Griffith SG, Grundman M, Zago W, Soto J, Atiee G, Ostrowitzki S, Kinney GG. First-in-human assessment of PRX002, an anti-alpha-synuclein monoclonal antibody, in healthy volunteers. Mov Disord. 2017;32:211\u20138.ArticleCASPubMedGoogle Scholar Schenk DB, Koller M, Ness DK, Griffith SG, Grundman M, Zago W, Soto J, Atiee G, Ostrowitzki S, Kinney GG. First-in-human assessment of PRX002, an anti-alpha-synuclein monoclonal antibody, in healthy volunteers. Mov Disord. 2017;32:211\u20138. ArticleCASPubMedGoogle Scholar Schenk DB, Koller M, Ness DK, Griffith SG, Grundman M, Zago W, Soto J, Atiee G, Ostrowitzki S, Kinney GG. First-in-human assessment of PRX002, an anti-alpha-synuclein monoclonal antibody, in healthy volunteers. Mov Disord. 2017;32:211\u20138. ArticleCASPubMedGoogle Scholar Pagano G, Taylor KI, Anzures-Cabrera J, Marchesi M, Simuni T, Marek K, Postuma RB, Pavese N, Stocchi F, Azulay JP, et al. Trial of Prasinezumab in Early-Stage Parkinson\u2019s Disease. N Engl J Med. 2022;387:421\u201332.ArticleCASPubMedGoogle Scholar Pagano G, Taylor KI, Anzures-Cabrera J, Marchesi M, Simuni T, Marek K, Postuma RB, Pavese N, Stocchi F, Azulay JP, et al. Trial of Prasinezumab in Early-Stage Parkinson\u2019s Disease. N Engl J Med. 2022;387:421\u201332. ArticleCASPubMedGoogle Scholar Pagano G, Taylor KI, Anzures-Cabrera J, Marchesi M, Simuni T, Marek K, Postuma RB, Pavese N, Stocchi F, Azulay JP, et al. Trial of Prasinezumab in Early-Stage Parkinson\u2019s Disease. N Engl J Med. 2022;387:421\u201332. ArticleCASPubMedGoogle Scholar Fjord-Larsen L, Thougaard A, Wegener KM, Christiansen J, Larsen F, Schr\u00f8der-Hansen LM, Kaarde M, Ditlevsen DK. Nonclinical safety evaluation, pharmacokinetics, and target engagement of Lu AF82422, a monoclonal IgG1 antibody against alpha-synuclein in development for treatment of synucleinopathies. MAbs. 2021;13:1994690.ArticlePubMedPubMed CentralGoogle Scholar Fjord-Larsen L, Thougaard A, Wegener KM, Christiansen J, Larsen F, Schr\u00f8der-Hansen LM, Kaarde M, Ditlevsen DK. Nonclinical safety evaluation, pharmacokinetics, and target engagement of Lu AF82422, a monoclonal IgG1 antibody against alpha-synuclein in development for treatment of synucleinopathies. MAbs. 2021;13:1994690. ArticlePubMedPubMed CentralGoogle Scholar Fjord-Larsen L, Thougaard A, Wegener KM, Christiansen J, Larsen F, Schr\u00f8der-Hansen LM, Kaarde M, Ditlevsen DK. Nonclinical safety evaluation, pharmacokinetics, and target engagement of Lu AF82422, a monoclonal IgG1 antibody against alpha-synuclein in development for treatment of synucleinopathies. MAbs. 2021;13:1994690. ArticlePubMedPubMed CentralGoogle Scholar Sevigny J, Chiao P, Bussi\u00e8re T, Weinreb PH, Williams L, Maier M, Dunstan R, Salloway S, Chen T, Ling Y, et al. The antibody aducanumab reduces A\u03b2 plaques in Alzheimer\u2019s disease. Nature. 2016;537:50\u20136.ArticleCASPubMedGoogle Scholar Sevigny J, Chiao P, Bussi\u00e8re T, Weinreb PH, Williams L, Maier M, Dunstan R, Salloway S, Chen T, Ling Y, et al. The antibody aducanumab reduces A\u03b2 plaques in Alzheimer\u2019s disease. Nature. 2016;537:50\u20136. ArticleCASPubMedGoogle Scholar Sevigny J, Chiao P, Bussi\u00e8re T, Weinreb PH, Williams L, Maier M, Dunstan R, Salloway S, Chen T, Ling Y, et al. The antibody aducanumab reduces A\u03b2 plaques in Alzheimer\u2019s disease. Nature. 2016;537:50\u20136. ArticleCASPubMedGoogle Scholar van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, Kanekiyo M, Li D, Reyderman L, Cohen S, et al. Lecanemab in Early Alzheimer\u2019s Disease. N Engl J Med. 2023;388:9\u201321.ArticlePubMedGoogle Scholar van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, Kanekiyo M, Li D, Reyderman L, Cohen S, et al. Lecanemab in Early Alzheimer\u2019s Disease. N Engl J Med. 2023;388:9\u201321. ArticlePubMedGoogle Scholar van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, Kanekiyo M, Li D, Reyderman L, Cohen S, et al. Lecanemab in Early Alzheimer\u2019s Disease. N Engl J Med. 2023;388:9\u201321. ArticlePubMedGoogle Scholar Weihofen A, Liu Y, Arndt JW, Huy C, Quan C, Smith BA, Baeriswyl JL, Cavegn N, Senn L, Su L, et al. Development of an aggregate-selective, human-derived \u03b1-synuclein antibody BIIB054 that ameliorates disease phenotypes in Parkinson\u2019s disease models. Neurobiol Dis. 2019;124:276\u201388.ArticleCASPubMedGoogle Scholar Weihofen A, Liu Y, Arndt JW, Huy C, Quan C, Smith BA, Baeriswyl JL, Cavegn N, Senn L, Su L, et al. Development of an aggregate-selective, human-derived \u03b1-synuclein antibody BIIB054 that ameliorates disease phenotypes in Parkinson\u2019s disease models. Neurobiol Dis. 2019;124:276\u201388. ArticleCASPubMedGoogle Scholar Weihofen A, Liu Y, Arndt JW, Huy C, Quan C, Smith BA, Baeriswyl JL, Cavegn N, Senn L, Su L, et al. Development of an aggregate-selective, human-derived \u03b1-synuclein antibody BIIB054 that ameliorates disease phenotypes in Parkinson\u2019s disease models. Neurobiol Dis. 2019;124:276\u201388. ArticleCASPubMedGoogle Scholar Lindstr\u00f6m V, Fagerqvist T, Nordstr\u00f6m E, Eriksson F, Lord A, Tucker S, Andersson J, Johannesson M, Schell H, Kahle PJ, et al. Immunotherapy targeting \u03b1-synuclein protofibrils reduced pathology in (Thy-1)-h[A30P] \u03b1-synuclein mice. Neurobiol Dis. 2014;69:134\u201343.ArticlePubMedGoogle Scholar Lindstr\u00f6m V, Fagerqvist T, Nordstr\u00f6m E, Eriksson F, Lord A, Tucker S, Andersson J, Johannesson M, Schell H, Kahle PJ, et al. Immunotherapy targeting \u03b1-synuclein protofibrils reduced pathology in (Thy-1)-h[A30P] \u03b1-synuclein mice. Neurobiol Dis. 2014;69:134\u201343. ArticlePubMedGoogle Scholar Lindstr\u00f6m V, Fagerqvist T, Nordstr\u00f6m E, Eriksson F, Lord A, Tucker S, Andersson J, Johannesson M, Schell H, Kahle PJ, et al. Immunotherapy targeting \u03b1-synuclein protofibrils reduced pathology in (Thy-1)-h[A30P] \u03b1-synuclein mice. Neurobiol Dis. 2014;69:134\u201343. ArticlePubMedGoogle Scholar Nordstr\u00f6m E, Eriksson F, Sigvardson J, Johannesson M, Kasrayan A, Jones-Kostalla M, Appelkvist P, S\u00f6derberg L, Nygren P, Blom M, et al. ABBV-0805, a novel antibody selective for soluble aggregated \u03b1-synuclein, prolongs lifespan and prevents buildup of \u03b1-synuclein pathology in mouse models of Parkinson\u2019s disease. Neurobiol Dis. 2021;161:105543.ArticlePubMedGoogle Scholar Nordstr\u00f6m E, Eriksson F, Sigvardson J, Johannesson M, Kasrayan A, Jones-Kostalla M, Appelkvist P, S\u00f6derberg L, Nygren P, Blom M, et al. ABBV-0805, a novel antibody selective for soluble aggregated \u03b1-synuclein, prolongs lifespan and prevents buildup of \u03b1-synuclein pathology in mouse models of Parkinson\u2019s disease. Neurobiol Dis. 2021;161:105543. ArticlePubMedGoogle Scholar Nordstr\u00f6m E, Eriksson F, Sigvardson J, Johannesson M, Kasrayan A, Jones-Kostalla M, Appelkvist P, S\u00f6derberg L, Nygren P, Blom M, et al. ABBV-0805, a novel antibody selective for soluble aggregated \u03b1-synuclein, prolongs lifespan and prevents buildup of \u03b1-synuclein pathology in mouse models of Parkinson\u2019s disease. Neurobiol Dis. 2021;161:105543. ArticlePubMedGoogle Scholar Chen SW, Drakulic S, Deas E, Ouberai M, Aprile FA, Arranz R, Ness S, Roodveldt C, Guilliams T, De-Genst EJ, et al. Structural characterization of toxic oligomers that are kinetically trapped during \u03b1-synuclein fibril formation. Proc Natl Acad Sci USA. 2015;112:E1994-2003.CASPubMedPubMed CentralGoogle Scholar Chen SW, Drakulic S, Deas E, Ouberai M, Aprile FA, Arranz R, Ness S, Roodveldt C, Guilliams T, De-Genst EJ, et al. Structural characterization of toxic oligomers that are kinetically trapped during \u03b1-synuclein fibril formation. Proc Natl Acad Sci USA. 2015;112:E1994-2003. CASPubMedPubMed CentralGoogle Scholar Chen SW, Drakulic S, Deas E, Ouberai M, Aprile FA, Arranz R, Ness S, Roodveldt C, Guilliams T, De-Genst EJ, et al. Structural characterization of toxic oligomers that are kinetically trapped during \u03b1-synuclein fibril formation. Proc Natl Acad Sci USA. 2015;112:E1994-2003. CASPubMedPubMed CentralGoogle Scholar Vaikath NN, Hmila I, Gupta V, Erskine D, Ingelsson M, El-Agnaf OMA. Antibodies against alpha-synuclein: tools and therapies. J Neurochem. 2019;150:612\u201325.ArticleCASPubMedGoogle Scholar Vaikath NN, Hmila I, Gupta V, Erskine D, Ingelsson M, El-Agnaf OMA. Antibodies against alpha-synuclein: tools and therapies. J Neurochem. 2019;150:612\u201325. ArticleCASPubMedGoogle Scholar Vaikath NN, Hmila I, Gupta V, Erskine D, Ingelsson M, El-Agnaf OMA. Antibodies against alpha-synuclein: tools and therapies. J Neurochem. 2019;150:612\u201325. ArticleCASPubMedGoogle Scholar Kariolis MS, Wells RC, Getz JA, Kwan W, Mahon CS, Tong R, Kim DJ, Srivastava A, Bedard C, Henne KR, et al. Brain delivery of therapeutic proteins using an Fc fragment blood-brain barrier transport vehicle in mice and monkeys. Sci Transl Med. 2020;12(545):eaay1359.ArticleCASPubMedGoogle Scholar Kariolis MS, Wells RC, Getz JA, Kwan W, Mahon CS, Tong R, Kim DJ, Srivastava A, Bedard C, Henne KR, et al. Brain delivery of therapeutic proteins using an Fc fragment blood-brain barrier transport vehicle in mice and monkeys. Sci Transl Med. 2020;12(545):eaay1359. ArticleCASPubMedGoogle Scholar Kariolis MS, Wells RC, Getz JA, Kwan W, Mahon CS, Tong R, Kim DJ, Srivastava A, Bedard C, Henne KR, et al. Brain delivery of therapeutic proteins using an Fc fragment blood-brain barrier transport vehicle in mice and monkeys. Sci Transl Med. 2020;12(545):eaay1359. ArticleCASPubMedGoogle Scholar Roshanbin S, Julku U, Xiong M, Eriksson J, Masliah E, Hultqvist G, Bergstr\u00f6m J, Ingelsson M, Syv\u00e4nen S, Sehlin D. Reduction of \u03b1SYN Pathology in a Mouse Model of PD Using a Brain-Penetrating Bispecific Antibody. Pharmaceutics. 2022;14(7):1412.ArticleCASPubMedPubMed CentralGoogle Scholar Roshanbin S, Julku U, Xiong M, Eriksson J, Masliah E, Hultqvist G, Bergstr\u00f6m J, Ingelsson M, Syv\u00e4nen S, Sehlin D. Reduction of \u03b1SYN Pathology in a Mouse Model of PD Using a Brain-Penetrating Bispecific Antibody. Pharmaceutics. 2022;14(7):1412. ArticleCASPubMedPubMed CentralGoogle Scholar Roshanbin S, Julku U, Xiong M, Eriksson J, Masliah E, Hultqvist G, Bergstr\u00f6m J, Ingelsson M, Syv\u00e4nen S, Sehlin D. Reduction of \u03b1SYN Pathology in a Mouse Model of PD Using a Brain-Penetrating Bispecific Antibody. Pharmaceutics. 2022;14(7):1412. ArticleCASPubMedPubMed CentralGoogle Scholar Langston JW, Ballard P, Tetrud JW, Irwin I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science. 1983;219:979\u201380.ArticleCASPubMedGoogle Scholar Langston JW, Ballard P, Tetrud JW, Irwin I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science. 1983;219:979\u201380. ArticleCASPubMedGoogle Scholar Langston JW, Ballard P, Tetrud JW, Irwin I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science. 1983;219:979\u201380. ArticleCASPubMedGoogle Scholar Burns RS, Chiueh CC, Markey SP, Ebert MH, Jacobowitz DM, Kopin IJ. A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc Natl Acad Sci USA. 1983;80:4546\u201350.ArticleCASPubMedPubMed CentralGoogle Scholar Burns RS, Chiueh CC, Markey SP, Ebert MH, Jacobowitz DM, Kopin IJ. A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc Natl Acad Sci USA. 1983;80:4546\u201350. ArticleCASPubMedPubMed CentralGoogle Scholar Burns RS, Chiueh CC, Markey SP, Ebert MH, Jacobowitz DM, Kopin IJ. A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc Natl Acad Sci USA. 1983;80:4546\u201350. ArticleCASPubMedPubMed CentralGoogle Scholar Langston JW, Forno LS, Rebert CS, Irwin I. Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyrine (MPTP) in the squirrel monkey. Brain Res. 1984;292:390\u20134.ArticleCASPubMedGoogle Scholar Langston JW, Forno LS, Rebert CS, Irwin I. Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyrine (MPTP) in the squirrel monkey. Brain Res. 1984;292:390\u20134. ArticleCASPubMedGoogle Scholar Langston JW, Forno LS, Rebert CS, Irwin I. Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyrine (MPTP) in the squirrel monkey. Brain Res. 1984;292:390\u20134. ArticleCASPubMedGoogle Scholar Schneider JS, Denaro FJ. Astrocytic responses to the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in cat and mouse brain. J Neuropathol Exp Neurol. 1988;47:452\u20138.ArticleCASPubMedGoogle Scholar Schneider JS, Denaro FJ. Astrocytic responses to the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in cat and mouse brain. J Neuropathol Exp Neurol. 1988;47:452\u20138. ArticleCASPubMedGoogle Scholar Schneider JS, Denaro FJ. Astrocytic responses to the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in cat and mouse brain. J Neuropathol Exp Neurol. 1988;47:452\u20138. ArticleCASPubMedGoogle Scholar Sayre LM. Biochemical mechanism of action of the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Toxicol Lett. 1989;48:121\u201349.ArticleCASPubMedGoogle Scholar Sayre LM. Biochemical mechanism of action of the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Toxicol Lett. 1989;48:121\u201349. ArticleCASPubMedGoogle Scholar Sayre LM. Biochemical mechanism of action of the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Toxicol Lett. 1989;48:121\u201349. ArticleCASPubMedGoogle Scholar Tipton KF, Singer TP. Advances in our understanding of the mechanisms of the neurotoxicity of MPTP and related compounds. J Neurochem. 1993;61:1191\u2013206.ArticleCASPubMedGoogle Scholar Tipton KF, Singer TP. Advances in our understanding of the mechanisms of the neurotoxicity of MPTP and related compounds. J Neurochem. 1993;61:1191\u2013206. ArticleCASPubMedGoogle Scholar Tipton KF, Singer TP. Advances in our understanding of the mechanisms of the neurotoxicity of MPTP and related compounds. J Neurochem. 1993;61:1191\u2013206. ArticleCASPubMedGoogle Scholar Schapira AH, Cooper JM, Dexter D, Clark JB, Jenner P, Marsden CD. Mitochondrial complex I deficiency in Parkinson\u2019s disease. J Neurochem. 1990;54:823\u20137.ArticleCASPubMedGoogle Scholar Schapira AH, Cooper JM, Dexter D, Clark JB, Jenner P, Marsden CD. Mitochondrial complex I deficiency in Parkinson\u2019s disease. J Neurochem. 1990;54:823\u20137. ArticleCASPubMedGoogle Scholar Schapira AH, Cooper JM, Dexter D, Clark JB, Jenner P, Marsden CD. Mitochondrial complex I deficiency in Parkinson\u2019s disease. J Neurochem. 1990;54:823\u20137. ArticleCASPubMedGoogle Scholar Greenamyre JT, Sherer TB, Betarbet R, Panov AV. Complex I and Parkinson\u2019s Disease. IUBMB Life. 2001;52:135\u201341.ArticleCASPubMedGoogle Scholar Greenamyre JT, Sherer TB, Betarbet R, Panov AV. Complex I and Parkinson\u2019s Disease. IUBMB Life. 2001;52:135\u201341. ArticleCASPubMedGoogle Scholar Greenamyre JT, Sherer TB, Betarbet R, Panov AV. Complex I and Parkinson\u2019s Disease. IUBMB Life. 2001;52:135\u201341. ArticleCASPubMedGoogle Scholar Su B, Wang X, Zheng L, Perry G, Smith MA, Zhu X. Abnormal mitochondrial dynamics and neurodegenerative diseases. Biochem Biophys Acta. 2010;1802:135\u201342.CASPubMedGoogle Scholar Su B, Wang X, Zheng L, Perry G, Smith MA, Zhu X. Abnormal mitochondrial dynamics and neurodegenerative diseases. Biochem Biophys Acta. 2010;1802:135\u201342. CASPubMedGoogle Scholar Su B, Wang X, Zheng L, Perry G, Smith MA, Zhu X. Abnormal mitochondrial dynamics and neurodegenerative diseases. Biochem Biophys Acta. 2010;1802:135\u201342. CASPubMedGoogle Scholar Henchcliffe C, Beal MF. Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis. Nat Clin Pract Neurol. 2008;4:600\u20139.ArticleCASPubMedGoogle Scholar Henchcliffe C, Beal MF. Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis. Nat Clin Pract Neurol. 2008;4:600\u20139. ArticleCASPubMedGoogle Scholar Henchcliffe C, Beal MF. Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis. Nat Clin Pract Neurol. 2008;4:600\u20139. ArticleCASPubMedGoogle Scholar Lin MT, Beal MF. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature. 2006;443:787\u201395.ArticleCASPubMedGoogle Scholar Lin MT, Beal MF. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature. 2006;443:787\u201395. ArticleCASPubMedGoogle Scholar Lin MT, Beal MF. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature. 2006;443:787\u201395. ArticleCASPubMedGoogle Scholar Bose A, Beal MF. Mitochondrial dysfunction in Parkinson\u2019s disease. J Neurochem. 2016;139(Suppl 1):216\u201331.ArticleCASPubMedGoogle Scholar Bose A, Beal MF. Mitochondrial dysfunction in Parkinson\u2019s disease. J Neurochem. 2016;139(Suppl 1):216\u201331. ArticleCASPubMedGoogle Scholar Bose A, Beal MF. Mitochondrial dysfunction in Parkinson\u2019s disease. J Neurochem. 2016;139(Suppl 1):216\u201331. ArticleCASPubMedGoogle Scholar Sulzer D, Zecca L. Intraneuronal dopamine-quinone synthesis: a review. Neurotox Res. 2000;1:181\u201395.ArticleCASPubMedGoogle Scholar Sulzer D, Zecca L. Intraneuronal dopamine-quinone synthesis: a review. Neurotox Res. 2000;1:181\u201395. ArticleCASPubMedGoogle Scholar Sulzer D, Zecca L. Intraneuronal dopamine-quinone synthesis: a review. Neurotox Res. 2000;1:181\u201395. ArticleCASPubMedGoogle Scholar Mansur A, Comley R, Lewis Y, Middleton L, Huiban M, Guo Q, Passchier J, Tsukada H, Gunn R, Rabiner E. MIND MAPS CONSORTIUM ft: <strong>Imaging of Mitochondrial Complex 1 with <sup>18</sup>F-BCPP-EF in the Healthy Human Brain</strong>. J Nucl Med. 2018;59:1709\u20131709.Google Scholar Mansur A, Comley R, Lewis Y, Middleton L, Huiban M, Guo Q, Passchier J, Tsukada H, Gunn R, Rabiner E. MIND MAPS CONSORTIUM ft: <strong>Imaging of Mitochondrial Complex 1 with <sup>18</sup>F-BCPP-EF in the Healthy Human Brain</strong>. J Nucl Med. 2018;59:1709\u20131709. Google Scholar Mansur A, Comley R, Lewis Y, Middleton L, Huiban M, Guo Q, Passchier J, Tsukada H, Gunn R, Rabiner E. MIND MAPS CONSORTIUM ft: <strong>Imaging of Mitochondrial Complex 1 with <sup>18</sup>F-BCPP-EF in the Healthy Human Brain</strong>. J Nucl Med. 2018;59:1709\u20131709. Google Scholar Berman DS, Maddahi J, Tamarappoo BK, Czernin J, Taillefer R, Udelson JE, Gibson CM, Devine M, Lazewatsky J, Bhat G, Washburn D. Phase II safety and clinical comparison with single-photon emission computed tomography myocardial perfusion imaging for detection of coronary artery disease: flurpiridaz F 18 positron emission tomography. J Am Coll Cardiol. 2013;61:469\u201377.ArticleCASPubMedGoogle Scholar Berman DS, Maddahi J, Tamarappoo BK, Czernin J, Taillefer R, Udelson JE, Gibson CM, Devine M, Lazewatsky J, Bhat G, Washburn D. Phase II safety and clinical comparison with single-photon emission computed tomography myocardial perfusion imaging for detection of coronary artery disease: flurpiridaz F 18 positron emission tomography. J Am Coll Cardiol. 2013;61:469\u201377. ArticleCASPubMedGoogle Scholar Berman DS, Maddahi J, Tamarappoo BK, Czernin J, Taillefer R, Udelson JE, Gibson CM, Devine M, Lazewatsky J, Bhat G, Washburn D. Phase II safety and clinical comparison with single-photon emission computed tomography myocardial perfusion imaging for detection of coronary artery disease: flurpiridaz F 18 positron emission tomography. J Am Coll Cardiol. 2013;61:469\u201377. ArticleCASPubMedGoogle Scholar Bengs S, Warnock GI, Portmann A, Mikail N, Rossi A, Ahmed H, Etter D, Treyer V, Gisler L, Pfister SK, et al. Rest/stress myocardial perfusion imaging by positron emission tomography with (18)F-Flurpiridaz: A feasibility study in mice. J Nucl Cardiol. 2022.https://doi.org/10.1007/s12350-022-02968-9. Bengs S, Warnock GI, Portmann A, Mikail N, Rossi A, Ahmed H, Etter D, Treyer V, Gisler L, Pfister SK, et al. Rest/stress myocardial perfusion imaging by positron emission tomography with (18)F-Flurpiridaz: A feasibility study in mice. J Nucl Cardiol. 2022.https://doi.org/10.1007/s12350-022-02968-9. Bengs S, Warnock GI, Portmann A, Mikail N, Rossi A, Ahmed H, Etter D, Treyer V, Gisler L, Pfister SK, et al. Rest/stress myocardial perfusion imaging by positron emission tomography with (18)F-Flurpiridaz: A feasibility study in mice. J Nucl Cardiol. 2022.https://doi.org/10.1007/s12350-022-02968-9. Haider A, Bengs S, Portmann A, Rossi A, Ahmed H, Etter D, Warnock GI, Mikail N, Gr\u00e4mer M, Meisel A, et al. Role of sex hormones in modulating myocardial perfusion and coronary flow reserve. Eur J Nucl Med Mol Imaging. 2022;49:2209\u201318.ArticleCASPubMedPubMed CentralGoogle Scholar Haider A, Bengs S, Portmann A, Rossi A, Ahmed H, Etter D, Warnock GI, Mikail N, Gr\u00e4mer M, Meisel A, et al. Role of sex hormones in modulating myocardial perfusion and coronary flow reserve. Eur J Nucl Med Mol Imaging. 2022;49:2209\u201318. ArticleCASPubMedPubMed CentralGoogle Scholar Haider A, Bengs S, Portmann A, Rossi A, Ahmed H, Etter D, Warnock GI, Mikail N, Gr\u00e4mer M, Meisel A, et al. Role of sex hormones in modulating myocardial perfusion and coronary flow reserve. Eur J Nucl Med Mol Imaging. 2022;49:2209\u201318. ArticleCASPubMedPubMed CentralGoogle Scholar Khan NL, Valente EM, Bentivoglio AR, Wood NW, Albanese A, Brooks DJ, Piccini P. Clinical and subclinical dopaminergic dysfunction in PARK6-linked parkinsonism: an 18F-dopa PET study. Ann Neurol. 2002;52:849\u201353.ArticlePubMedGoogle Scholar Khan NL, Valente EM, Bentivoglio AR, Wood NW, Albanese A, Brooks DJ, Piccini P. Clinical and subclinical dopaminergic dysfunction in PARK6-linked parkinsonism: an 18F-dopa PET study. Ann Neurol. 2002;52:849\u201353. ArticlePubMedGoogle Scholar Khan NL, Valente EM, Bentivoglio AR, Wood NW, Albanese A, Brooks DJ, Piccini P. Clinical and subclinical dopaminergic dysfunction in PARK6-linked parkinsonism: an 18F-dopa PET study. Ann Neurol. 2002;52:849\u201353. ArticlePubMedGoogle Scholar Gan-Or Z, Liong C, Alcalay RN. GBA-Associated Parkinson\u2019s Disease and Other Synucleinopathies. Curr Neurol Neurosci Rep. 2018;18:44.ArticlePubMedGoogle Scholar Gan-Or Z, Liong C, Alcalay RN. GBA-Associated Parkinson\u2019s Disease and Other Synucleinopathies. Curr Neurol Neurosci Rep. 2018;18:44. ArticlePubMedGoogle Scholar Gan-Or Z, Liong C, Alcalay RN. GBA-Associated Parkinson\u2019s Disease and Other Synucleinopathies. Curr Neurol Neurosci Rep. 2018;18:44. ArticlePubMedGoogle Scholar Choi JH, Stubblefield B, Cookson MR, Goldin E, Velayati A, Tayebi N, Sidransky E. Aggregation of alpha-synuclein in brain samples from subjects with glucocerebrosidase mutations. Mol Genet Metab. 2011;104:185\u20138.ArticleCASPubMedPubMed CentralGoogle Scholar Choi JH, Stubblefield B, Cookson MR, Goldin E, Velayati A, Tayebi N, Sidransky E. Aggregation of alpha-synuclein in brain samples from subjects with glucocerebrosidase mutations. Mol Genet Metab. 2011;104:185\u20138. ArticleCASPubMedPubMed CentralGoogle Scholar Choi JH, Stubblefield B, Cookson MR, Goldin E, Velayati A, Tayebi N, Sidransky E. Aggregation of alpha-synuclein in brain samples from subjects with glucocerebrosidase mutations. Mol Genet Metab. 2011;104:185\u20138. ArticleCASPubMedPubMed CentralGoogle Scholar Mazzulli JR, Xu YH, Sun Y, Knight AL, McLean PJ, Caldwell GA, Sidransky E, Grabowski GA, Krainc D. Gaucher disease glucocerebrosidase and alpha-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell. 2011;146:37\u201352.ArticleCASPubMedPubMed CentralGoogle Scholar Mazzulli JR, Xu YH, Sun Y, Knight AL, McLean PJ, Caldwell GA, Sidransky E, Grabowski GA, Krainc D. Gaucher disease glucocerebrosidase and alpha-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell. 2011;146:37\u201352. ArticleCASPubMedPubMed CentralGoogle Scholar Mazzulli JR, Xu YH, Sun Y, Knight AL, McLean PJ, Caldwell GA, Sidransky E, Grabowski GA, Krainc D. Gaucher disease glucocerebrosidase and alpha-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell. 2011;146:37\u201352. ArticleCASPubMedPubMed CentralGoogle Scholar Migdalska-Richards A, Daly L, Bezard E, Schapira AH. Ambroxol effects in glucocerebrosidase and alpha-synuclein transgenic mice. Ann Neurol. 2016;80:766\u201375.ArticleCASPubMedPubMed CentralGoogle Scholar Migdalska-Richards A, Daly L, Bezard E, Schapira AH. Ambroxol effects in glucocerebrosidase and alpha-synuclein transgenic mice. Ann Neurol. 2016;80:766\u201375. ArticleCASPubMedPubMed CentralGoogle Scholar Migdalska-Richards A, Daly L, Bezard E, Schapira AH. Ambroxol effects in glucocerebrosidase and alpha-synuclein transgenic mice. Ann Neurol. 2016;80:766\u201375. ArticleCASPubMedPubMed CentralGoogle Scholar Zimprich A, Biskup S, Leitner P, Lichtner P, Farrer M, Lincoln S, Kachergus J, Hulihan M, Uitti RJ, Calne DB, et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron. 2004;44:601\u20137.ArticleCASPubMedGoogle Scholar Zimprich A, Biskup S, Leitner P, Lichtner P, Farrer M, Lincoln S, Kachergus J, Hulihan M, Uitti RJ, Calne DB, et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron. 2004;44:601\u20137. ArticleCASPubMedGoogle Scholar Zimprich A, Biskup S, Leitner P, Lichtner P, Farrer M, Lincoln S, Kachergus J, Hulihan M, Uitti RJ, Calne DB, et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron. 2004;44:601\u20137. ArticleCASPubMedGoogle Scholar Chen J, Chen Y, Pu J. Leucine-Rich Repeat Kinase 2 in Parkinson\u2019s Disease: Updated from Pathogenesis to Potential Therapeutic Target. Eur Neurol. 2018;79:256\u201365.ArticleCASPubMedGoogle Scholar Chen J, Chen Y, Pu J. Leucine-Rich Repeat Kinase 2 in Parkinson\u2019s Disease: Updated from Pathogenesis to Potential Therapeutic Target. Eur Neurol. 2018;79:256\u201365. ArticleCASPubMedGoogle Scholar Chen J, Chen Y, Pu J. Leucine-Rich Repeat Kinase 2 in Parkinson\u2019s Disease: Updated from Pathogenesis to Potential Therapeutic Target. Eur Neurol. 2018;79:256\u201365. ArticleCASPubMedGoogle Scholar Chen Z, Shao T, Gao W, Fu H, Collier TL, Rong J, Deng X, Yu Q, Zhang X, Davenport AT, et al. Synthesis and Preliminary Evaluation of [(11) C]GNE-1023 as a Potent PET Probe for Imaging Leucine-Rich Repeat Kinase 2 (LRRK2) in Parkinson\u2019s Disease. ChemMedChem. 2019;14:1580\u20135.ArticleCASPubMedPubMed CentralGoogle Scholar Chen Z, Shao T, Gao W, Fu H, Collier TL, Rong J, Deng X, Yu Q, Zhang X, Davenport AT, et al. Synthesis and Preliminary Evaluation of [(11) C]GNE-1023 as a Potent PET Probe for Imaging Leucine-Rich Repeat Kinase 2 (LRRK2) in Parkinson\u2019s Disease. ChemMedChem. 2019;14:1580\u20135. ArticleCASPubMedPubMed CentralGoogle Scholar Chen Z, Shao T, Gao W, Fu H, Collier TL, Rong J, Deng X, Yu Q, Zhang X, Davenport AT, et al. Synthesis and Preliminary Evaluation of [(11) C]GNE-1023 as a Potent PET Probe for Imaging Leucine-Rich Repeat Kinase 2 (LRRK2) in Parkinson\u2019s Disease. ChemMedChem. 2019;14:1580\u20135. ArticleCASPubMedPubMed CentralGoogle Scholar Malik N, Kornelsen R, McCormick S, Colpo N, Merkens H, Bendre S, Benard F, Sossi V, Schirrmacher R, Schaffer P. Development and biological evaluation of[(18)F]FMN3PA & [(18)F]FMN3PU for leucine-rich repeat kinase 2 (LRRK2) in vivo PET imaging. Eur J Med Chem. 2021;211:113005.ArticleCASPubMedGoogle Scholar Malik N, Kornelsen R, McCormick S, Colpo N, Merkens H, Bendre S, Benard F, Sossi V, Schirrmacher R, Schaffer P. Development and biological evaluation of[(18)F]FMN3PA & [(18)F]FMN3PU for leucine-rich repeat kinase 2 (LRRK2) in vivo PET imaging. Eur J Med Chem. 2021;211:113005. ArticleCASPubMedGoogle Scholar Malik N, Kornelsen R, McCormick S, Colpo N, Merkens H, Bendre S, Benard F, Sossi V, Schirrmacher R, Schaffer P. Development and biological evaluation of[(18)F]FMN3PA & [(18)F]FMN3PU for leucine-rich repeat kinase 2 (LRRK2) in vivo PET imaging. Eur J Med Chem. 2021;211:113005. ArticleCASPubMedGoogle Scholar Rideout HJ, Chartier-Harlin MC, Fell MJ, Hirst WD, Huntwork-Rodriguez S, Leyns CEG, Mabrouk OS, Taymans JM. The Current State-of-the Art of LRRK2-Based Biomarker Assay Development in Parkinson\u2019s Disease. Front Neurosci. 2020;14:865.ArticlePubMedPubMed CentralGoogle Scholar Rideout HJ, Chartier-Harlin MC, Fell MJ, Hirst WD, Huntwork-Rodriguez S, Leyns CEG, Mabrouk OS, Taymans JM. The Current State-of-the Art of LRRK2-Based Biomarker Assay Development in Parkinson\u2019s Disease. Front Neurosci. 2020;14:865. ArticlePubMedPubMed CentralGoogle Scholar Rideout HJ, Chartier-Harlin MC, Fell MJ, Hirst WD, Huntwork-Rodriguez S, Leyns CEG, Mabrouk OS, Taymans JM. The Current State-of-the Art of LRRK2-Based Biomarker Assay Development in Parkinson\u2019s Disease. Front Neurosci. 2020;14:865. ArticlePubMedPubMed CentralGoogle Scholar Chen Z, Chen J, Chen L, Yoo C-H, Rong J, Fu H, Shao T, Coffman K, Steyn SJ, Davenport AT, et al: Imaging Leucine-Rich Repeat Kinase 2 In Vivo with 18F-Labeled Positron Emission Tomography Ligand. J Med Chem. 2022. Chen Z, Chen J, Chen L, Yoo C-H, Rong J, Fu H, Shao T, Coffman K, Steyn SJ, Davenport AT, et al: Imaging Leucine-Rich Repeat Kinase 2 In Vivo with 18F-Labeled Positron Emission Tomography Ligand. J Med Chem. 2022. Chen Z, Chen J, Chen L, Yoo C-H, Rong J, Fu H, Shao T, Coffman K, Steyn SJ, Davenport AT, et al: Imaging Leucine-Rich Repeat Kinase 2 In Vivo with 18F-Labeled Positron Emission Tomography Ligand. J Med Chem. 2022. Tolosa E, Vila M, Klein C, Rascol O. LRRK2 in Parkinson disease: challenges of clinical trials. Nat Rev Neurol. 2020;16:97\u2013107.ArticlePubMedGoogle Scholar Tolosa E, Vila M, Klein C, Rascol O. LRRK2 in Parkinson disease: challenges of clinical trials. Nat Rev Neurol. 2020;16:97\u2013107. ArticlePubMedGoogle Scholar Tolosa E, Vila M, Klein C, Rascol O. LRRK2 in Parkinson disease: challenges of clinical trials. Nat Rev Neurol. 2020;16:97\u2013107. ArticlePubMedGoogle Scholar Lin X, Parisiadou L, Gu XL, Wang L, Shim H, Sun L, Xie C, Long CX, Yang WJ, Ding J, et al. Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson\u2019s-disease-related mutant alpha-synuclein. Neuron. 2009;64:807\u201327.ArticleCASPubMedPubMed CentralGoogle Scholar Lin X, Parisiadou L, Gu XL, Wang L, Shim H, Sun L, Xie C, Long CX, Yang WJ, Ding J, et al. Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson\u2019s-disease-related mutant alpha-synuclein. Neuron. 2009;64:807\u201327. ArticleCASPubMedPubMed CentralGoogle Scholar Lin X, Parisiadou L, Gu XL, Wang L, Shim H, Sun L, Xie C, Long CX, Yang WJ, Ding J, et al. Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson\u2019s-disease-related mutant alpha-synuclein. Neuron. 2009;64:807\u201327. ArticleCASPubMedPubMed CentralGoogle Scholar Cookson MR. The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson\u2019s disease. Nat Rev Neurosci. 2010;11:791\u20137.ArticleCASPubMedPubMed CentralGoogle Scholar Cookson MR. The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson\u2019s disease. Nat Rev Neurosci. 2010;11:791\u20137. ArticleCASPubMedPubMed CentralGoogle Scholar Cookson MR. The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson\u2019s disease. Nat Rev Neurosci. 2010;11:791\u20137. ArticleCASPubMedPubMed CentralGoogle Scholar Simunovic F, Yi M, Wang Y, Macey L, Brown LT, Krichevsky AM, Andersen SL, Stephens RM, Benes FM, Sonntag KC. Gene expression profiling of substantia nigra dopamine neurons: further insights into Parkinson\u2019s disease pathology. Brain. 2009;132:1795\u2013809.ArticlePubMedGoogle Scholar Simunovic F, Yi M, Wang Y, Macey L, Brown LT, Krichevsky AM, Andersen SL, Stephens RM, Benes FM, Sonntag KC. Gene expression profiling of substantia nigra dopamine neurons: further insights into Parkinson\u2019s disease pathology. Brain. 2009;132:1795\u2013809. ArticlePubMedGoogle Scholar Simunovic F, Yi M, Wang Y, Macey L, Brown LT, Krichevsky AM, Andersen SL, Stephens RM, Benes FM, Sonntag KC. Gene expression profiling of substantia nigra dopamine neurons: further insights into Parkinson\u2019s disease pathology. Brain. 2009;132:1795\u2013809. ArticlePubMedGoogle Scholar Manzoni C, Lewis PA. LRRK2 and Autophagy. Adv Neurobiol. 2017;14:89\u2013105.ArticlePubMedGoogle Scholar Manzoni C, Lewis PA. LRRK2 and Autophagy. Adv Neurobiol. 2017;14:89\u2013105. ArticlePubMedGoogle Scholar Manzoni C, Lewis PA. LRRK2 and Autophagy. Adv Neurobiol. 2017;14:89\u2013105. ArticlePubMedGoogle Scholar Jennings D, Huntwork-Rodriguez S, Henry AG, Sasaki JC, Meisner R, Diaz D, Solanoy H, Wang X, Negrou E, Bondar VV, et al: Preclinical and clinical evaluation of the LRRK2 inhibitor DNL201 for Parkinson's disease. Sci Transl Med. 2022;14:eabj2658. Jennings D, Huntwork-Rodriguez S, Henry AG, Sasaki JC, Meisner R, Diaz D, Solanoy H, Wang X, Negrou E, Bondar VV, et al: Preclinical and clinical evaluation of the LRRK2 inhibitor DNL201 for Parkinson's disease. Sci Transl Med. 2022;14:eabj2658. Jennings D, Huntwork-Rodriguez S, Henry AG, Sasaki JC, Meisner R, Diaz D, Solanoy H, Wang X, Negrou E, Bondar VV, et al: Preclinical and clinical evaluation of the LRRK2 inhibitor DNL201 for Parkinson's disease. Sci Transl Med. 2022;14:eabj2658. West AB. Achieving neuroprotection with LRRK2 kinase inhibitors in Parkinson disease. Exp Neurol. 2017;298:236\u201345.ArticleCASPubMedPubMed CentralGoogle Scholar West AB. Achieving neuroprotection with LRRK2 kinase inhibitors in Parkinson disease. Exp Neurol. 2017;298:236\u201345. ArticleCASPubMedPubMed CentralGoogle Scholar West AB. Achieving neuroprotection with LRRK2 kinase inhibitors in Parkinson disease. Exp Neurol. 2017;298:236\u201345. ArticleCASPubMedPubMed CentralGoogle Scholar Zhao HT, John N, Delic V, Ikeda-Lee K, Kim A, Weihofen A, Swayze EE, Kordasiewicz HB, West AB, Volpicelli-Daley LA. LRRK2 Antisense Oligonucleotides Ameliorate alpha-Synuclein Inclusion Formation in a Parkinson\u2019s Disease Mouse Model. Mol Therapy Nucleic Acids. 2017;8:508\u201319.ArticleCASPubMedGoogle Scholar Zhao HT, John N, Delic V, Ikeda-Lee K, Kim A, Weihofen A, Swayze EE, Kordasiewicz HB, West AB, Volpicelli-Daley LA. LRRK2 Antisense Oligonucleotides Ameliorate alpha-Synuclein Inclusion Formation in a Parkinson\u2019s Disease Mouse Model. Mol Therapy Nucleic Acids. 2017;8:508\u201319. ArticleCASPubMedGoogle Scholar Zhao HT, John N, Delic V, Ikeda-Lee K, Kim A, Weihofen A, Swayze EE, Kordasiewicz HB, West AB, Volpicelli-Daley LA. LRRK2 Antisense Oligonucleotides Ameliorate alpha-Synuclein Inclusion Formation in a Parkinson\u2019s Disease Mouse Model. Mol Therapy Nucleic Acids. 2017;8:508\u201319. ArticleCASPubMedGoogle Scholar Ntetsika T, Papathoma PE, Markaki I. Novel targeted therapies for Parkinson\u2019s disease. Mol Med. 2021;27:17.ArticleCASPubMedPubMed CentralGoogle Scholar Ntetsika T, Papathoma PE, Markaki I. Novel targeted therapies for Parkinson\u2019s disease. Mol Med. 2021;27:17. ArticleCASPubMedPubMed CentralGoogle Scholar Ntetsika T, Papathoma PE, Markaki I. Novel targeted therapies for Parkinson\u2019s disease. Mol Med. 2021;27:17. ArticleCASPubMedPubMed CentralGoogle Scholar Lee JY, Koga H, Kawaguchi Y, Tang W, Wong E, Gao YS, Pandey UB, Kaushik S, Tresse E, Lu J, et al. HDAC6 controls autophagosome maturation essential for ubiquitin-selective quality-control autophagy. Embo j. 2010;29:969\u201380.ArticleCASPubMedPubMed CentralGoogle Scholar Lee JY, Koga H, Kawaguchi Y, Tang W, Wong E, Gao YS, Pandey UB, Kaushik S, Tresse E, Lu J, et al. HDAC6 controls autophagosome maturation essential for ubiquitin-selective quality-control autophagy. Embo j. 2010;29:969\u201380. ArticleCASPubMedPubMed CentralGoogle Scholar Lee JY, Koga H, Kawaguchi Y, Tang W, Wong E, Gao YS, Pandey UB, Kaushik S, Tresse E, Lu J, et al. HDAC6 controls autophagosome maturation essential for ubiquitin-selective quality-control autophagy. Embo j. 2010;29:969\u201380. ArticleCASPubMedPubMed CentralGoogle Scholar Pandey UB, Nie Z, Batlevi Y, McCray BA, Ritson GP, Nedelsky NB, Schwartz SL, DiProspero NA, Knight MA, Schuldiner O, et al. HDAC6 rescues neurodegeneration and provides an essential link between autophagy and the UPS. Nature. 2007;447:860\u20134.ArticleGoogle Scholar Pandey UB, Nie Z, Batlevi Y, McCray BA, Ritson GP, Nedelsky NB, Schwartz SL, DiProspero NA, Knight MA, Schuldiner O, et al. HDAC6 rescues neurodegeneration and provides an essential link between autophagy and the UPS. Nature. 2007;447:860\u20134. ArticleGoogle Scholar Pandey UB, Nie Z, Batlevi Y, McCray BA, Ritson GP, Nedelsky NB, Schwartz SL, DiProspero NA, Knight MA, Schuldiner O, et al. HDAC6 rescues neurodegeneration and provides an essential link between autophagy and the UPS. Nature. 2007;447:860\u20134. ArticleGoogle Scholar Sim\u00f5es-Pires C, Zwick V, Nurisso A, Schenker E, Carrupt PA, Cuendet M. HDAC6 as a target for neurodegenerative diseases: what makes it different from the other HDACs? Mol Neurodegener. 2013;8:7.ArticlePubMedPubMed CentralGoogle Scholar Sim\u00f5es-Pires C, Zwick V, Nurisso A, Schenker E, Carrupt PA, Cuendet M. HDAC6 as a target for neurodegenerative diseases: what makes it different from the other HDACs? Mol Neurodegener. 2013;8:7. ArticlePubMedPubMed CentralGoogle Scholar Sim\u00f5es-Pires C, Zwick V, Nurisso A, Schenker E, Carrupt PA, Cuendet M. HDAC6 as a target for neurodegenerative diseases: what makes it different from the other HDACs? Mol Neurodegener. 2013;8:7. ArticlePubMedPubMed CentralGoogle Scholar Koole M, Van Weehaeghe D, Serdons K, Herbots M, Cawthorne C, Celen S, Schroeder FA, Hooker JM, Bormans G, de Hoon J, et al. Clinical validation of the novel HDAC6 radiotracer [(18)F]EKZ-001 in the human brain. Eur J Nucl Med Mol Imaging. 2021;48:596\u2013611.ArticleCASPubMedGoogle Scholar Koole M, Van Weehaeghe D, Serdons K, Herbots M, Cawthorne C, Celen S, Schroeder FA, Hooker JM, Bormans G, de Hoon J, et al. Clinical validation of the novel HDAC6 radiotracer [(18)F]EKZ-001 in the human brain. Eur J Nucl Med Mol Imaging. 2021;48:596\u2013611. ArticleCASPubMedGoogle Scholar Koole M, Van Weehaeghe D, Serdons K, Herbots M, Cawthorne C, Celen S, Schroeder FA, Hooker JM, Bormans G, de Hoon J, et al. Clinical validation of the novel HDAC6 radiotracer [(18)F]EKZ-001 in the human brain. Eur J Nucl Med Mol Imaging. 2021;48:596\u2013611. ArticleCASPubMedGoogle Scholar Vila M, Jackson-Lewis V, Guegan C, Wu DC, Teismann P, Choi DK, Tieu K, Przedborski S. The role of glial cells in Parkinson\u2019s disease. Curr Opin Neurol. 2001;14:483\u20139.ArticleCASPubMedGoogle Scholar Vila M, Jackson-Lewis V, Guegan C, Wu DC, Teismann P, Choi DK, Tieu K, Przedborski S. The role of glial cells in Parkinson\u2019s disease. Curr Opin Neurol. 2001;14:483\u20139. ArticleCASPubMedGoogle Scholar Vila M, Jackson-Lewis V, Guegan C, Wu DC, Teismann P, Choi DK, Tieu K, Przedborski S. The role of glial cells in Parkinson\u2019s disease. Curr Opin Neurol. 2001;14:483\u20139. ArticleCASPubMedGoogle Scholar Kurkowska-Jastrzebska I, Wronska A, Kohutnicka M, Czlonkowski A, Czlonkowska A. The inflammatory reaction following 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine intoxication in mouse. Exp Neurol. 1999;156:50\u201361.ArticleCASPubMedGoogle Scholar Kurkowska-Jastrzebska I, Wronska A, Kohutnicka M, Czlonkowski A, Czlonkowska A. The inflammatory reaction following 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine intoxication in mouse. Exp Neurol. 1999;156:50\u201361. ArticleCASPubMedGoogle Scholar Kurkowska-Jastrzebska I, Wronska A, Kohutnicka M, Czlonkowski A, Czlonkowska A. The inflammatory reaction following 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine intoxication in mouse. Exp Neurol. 1999;156:50\u201361. ArticleCASPubMedGoogle Scholar Fu R, Shen Q, Xu P, Luo JJ, Tang Y. Phagocytosis of microglia in the central nervous system diseases. Mol Neurobiol. 2014;49:1422\u201334.ArticleCASPubMedPubMed CentralGoogle Scholar Fu R, Shen Q, Xu P, Luo JJ, Tang Y. Phagocytosis of microglia in the central nervous system diseases. Mol Neurobiol. 2014;49:1422\u201334. ArticleCASPubMedPubMed CentralGoogle Scholar Fu R, Shen Q, Xu P, Luo JJ, Tang Y. Phagocytosis of microglia in the central nervous system diseases. Mol Neurobiol. 2014;49:1422\u201334. ArticleCASPubMedPubMed CentralGoogle Scholar Nayak D, Roth TL, McGavern DB. Microglia development and function. Annu Rev Immunol. 2014;32:367\u2013402.ArticleCASPubMedPubMed CentralGoogle Scholar Nayak D, Roth TL, McGavern DB. Microglia development and function. Annu Rev Immunol. 2014;32:367\u2013402. ArticleCASPubMedPubMed CentralGoogle Scholar Nayak D, Roth TL, McGavern DB. Microglia development and function. Annu Rev Immunol. 2014;32:367\u2013402. ArticleCASPubMedPubMed CentralGoogle Scholar Rupprecht R, Papadopoulos V, Rammes G, Baghai TC, Fan J, Akula N, Groyer G, Adams D, Schumacher M. Translocator protein (18 kDa) (TSPO) as a therapeutic target for neurological and psychiatric disorders. Nat Rev Drug Discovery. 2010;9:971\u201388.ArticleCASPubMedGoogle Scholar Rupprecht R, Papadopoulos V, Rammes G, Baghai TC, Fan J, Akula N, Groyer G, Adams D, Schumacher M. Translocator protein (18 kDa) (TSPO) as a therapeutic target for neurological and psychiatric disorders. Nat Rev Drug Discovery. 2010;9:971\u201388. ArticleCASPubMedGoogle Scholar Rupprecht R, Papadopoulos V, Rammes G, Baghai TC, Fan J, Akula N, Groyer G, Adams D, Schumacher M. Translocator protein (18 kDa) (TSPO) as a therapeutic target for neurological and psychiatric disorders. Nat Rev Drug Discovery. 2010;9:971\u201388. ArticleCASPubMedGoogle Scholar Venneti S, Lopresti BJ, Wiley CA. The peripheral benzodiazepine receptor (Translocator protein 18kDa) in microglia: from pathology to imaging. Prog Neurobiol. 2006;80:308\u201322.ArticleCASPubMedPubMed CentralGoogle Scholar Venneti S, Lopresti BJ, Wiley CA. The peripheral benzodiazepine receptor (Translocator protein 18kDa) in microglia: from pathology to imaging. Prog Neurobiol. 2006;80:308\u201322. ArticleCASPubMedPubMed CentralGoogle Scholar Venneti S, Lopresti BJ, Wiley CA. The peripheral benzodiazepine receptor (Translocator protein 18kDa) in microglia: from pathology to imaging. Prog Neurobiol. 2006;80:308\u201322. ArticleCASPubMedPubMed CentralGoogle Scholar Brooks DJ. Technology Insight: imaging neurodegeneration in Parkinson\u2019s disease. Nat Clin Pract Neurol. 2008;4:267\u201377.ArticleCASPubMedGoogle Scholar Brooks DJ. Technology Insight: imaging neurodegeneration in Parkinson\u2019s disease. Nat Clin Pract Neurol. 2008;4:267\u201377. ArticleCASPubMedGoogle Scholar Brooks DJ. Technology Insight: imaging neurodegeneration in Parkinson\u2019s disease. Nat Clin Pract Neurol. 2008;4:267\u201377. ArticleCASPubMedGoogle Scholar Imamura K, Hishikawa N, Sawada M, Nagatsu T, Yoshida M, Hashizume Y. Distribution of major histocompatibility complex class II-positive microglia and cytokine profile of Parkinson\u2019s disease brains. Acta Neuropathol. 2003;106:518\u201326.ArticleCASPubMedGoogle Scholar Imamura K, Hishikawa N, Sawada M, Nagatsu T, Yoshida M, Hashizume Y. Distribution of major histocompatibility complex class II-positive microglia and cytokine profile of Parkinson\u2019s disease brains. Acta Neuropathol. 2003;106:518\u201326. ArticleCASPubMedGoogle Scholar Imamura K, Hishikawa N, Sawada M, Nagatsu T, Yoshida M, Hashizume Y. Distribution of major histocompatibility complex class II-positive microglia and cytokine profile of Parkinson\u2019s disease brains. Acta Neuropathol. 2003;106:518\u201326. ArticleCASPubMedGoogle Scholar Bartels AL, Willemsen AT, Doorduin J, de Vries EF, Dierckx RA, Leenders KL. [11C]-PK11195 PET: quantification of neuroinflammation and a monitor of anti-inflammatory treatment in Parkinson\u2019s disease? Parkinsonism Relat Disord. 2010;16:57\u20139.ArticleCASPubMedGoogle Scholar Bartels AL, Willemsen AT, Doorduin J, de Vries EF, Dierckx RA, Leenders KL. [11C]-PK11195 PET: quantification of neuroinflammation and a monitor of anti-inflammatory treatment in Parkinson\u2019s disease? Parkinsonism Relat Disord. 2010;16:57\u20139. ArticleCASPubMedGoogle Scholar Bartels AL, Willemsen AT, Doorduin J, de Vries EF, Dierckx RA, Leenders KL. [11C]-PK11195 PET: quantification of neuroinflammation and a monitor of anti-inflammatory treatment in Parkinson\u2019s disease? Parkinsonism Relat Disord. 2010;16:57\u20139. ArticleCASPubMedGoogle Scholar Gerhard A, Pavese N, Hotton G, Turkheimer F, Es M, Hammers A, Eggert K, Oertel W, Banati RB, Brooks DJ. In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson\u2019s disease. Neurobiol Dis. 2006;21:404\u201312.ArticleCASPubMedGoogle Scholar Gerhard A, Pavese N, Hotton G, Turkheimer F, Es M, Hammers A, Eggert K, Oertel W, Banati RB, Brooks DJ. In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson\u2019s disease. Neurobiol Dis. 2006;21:404\u201312. ArticleCASPubMedGoogle Scholar Gerhard A, Pavese N, Hotton G, Turkheimer F, Es M, Hammers A, Eggert K, Oertel W, Banati RB, Brooks DJ. In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson\u2019s disease. Neurobiol Dis. 2006;21:404\u201312. ArticleCASPubMedGoogle Scholar Ouchi Y, Yoshikawa E, Sekine Y, Futatsubashi M, Kanno T, Ogusu T, Torizuka T. Microglial activation and dopamine terminal loss in early Parkinson\u2019s disease. Ann Neurol. 2005;57:168\u201375.ArticleCASPubMedGoogle Scholar Ouchi Y, Yoshikawa E, Sekine Y, Futatsubashi M, Kanno T, Ogusu T, Torizuka T. Microglial activation and dopamine terminal loss in early Parkinson\u2019s disease. Ann Neurol. 2005;57:168\u201375. ArticleCASPubMedGoogle Scholar Ouchi Y, Yoshikawa E, Sekine Y, Futatsubashi M, Kanno T, Ogusu T, Torizuka T. Microglial activation and dopamine terminal loss in early Parkinson\u2019s disease. Ann Neurol. 2005;57:168\u201375. ArticleCASPubMedGoogle Scholar Kobylecki C, Counsell SJ, Cabanel N, W\u00e4chter T, Turkheimer FE, Eggert K, Oertel W, Brooks DJ, Gerhard A. Diffusion-weighted imaging and its relationship to microglial activation in parkinsonian syndromes. Parkinsonism Relat Disord. 2013;19:527\u201332.ArticlePubMedGoogle Scholar Kobylecki C, Counsell SJ, Cabanel N, W\u00e4chter T, Turkheimer FE, Eggert K, Oertel W, Brooks DJ, Gerhard A. Diffusion-weighted imaging and its relationship to microglial activation in parkinsonian syndromes. Parkinsonism Relat Disord. 2013;19:527\u201332. ArticlePubMedGoogle Scholar Kobylecki C, Counsell SJ, Cabanel N, W\u00e4chter T, Turkheimer FE, Eggert K, Oertel W, Brooks DJ, Gerhard A. Diffusion-weighted imaging and its relationship to microglial activation in parkinsonian syndromes. Parkinsonism Relat Disord. 2013;19:527\u201332. ArticlePubMedGoogle Scholar Chauveau F, Van Camp N, Dolle F, Kuhnast B, Hinnen F, Damont A, Boutin H, James M, Kassiou M, Tavitian B. Comparative evaluation of the translocator protein radioligands 11C-DPA-713, 18F-DPA-714, and 11C-PK11195 in a rat model of acute neuroinflammation. J Nucl Med. 2009;50:468\u201376.ArticleCASPubMedGoogle Scholar Chauveau F, Van Camp N, Dolle F, Kuhnast B, Hinnen F, Damont A, Boutin H, James M, Kassiou M, Tavitian B. Comparative evaluation of the translocator protein radioligands 11C-DPA-713, 18F-DPA-714, and 11C-PK11195 in a rat model of acute neuroinflammation. J Nucl Med. 2009;50:468\u201376. ArticleCASPubMedGoogle Scholar Chauveau F, Van Camp N, Dolle F, Kuhnast B, Hinnen F, Damont A, Boutin H, James M, Kassiou M, Tavitian B. Comparative evaluation of the translocator protein radioligands 11C-DPA-713, 18F-DPA-714, and 11C-PK11195 in a rat model of acute neuroinflammation. J Nucl Med. 2009;50:468\u201376. ArticleCASPubMedGoogle Scholar Zhang M-R, Maeda J, Furutsuka K, Yoshida Y, Ogawa M, Suhara T, Suzuki K. [18F]FMDAA1106 and [18F]FEDAA1106: two positron-Emitter labeled ligands for peripheral benzodiazepine receptor (PBR). Bioorg Med Chem Lett. 2003;13:201\u20134.ArticleCASPubMedGoogle Scholar Zhang M-R, Maeda J, Furutsuka K, Yoshida Y, Ogawa M, Suhara T, Suzuki K. [18F]FMDAA1106 and [18F]FEDAA1106: two positron-Emitter labeled ligands for peripheral benzodiazepine receptor (PBR). Bioorg Med Chem Lett. 2003;13:201\u20134. ArticleCASPubMedGoogle Scholar Zhang M-R, Maeda J, Furutsuka K, Yoshida Y, Ogawa M, Suhara T, Suzuki K. [18F]FMDAA1106 and [18F]FEDAA1106: two positron-Emitter labeled ligands for peripheral benzodiazepine receptor (PBR). Bioorg Med Chem Lett. 2003;13:201\u20134. ArticleCASPubMedGoogle Scholar Zhang M-R, Kida T, Noguchi J, Furutsuka K, Maeda J, Suhara T, Suzuki K. [11C]DAA1106: radiosynthesis and in vivo binding to peripheral benzodiazepine receptors in mouse brain. Nucl Med Biol. 2003;30:513\u20139.ArticleCASPubMedGoogle Scholar Zhang M-R, Kida T, Noguchi J, Furutsuka K, Maeda J, Suhara T, Suzuki K. [11C]DAA1106: radiosynthesis and in vivo binding to peripheral benzodiazepine receptors in mouse brain. Nucl Med Biol. 2003;30:513\u20139. ArticleCASPubMedGoogle Scholar Zhang M-R, Kida T, Noguchi J, Furutsuka K, Maeda J, Suhara T, Suzuki K. [11C]DAA1106: radiosynthesis and in vivo binding to peripheral benzodiazepine receptors in mouse brain. Nucl Med Biol. 2003;30:513\u20139. ArticleCASPubMedGoogle Scholar Maeda J, Suhara T, Zhang MR, Okauchi T, Yasuno F, Ikoma Y, Inaji M, Nagai Y, Takano A, Obayashi S, Suzuki K. Novel peripheral benzodiazepine receptor ligand [11C]DAA1106 for PET: an imaging tool for glial cells in the brain. Synapse. 2004;52:283\u201391.ArticleCASPubMedGoogle Scholar Maeda J, Suhara T, Zhang MR, Okauchi T, Yasuno F, Ikoma Y, Inaji M, Nagai Y, Takano A, Obayashi S, Suzuki K. Novel peripheral benzodiazepine receptor ligand [11C]DAA1106 for PET: an imaging tool for glial cells in the brain. Synapse. 2004;52:283\u201391. ArticleCASPubMedGoogle Scholar Maeda J, Suhara T, Zhang MR, Okauchi T, Yasuno F, Ikoma Y, Inaji M, Nagai Y, Takano A, Obayashi S, Suzuki K. Novel peripheral benzodiazepine receptor ligand [11C]DAA1106 for PET: an imaging tool for glial cells in the brain. Synapse. 2004;52:283\u201391. ArticleCASPubMedGoogle Scholar Yui J, Hatori A, Kawamura K, Yanamoto K, Yamasaki T, Ogawa M, Yoshida Y, Kumata K, Fujinaga M, Nengaki N, et al. Visualization of early infarction in rat brain after ischemia using a translocator protein (18 kDa) PET ligand [11C]DAC with ultra-high specific activity. Neuroimage. 2011;54:123\u201330.ArticleCASPubMedGoogle Scholar Yui J, Hatori A, Kawamura K, Yanamoto K, Yamasaki T, Ogawa M, Yoshida Y, Kumata K, Fujinaga M, Nengaki N, et al. Visualization of early infarction in rat brain after ischemia using a translocator protein (18 kDa) PET ligand [11C]DAC with ultra-high specific activity. Neuroimage. 2011;54:123\u201330. ArticleCASPubMedGoogle Scholar Yui J, Hatori A, Kawamura K, Yanamoto K, Yamasaki T, Ogawa M, Yoshida Y, Kumata K, Fujinaga M, Nengaki N, et al. Visualization of early infarction in rat brain after ischemia using a translocator protein (18 kDa) PET ligand [11C]DAC with ultra-high specific activity. Neuroimage. 2011;54:123\u201330. ArticleCASPubMedGoogle Scholar Gulyas B, Toth M, Vas A, Shchukin E, Kostulas K, Hillert J, Halldin C. Visualising neuroinflammation in post-stroke patients: a comparative PET study with the TSPO molecular imaging biomarkers [11C]PK11195 and [11C]vinpocetine. Curr Radiopharm. 2012;5:19\u201328.ArticleCASPubMedGoogle Scholar Gulyas B, Toth M, Vas A, Shchukin E, Kostulas K, Hillert J, Halldin C. Visualising neuroinflammation in post-stroke patients: a comparative PET study with the TSPO molecular imaging biomarkers [11C]PK11195 and [11C]vinpocetine. Curr Radiopharm. 2012;5:19\u201328. ArticleCASPubMedGoogle Scholar Gulyas B, Toth M, Vas A, Shchukin E, Kostulas K, Hillert J, Halldin C. Visualising neuroinflammation in post-stroke patients: a comparative PET study with the TSPO molecular imaging biomarkers [11C]PK11195 and [11C]vinpocetine. Curr Radiopharm. 2012;5:19\u201328. ArticleCASPubMedGoogle Scholar Brody AL, Gehlbach D, Garcia LY, Enoki R, Hoh C, Vera D, Kotta KK, London ED, Okita K, Nurmi EL, et al. Effect of overnight smoking abstinence on a marker for microglial activation: a [(11)C]DAA1106 positron emission tomography study. Psychopharmacology. 2018;235:3525\u201334.ArticleCASPubMedPubMed CentralGoogle Scholar Brody AL, Gehlbach D, Garcia LY, Enoki R, Hoh C, Vera D, Kotta KK, London ED, Okita K, Nurmi EL, et al. Effect of overnight smoking abstinence on a marker for microglial activation: a [(11)C]DAA1106 positron emission tomography study. Psychopharmacology. 2018;235:3525\u201334. ArticleCASPubMedPubMed CentralGoogle Scholar Brody AL, Gehlbach D, Garcia LY, Enoki R, Hoh C, Vera D, Kotta KK, London ED, Okita K, Nurmi EL, et al. Effect of overnight smoking abstinence on a marker for microglial activation: a [(11)C]DAA1106 positron emission tomography study. Psychopharmacology. 2018;235:3525\u201334. ArticleCASPubMedPubMed CentralGoogle Scholar Best L, Ghadery C, Pavese N, Tai YF, Strafella AP. New and Old TSPO PET Radioligands for Imaging Brain Microglial Activation in Neurodegenerative Disease. Curr Neurol Neurosci Rep. 2019;19:24.ArticlePubMedGoogle Scholar Best L, Ghadery C, Pavese N, Tai YF, Strafella AP. New and Old TSPO PET Radioligands for Imaging Brain Microglial Activation in Neurodegenerative Disease. Curr Neurol Neurosci Rep. 2019;19:24. ArticlePubMedGoogle Scholar Best L, Ghadery C, Pavese N, Tai YF, Strafella AP. New and Old TSPO PET Radioligands for Imaging Brain Microglial Activation in Neurodegenerative Disease. Curr Neurol Neurosci Rep. 2019;19:24. ArticlePubMedGoogle Scholar Zhang L, Hu K, Shao T, Hou L, Zhang S, Ye W, Josephson L, Meyer JH, Zhang MR, Vasdev N, et al. Recent developments on PET radiotracers for TSPO and their applications in neuroimaging. Acta pharmaceutica Sinica B. 2021;11:373\u201393.ArticleCASPubMedGoogle Scholar Zhang L, Hu K, Shao T, Hou L, Zhang S, Ye W, Josephson L, Meyer JH, Zhang MR, Vasdev N, et al. Recent developments on PET radiotracers for TSPO and their applications in neuroimaging. Acta pharmaceutica Sinica B. 2021;11:373\u201393. ArticleCASPubMedGoogle Scholar Zhang L, Hu K, Shao T, Hou L, Zhang S, Ye W, Josephson L, Meyer JH, Zhang MR, Vasdev N, et al. Recent developments on PET radiotracers for TSPO and their applications in neuroimaging. Acta pharmaceutica Sinica B. 2021;11:373\u201393. ArticleCASPubMedGoogle Scholar Unterrainer M, Mahler C, Vomacka L, Lindner S, Havla J, Brendel M, B\u00f6ning G, Ertl-Wagner B, K\u00fcmpfel T, Milenkovic VM, et al. TSPO PET with [18F]GE-180 sensitively detects focal neuroinflammation in patients with relapsing\u2013remitting multiple sclerosis. Eur J Nucl Med Mol Imaging. 2018;45:1423\u201331.ArticlePubMedGoogle Scholar Unterrainer M, Mahler C, Vomacka L, Lindner S, Havla J, Brendel M, B\u00f6ning G, Ertl-Wagner B, K\u00fcmpfel T, Milenkovic VM, et al. TSPO PET with [18F]GE-180 sensitively detects focal neuroinflammation in patients with relapsing\u2013remitting multiple sclerosis. Eur J Nucl Med Mol Imaging. 2018;45:1423\u201331. ArticlePubMedGoogle Scholar Unterrainer M, Mahler C, Vomacka L, Lindner S, Havla J, Brendel M, B\u00f6ning G, Ertl-Wagner B, K\u00fcmpfel T, Milenkovic VM, et al. TSPO PET with [18F]GE-180 sensitively detects focal neuroinflammation in patients with relapsing\u2013remitting multiple sclerosis. Eur J Nucl Med Mol Imaging. 2018;45:1423\u201331. ArticlePubMedGoogle Scholar Wadsworth H, Jones PA, Chau WF, Durrant C, Fouladi N, Passmore J, O\u2019Shea D, Wynn D, Morisson-Iveson V, Ewan A, et al. [18F]GE-180: a novel fluorine-18 labelled PET tracer for imaging Translocator protein 18 kDa (TSPO). Bioorg Med Chem Lett. 2012;22:1308\u201313.ArticleCASPubMedGoogle Scholar Wadsworth H, Jones PA, Chau WF, Durrant C, Fouladi N, Passmore J, O\u2019Shea D, Wynn D, Morisson-Iveson V, Ewan A, et al. [18F]GE-180: a novel fluorine-18 labelled PET tracer for imaging Translocator protein 18 kDa (TSPO). Bioorg Med Chem Lett. 2012;22:1308\u201313. ArticleCASPubMedGoogle Scholar Wadsworth H, Jones PA, Chau WF, Durrant C, Fouladi N, Passmore J, O\u2019Shea D, Wynn D, Morisson-Iveson V, Ewan A, et al. [18F]GE-180: a novel fluorine-18 labelled PET tracer for imaging Translocator protein 18 kDa (TSPO). Bioorg Med Chem Lett. 2012;22:1308\u201313. ArticleCASPubMedGoogle Scholar Alam MM, Lee J, Lee SY. Recent Progress in the Development of TSPO PET Ligands for Neuroinflammation Imaging in Neurological Diseases. Nucl Med Mol Imaging. 2017;51:283\u201396.ArticleCASPubMedPubMed CentralGoogle Scholar Alam MM, Lee J, Lee SY. Recent Progress in the Development of TSPO PET Ligands for Neuroinflammation Imaging in Neurological Diseases. Nucl Med Mol Imaging. 2017;51:283\u201396. ArticleCASPubMedPubMed CentralGoogle Scholar Alam MM, Lee J, Lee SY. Recent Progress in the Development of TSPO PET Ligands for Neuroinflammation Imaging in Neurological Diseases. Nucl Med Mol Imaging. 2017;51:283\u201396. ArticleCASPubMedPubMed CentralGoogle Scholar Ikawa M, Lohith TG, Shrestha S, Telu S, Zoghbi SS, Castellano S, Taliani S, Da Settimo F, Fujita M, Pike VW, Innis RB. 11C-ER176, a Radioligand for 18-kDa Translocator Protein, Has Adequate Sensitivity to Robustly Image All Three Affinity Genotypes in Human Brain. J Nucl Med. 2017;58:320\u20135.ArticleCASPubMedPubMed CentralGoogle Scholar Ikawa M, Lohith TG, Shrestha S, Telu S, Zoghbi SS, Castellano S, Taliani S, Da Settimo F, Fujita M, Pike VW, Innis RB. 11C-ER176, a Radioligand for 18-kDa Translocator Protein, Has Adequate Sensitivity to Robustly Image All Three Affinity Genotypes in Human Brain. J Nucl Med. 2017;58:320\u20135. ArticleCASPubMedPubMed CentralGoogle Scholar Ikawa M, Lohith TG, Shrestha S, Telu S, Zoghbi SS, Castellano S, Taliani S, Da Settimo F, Fujita M, Pike VW, Innis RB. 11C-ER176, a Radioligand for 18-kDa Translocator Protein, Has Adequate Sensitivity to Robustly Image All Three Affinity Genotypes in Human Brain. J Nucl Med. 2017;58:320\u20135. ArticleCASPubMedPubMed CentralGoogle Scholar Sim\u00e9on FG, Lee J-H, Morse CL, Stukes I, Zoghbi SS, Manly LS, Liow J-S, Gladding RL, Dick RM, Yan X, et al. Synthesis and Screening in Mice of Fluorine-Containing PET Radioligands for TSPO: Discovery of a Promising 18F-Labeled Ligand. J Med Chem. 2021;64:16731\u201345.ArticlePubMedPubMed CentralGoogle Scholar Sim\u00e9on FG, Lee J-H, Morse CL, Stukes I, Zoghbi SS, Manly LS, Liow J-S, Gladding RL, Dick RM, Yan X, et al. Synthesis and Screening in Mice of Fluorine-Containing PET Radioligands for TSPO: Discovery of a Promising 18F-Labeled Ligand. J Med Chem. 2021;64:16731\u201345. ArticlePubMedPubMed CentralGoogle Scholar Sim\u00e9on FG, Lee J-H, Morse CL, Stukes I, Zoghbi SS, Manly LS, Liow J-S, Gladding RL, Dick RM, Yan X, et al. Synthesis and Screening in Mice of Fluorine-Containing PET Radioligands for TSPO: Discovery of a Promising 18F-Labeled Ligand. J Med Chem. 2021;64:16731\u201345. ArticlePubMedPubMed CentralGoogle Scholar Athauda D, Maclagan K, Skene SS, Bajwa-Joseph M, Letchford D, Chowdhury K, Hibbert S, Budnik N, Zampedri L, Dickson J, et al. Exenatide once weekly versus placebo in Parkinson\u2019s disease: a randomised, double-blind, placebo-controlled trial. Lancet. 2017;390:1664\u201375.ArticleCASPubMedPubMed CentralGoogle Scholar Athauda D, Maclagan K, Skene SS, Bajwa-Joseph M, Letchford D, Chowdhury K, Hibbert S, Budnik N, Zampedri L, Dickson J, et al. Exenatide once weekly versus placebo in Parkinson\u2019s disease: a randomised, double-blind, placebo-controlled trial. Lancet. 2017;390:1664\u201375. ArticleCASPubMedPubMed CentralGoogle Scholar Athauda D, Maclagan K, Skene SS, Bajwa-Joseph M, Letchford D, Chowdhury K, Hibbert S, Budnik N, Zampedri L, Dickson J, et al. Exenatide once weekly versus placebo in Parkinson\u2019s disease: a randomised, double-blind, placebo-controlled trial. Lancet. 2017;390:1664\u201375. ArticleCASPubMedPubMed CentralGoogle Scholar Tansey MG, Wallings RL, Houser MC, Herrick MK, Keating CE, Joers V. Inflammation and immune dysfunction in Parkinson disease. Nat Rev Immunol. 2022;22(11):657\u201373.ArticleCASPubMedPubMed CentralGoogle Scholar Tansey MG, Wallings RL, Houser MC, Herrick MK, Keating CE, Joers V. Inflammation and immune dysfunction in Parkinson disease. Nat Rev Immunol. 2022;22(11):657\u201373. ArticleCASPubMedPubMed CentralGoogle Scholar Tansey MG, Wallings RL, Houser MC, Herrick MK, Keating CE, Joers V. Inflammation and immune dysfunction in Parkinson disease. Nat Rev Immunol. 2022;22(11):657\u201373. ArticleCASPubMedPubMed CentralGoogle Scholar Fujimoto H, Fujita N, Hamamatsu K, Murakami T, Nakamoto Y, Saga T, Ishimori T, Shimizu Y, Watanabe H, Sano K, et al. First-in-Human Evaluation of Positron Emission Tomography/Computed Tomography With [(18)F]FB(ePEG12)12-Exendin-4: A Phase 1 Clinical Study Targeting GLP-1 Receptor Expression Cells in Pancreas. Front Endocrinol (Lausanne). 2021;12:717101.ArticlePubMedGoogle Scholar Fujimoto H, Fujita N, Hamamatsu K, Murakami T, Nakamoto Y, Saga T, Ishimori T, Shimizu Y, Watanabe H, Sano K, et al. First-in-Human Evaluation of Positron Emission Tomography/Computed Tomography With [(18)F]FB(ePEG12)12-Exendin-4: A Phase 1 Clinical Study Targeting GLP-1 Receptor Expression Cells in Pancreas. Front Endocrinol (Lausanne). 2021;12:717101. ArticlePubMedGoogle Scholar Fujimoto H, Fujita N, Hamamatsu K, Murakami T, Nakamoto Y, Saga T, Ishimori T, Shimizu Y, Watanabe H, Sano K, et al. First-in-Human Evaluation of Positron Emission Tomography/Computed Tomography With [(18)F]FB(ePEG12)12-Exendin-4: A Phase 1 Clinical Study Targeting GLP-1 Receptor Expression Cells in Pancreas. Front Endocrinol (Lausanne). 2021;12:717101. ArticlePubMedGoogle Scholar Luo Y, Pan Q, Yao S, Yu M, Wu W, Xue H, Kiesewetter DO, Zhu Z, Li F, Zhao Y, Chen X. Glucagon-Like Peptide-1 Receptor PET/CT with 68Ga-NOTA-Exendin-4 for Detecting Localized Insulinoma: A Prospective Cohort Study. J Nucl Med. 2016;57:715\u201320.ArticleCASPubMedGoogle Scholar Luo Y, Pan Q, Yao S, Yu M, Wu W, Xue H, Kiesewetter DO, Zhu Z, Li F, Zhao Y, Chen X. Glucagon-Like Peptide-1 Receptor PET/CT with 68Ga-NOTA-Exendin-4 for Detecting Localized Insulinoma: A Prospective Cohort Study. J Nucl Med. 2016;57:715\u201320. ArticleCASPubMedGoogle Scholar Luo Y, Pan Q, Yao S, Yu M, Wu W, Xue H, Kiesewetter DO, Zhu Z, Li F, Zhao Y, Chen X. Glucagon-Like Peptide-1 Receptor PET/CT with 68Ga-NOTA-Exendin-4 for Detecting Localized Insulinoma: A Prospective Cohort Study. J Nucl Med. 2016;57:715\u201320. ArticleCASPubMedGoogle Scholar Antwi K, Fani M, Nicolas G, Rottenburger C, Heye T, Reubi JC, Gloor B, Christ E, Wild D. Localization of Hidden Insulinomas with68Ga-DOTA-Exendin-4 PET/CT: A Pilot Study. J Nucl Med. 2015;56:1075\u20138.ArticleCASPubMedGoogle Scholar Antwi K, Fani M, Nicolas G, Rottenburger C, Heye T, Reubi JC, Gloor B, Christ E, Wild D. Localization of Hidden Insulinomas with68Ga-DOTA-Exendin-4 PET/CT: A Pilot Study. J Nucl Med. 2015;56:1075\u20138. ArticleCASPubMedGoogle Scholar Antwi K, Fani M, Nicolas G, Rottenburger C, Heye T, Reubi JC, Gloor B, Christ E, Wild D. Localization of Hidden Insulinomas with68Ga-DOTA-Exendin-4 PET/CT: A Pilot Study. J Nucl Med. 2015;56:1075\u20138. ArticleCASPubMedGoogle Scholar Liu Y, Liu S, Liu L, Gong X, Liu J, Sun L, Liu X, Wu L, Chen L, Wang L, et al. Fine Comparison of the Efficacy and Safety Between GB242 and Infliximab in Patients with Rheumatoid Arthritis: A Phase III Study. Rheumatol Ther. 2022;9:175\u201389.ArticleCASPubMedGoogle Scholar Liu Y, Liu S, Liu L, Gong X, Liu J, Sun L, Liu X, Wu L, Chen L, Wang L, et al. Fine Comparison of the Efficacy and Safety Between GB242 and Infliximab in Patients with Rheumatoid Arthritis: A Phase III Study. Rheumatol Ther. 2022;9:175\u201389. ArticleCASPubMedGoogle Scholar Liu Y, Liu S, Liu L, Gong X, Liu J, Sun L, Liu X, Wu L, Chen L, Wang L, et al. Fine Comparison of the Efficacy and Safety Between GB242 and Infliximab in Patients with Rheumatoid Arthritis: A Phase III Study. Rheumatol Ther. 2022;9:175\u201389. ArticleCASPubMedGoogle Scholar Tobinick EL, Chen K, Chen X. Rapid intracerebroventricular delivery of Cu-DOTA-etanercept after peripheral administration demonstrated by PET imaging. BMC Res Notes. 2009;2:28.ArticlePubMedPubMed CentralGoogle Scholar Tobinick EL, Chen K, Chen X. Rapid intracerebroventricular delivery of Cu-DOTA-etanercept after peripheral administration demonstrated by PET imaging. BMC Res Notes. 2009;2:28. ArticlePubMedPubMed CentralGoogle Scholar Tobinick EL, Chen K, Chen X. Rapid intracerebroventricular delivery of Cu-DOTA-etanercept after peripheral administration demonstrated by PET imaging. BMC Res Notes. 2009;2:28. ArticlePubMedPubMed CentralGoogle Scholar Colonna M. TREMs in the immune system and beyond. Nat Rev Immunol. 2003;3:445\u201353.ArticleCASPubMedGoogle Scholar Colonna M. TREMs in the immune system and beyond. Nat Rev Immunol. 2003;3:445\u201353. ArticleCASPubMedGoogle Scholar Colonna M. TREMs in the immune system and beyond. Nat Rev Immunol. 2003;3:445\u201353. ArticleCASPubMedGoogle Scholar Guo Y, Wei X, Yan H, Qin Y, Yan S, Liu J, Zhao Y, Jiang F, Lou H. TREM2 deficiency aggravates \u03b1-synuclein-induced neurodegeneration and neuroinflammation in Parkinson\u2019s disease models. Faseb j. 2019;33:12164\u201374.ArticleCASPubMedPubMed CentralGoogle Scholar Guo Y, Wei X, Yan H, Qin Y, Yan S, Liu J, Zhao Y, Jiang F, Lou H. TREM2 deficiency aggravates \u03b1-synuclein-induced neurodegeneration and neuroinflammation in Parkinson\u2019s disease models. Faseb j. 2019;33:12164\u201374. ArticleCASPubMedPubMed CentralGoogle Scholar Guo Y, Wei X, Yan H, Qin Y, Yan S, Liu J, Zhao Y, Jiang F, Lou H. TREM2 deficiency aggravates \u03b1-synuclein-induced neurodegeneration and neuroinflammation in Parkinson\u2019s disease models. Faseb j. 2019;33:12164\u201374. ArticleCASPubMedPubMed CentralGoogle Scholar Wilson EN, Swarovski MS, Linortner P, Shahid M, Zuckerman AJ, Wang Q, Channappa D, Minhas PS, Mhatre SD, Plowey ED, et al. Soluble TREM2 is elevated in Parkinson\u2019s disease subgroups with increased CSF tau. Brain. 2020;143:932\u201343.ArticlePubMedPubMed CentralGoogle Scholar Wilson EN, Swarovski MS, Linortner P, Shahid M, Zuckerman AJ, Wang Q, Channappa D, Minhas PS, Mhatre SD, Plowey ED, et al. Soluble TREM2 is elevated in Parkinson\u2019s disease subgroups with increased CSF tau. Brain. 2020;143:932\u201343. ArticlePubMedPubMed CentralGoogle Scholar Wilson EN, Swarovski MS, Linortner P, Shahid M, Zuckerman AJ, Wang Q, Channappa D, Minhas PS, Mhatre SD, Plowey ED, et al. Soluble TREM2 is elevated in Parkinson\u2019s disease subgroups with increased CSF tau. Brain. 2020;143:932\u201343. ArticlePubMedPubMed CentralGoogle Scholar Meier SR, Sehlin D, Hultqvist G, Syv\u00e4nen S. Pinpointing Brain TREM2 Levels in Two Mouse Models of Alzheimer\u2019s Disease. Mol Imaging Biol. 2021;23:665\u201375.ArticleCASPubMedPubMed CentralGoogle Scholar Meier SR, Sehlin D, Hultqvist G, Syv\u00e4nen S. Pinpointing Brain TREM2 Levels in Two Mouse Models of Alzheimer\u2019s Disease. Mol Imaging Biol. 2021;23:665\u201375. ArticleCASPubMedPubMed CentralGoogle Scholar Meier SR, Sehlin D, Hultqvist G, Syv\u00e4nen S. Pinpointing Brain TREM2 Levels in Two Mouse Models of Alzheimer\u2019s Disease. Mol Imaging Biol. 2021;23:665\u201375. ArticleCASPubMedPubMed CentralGoogle Scholar Sanjari Moghaddam H, Zare-Shahabadi A, Rahmani F, Rezaei N. Neurotransmission systems in Parkinson\u2019s disease. Rev Neurosci. 2017;28:509\u201336.ArticlePubMedGoogle Scholar Sanjari Moghaddam H, Zare-Shahabadi A, Rahmani F, Rezaei N. Neurotransmission systems in Parkinson\u2019s disease. Rev Neurosci. 2017;28:509\u201336. ArticlePubMedGoogle Scholar Sanjari Moghaddam H, Zare-Shahabadi A, Rahmani F, Rezaei N. Neurotransmission systems in Parkinson\u2019s disease. Rev Neurosci. 2017;28:509\u201336. ArticlePubMedGoogle Scholar Tanimura A, Pancani T, Lim SAO, Tubert C, Melendez AE, Shen W, Surmeier DJ. Striatal cholinergic interneurons and Parkinson\u2019s disease. Eur J Neurosci. 2018;47:1148\u201358.ArticlePubMedGoogle Scholar Tanimura A, Pancani T, Lim SAO, Tubert C, Melendez AE, Shen W, Surmeier DJ. Striatal cholinergic interneurons and Parkinson\u2019s disease. Eur J Neurosci. 2018;47:1148\u201358. ArticlePubMedGoogle Scholar Tanimura A, Pancani T, Lim SAO, Tubert C, Melendez AE, Shen W, Surmeier DJ. Striatal cholinergic interneurons and Parkinson\u2019s disease. Eur J Neurosci. 2018;47:1148\u201358. ArticlePubMedGoogle Scholar Aosaki T, Miura M, Suzuki T, Nishimura K, Masuda M. Acetylcholine-dopamine balance hypothesis in the striatum: an update. Geriatr Gerontol Int. 2010;10(Suppl 1):S148-157.PubMedGoogle Scholar Aosaki T, Miura M, Suzuki T, Nishimura K, Masuda M. Acetylcholine-dopamine balance hypothesis in the striatum: an update. Geriatr Gerontol Int. 2010;10(Suppl 1):S148-157. PubMedGoogle Scholar Aosaki T, Miura M, Suzuki T, Nishimura K, Masuda M. Acetylcholine-dopamine balance hypothesis in the striatum: an update. Geriatr Gerontol Int. 2010;10(Suppl 1):S148-157. PubMedGoogle Scholar Maurice N, Liberge M, Jaouen F, Ztaou S, Hanini M, Camon J, Deisseroth K, Amalric M, Kerkerian-Le Goff L, Beurrier C. Striatal Cholinergic Interneurons Control Motor Behavior and Basal Ganglia Function in Experimental Parkinsonism. Cell Rep. 2015;13:657\u201366.ArticleCASPubMedGoogle Scholar Maurice N, Liberge M, Jaouen F, Ztaou S, Hanini M, Camon J, Deisseroth K, Amalric M, Kerkerian-Le Goff L, Beurrier C. Striatal Cholinergic Interneurons Control Motor Behavior and Basal Ganglia Function in Experimental Parkinsonism. Cell Rep. 2015;13:657\u201366. ArticleCASPubMedGoogle Scholar Maurice N, Liberge M, Jaouen F, Ztaou S, Hanini M, Camon J, Deisseroth K, Amalric M, Kerkerian-Le Goff L, Beurrier C. Striatal Cholinergic Interneurons Control Motor Behavior and Basal Ganglia Function in Experimental Parkinsonism. Cell Rep. 2015;13:657\u201366. ArticleCASPubMedGoogle Scholar Pisani A, Bernardi G, Ding J, Surmeier DJ. Re-emergence of striatal cholinergic interneurons in movement disorders. Trends Neurosci. 2007;30:545\u201353.ArticleCASPubMedGoogle Scholar Pisani A, Bernardi G, Ding J, Surmeier DJ. Re-emergence of striatal cholinergic interneurons in movement disorders. Trends Neurosci. 2007;30:545\u201353. ArticleCASPubMedGoogle Scholar Pisani A, Bernardi G, Ding J, Surmeier DJ. Re-emergence of striatal cholinergic interneurons in movement disorders. Trends Neurosci. 2007;30:545\u201353. ArticleCASPubMedGoogle Scholar Ztaou S, Amalric M. Contribution of cholinergic interneurons to striatal pathophysiology in Parkinson\u2019s disease. Neurochem Int. 2019;126:1\u201310.ArticleCASPubMedGoogle Scholar Ztaou S, Amalric M. Contribution of cholinergic interneurons to striatal pathophysiology in Parkinson\u2019s disease. Neurochem Int. 2019;126:1\u201310. ArticleCASPubMedGoogle Scholar Ztaou S, Amalric M. Contribution of cholinergic interneurons to striatal pathophysiology in Parkinson\u2019s disease. Neurochem Int. 2019;126:1\u201310. ArticleCASPubMedGoogle Scholar DeMaagd G, Philip A. Parkinson\u2019s Disease and Its Management: Part 3: Nondopaminergic and Nonpharmacological Treatment Options. P T. 2015;40:668\u201379.PubMedPubMed CentralGoogle Scholar DeMaagd G, Philip A. Parkinson\u2019s Disease and Its Management: Part 3: Nondopaminergic and Nonpharmacological Treatment Options. P T. 2015;40:668\u201379. PubMedPubMed CentralGoogle Scholar DeMaagd G, Philip A. Parkinson\u2019s Disease and Its Management: Part 3: Nondopaminergic and Nonpharmacological Treatment Options. P T. 2015;40:668\u201379. PubMedPubMed CentralGoogle Scholar Appenzeller O, Goss JE. Autonomic deficits in Parkinson\u2019s syndrome. Arch Neurol. 1971;24:50\u20137.ArticleCASPubMedGoogle Scholar Appenzeller O, Goss JE. Autonomic deficits in Parkinson\u2019s syndrome. Arch Neurol. 1971;24:50\u20137. ArticleCASPubMedGoogle Scholar Appenzeller O, Goss JE. Autonomic deficits in Parkinson\u2019s syndrome. Arch Neurol. 1971;24:50\u20137. ArticleCASPubMedGoogle Scholar Chen Z, Li G, Liu J. Autonomic dysfunction in Parkinson\u2019s disease: Implications for pathophysiology, diagnosis, and treatment. Neurobiol Dis. 2020;134: 104700.ArticlePubMedGoogle Scholar Chen Z, Li G, Liu J. Autonomic dysfunction in Parkinson\u2019s disease: Implications for pathophysiology, diagnosis, and treatment. Neurobiol Dis. 2020;134: 104700. ArticlePubMedGoogle Scholar Chen Z, Li G, Liu J. Autonomic dysfunction in Parkinson\u2019s disease: Implications for pathophysiology, diagnosis, and treatment. Neurobiol Dis. 2020;134: 104700. ArticlePubMedGoogle Scholar Orimo S, Uchihara T, Nakamura A, Mori F, Kakita A, Wakabayashi K, Takahashi H. Axonal alpha-synuclein aggregates herald centripetal degeneration of cardiac sympathetic nerve in Parkinson\u2019s disease. Brain. 2008;131:642\u201350.ArticlePubMedGoogle Scholar Orimo S, Uchihara T, Nakamura A, Mori F, Kakita A, Wakabayashi K, Takahashi H. Axonal alpha-synuclein aggregates herald centripetal degeneration of cardiac sympathetic nerve in Parkinson\u2019s disease. Brain. 2008;131:642\u201350. ArticlePubMedGoogle Scholar Orimo S, Uchihara T, Nakamura A, Mori F, Kakita A, Wakabayashi K, Takahashi H. Axonal alpha-synuclein aggregates herald centripetal degeneration of cardiac sympathetic nerve in Parkinson\u2019s disease. Brain. 2008;131:642\u201350. ArticlePubMedGoogle Scholar Phillips RJ, Walter GC, Wilder SL, Baronowsky EA, Powley TL. Alpha-synuclein-immunopositive myenteric neurons and vagal preganglionic terminals: autonomic pathway implicated in Parkinson\u2019s disease? Neuroscience. 2008;153:733\u201350.ArticleCASPubMedGoogle Scholar Phillips RJ, Walter GC, Wilder SL, Baronowsky EA, Powley TL. Alpha-synuclein-immunopositive myenteric neurons and vagal preganglionic terminals: autonomic pathway implicated in Parkinson\u2019s disease? Neuroscience. 2008;153:733\u201350. ArticleCASPubMedGoogle Scholar Phillips RJ, Walter GC, Wilder SL, Baronowsky EA, Powley TL. Alpha-synuclein-immunopositive myenteric neurons and vagal preganglionic terminals: autonomic pathway implicated in Parkinson\u2019s disease? Neuroscience. 2008;153:733\u201350. ArticleCASPubMedGoogle Scholar Goldstein DS, Sharabi Y, Karp BI, Bentho O, Saleem A, Pacak K, Eisenhofer G. Cardiac sympathetic denervation preceding motor signs in Parkinson disease. Clin Auton Res. 2007;17:118\u201321.ArticlePubMedPubMed CentralGoogle Scholar Goldstein DS, Sharabi Y, Karp BI, Bentho O, Saleem A, Pacak K, Eisenhofer G. Cardiac sympathetic denervation preceding motor signs in Parkinson disease. Clin Auton Res. 2007;17:118\u201321. ArticlePubMedPubMed CentralGoogle Scholar Goldstein DS, Sharabi Y, Karp BI, Bentho O, Saleem A, Pacak K, Eisenhofer G. Cardiac sympathetic denervation preceding motor signs in Parkinson disease. Clin Auton Res. 2007;17:118\u201321. ArticlePubMedPubMed CentralGoogle Scholar Goldstein DS. Dysautonomia in Parkinson\u2019s disease: neurocardiological abnormalities. Lancet Neurol. 2003;2:669\u201376.ArticlePubMedGoogle Scholar Goldstein DS. Dysautonomia in Parkinson\u2019s disease: neurocardiological abnormalities. Lancet Neurol. 2003;2:669\u201376. ArticlePubMedGoogle Scholar Goldstein DS. Dysautonomia in Parkinson\u2019s disease: neurocardiological abnormalities. Lancet Neurol. 2003;2:669\u201376. ArticlePubMedGoogle Scholar Treglia G, Cason E, Stefanelli A, Cocciolillo F, Di Giuda D, Fagioli G, Giordano A. MIBG scintigraphy in differential diagnosis of Parkinsonism: a meta-analysis. Clin Auton Res. 2012;22:43\u201355.ArticlePubMedGoogle Scholar Treglia G, Cason E, Stefanelli A, Cocciolillo F, Di Giuda D, Fagioli G, Giordano A. MIBG scintigraphy in differential diagnosis of Parkinsonism: a meta-analysis. Clin Auton Res. 2012;22:43\u201355. ArticlePubMedGoogle Scholar Treglia G, Cason E, Stefanelli A, Cocciolillo F, Di Giuda D, Fagioli G, Giordano A. MIBG scintigraphy in differential diagnosis of Parkinsonism: a meta-analysis. Clin Auton Res. 2012;22:43\u201355. ArticlePubMedGoogle Scholar Beaulieu J-M, Espinoza S, Gainetdinov RR. Dopamine receptors - IUPHAR Review 13. Br J Pharmacol. 2015;172:1\u201323.ArticleCASPubMedGoogle Scholar Beaulieu J-M, Espinoza S, Gainetdinov RR. Dopamine receptors - IUPHAR Review 13. Br J Pharmacol. 2015;172:1\u201323. ArticleCASPubMedGoogle Scholar Beaulieu J-M, Espinoza S, Gainetdinov RR. Dopamine receptors - IUPHAR Review 13. Br J Pharmacol. 2015;172:1\u201323. ArticleCASPubMedGoogle Scholar Seeman P, Niznik HB. Dopamine receptors and transporters in Parkinson\u2019s disease and schizophrenia. FASEB J. 1990;4:2737\u201344.ArticleCASPubMedGoogle Scholar Seeman P, Niznik HB. Dopamine receptors and transporters in Parkinson\u2019s disease and schizophrenia. FASEB J. 1990;4:2737\u201344. ArticleCASPubMedGoogle Scholar Seeman P, Niznik HB. Dopamine receptors and transporters in Parkinson\u2019s disease and schizophrenia. FASEB J. 1990;4:2737\u201344. ArticleCASPubMedGoogle Scholar Kaasinen V, Ruottinen HM, N\u00e5gren K, Lehikoinen P, Oikonen V, Rinne JO. Upregulation of putaminal dopamine D2 receptors in early Parkinson\u2019s disease: a comparative PET study with [11C] raclopride and [11C]N-methylspiperone. J Nucl Med. 2000;41:65\u201370.CASPubMedGoogle Scholar Kaasinen V, Ruottinen HM, N\u00e5gren K, Lehikoinen P, Oikonen V, Rinne JO. Upregulation of putaminal dopamine D2 receptors in early Parkinson\u2019s disease: a comparative PET study with [11C] raclopride and [11C]N-methylspiperone. J Nucl Med. 2000;41:65\u201370. CASPubMedGoogle Scholar Kaasinen V, Ruottinen HM, N\u00e5gren K, Lehikoinen P, Oikonen V, Rinne JO. Upregulation of putaminal dopamine D2 receptors in early Parkinson\u2019s disease: a comparative PET study with [11C] raclopride and [11C]N-methylspiperone. J Nucl Med. 2000;41:65\u201370. CASPubMedGoogle Scholar Farde L, Halldin C, Stone-Elander S, Sedvall G. PET analysis of human dopamine receptor subtypes using 11C-SCH 23390 and 11C-raclopride. Psychopharmacology. 1987;92(3):278\u201384.ArticleCASPubMedGoogle Scholar Farde L, Halldin C, Stone-Elander S, Sedvall G. PET analysis of human dopamine receptor subtypes using 11C-SCH 23390 and 11C-raclopride. Psychopharmacology. 1987;92(3):278\u201384. ArticleCASPubMedGoogle Scholar Farde L, Halldin C, Stone-Elander S, Sedvall G. PET analysis of human dopamine receptor subtypes using 11C-SCH 23390 and 11C-raclopride. Psychopharmacology. 1987;92(3):278\u201384. ArticleCASPubMedGoogle Scholar Halldin C, Farde L, Barnett A, Sedvall G. Synthesis of carbon-11 labelled SCH 39166, a new selective dopamine D-1 receptor ligand, and preliminary PET investigations. Int J Rad Appl Instrum A. 1991;42:451\u20135.ArticleCASPubMedGoogle Scholar Halldin C, Farde L, Barnett A, Sedvall G. Synthesis of carbon-11 labelled SCH 39166, a new selective dopamine D-1 receptor ligand, and preliminary PET investigations. Int J Rad Appl Instrum A. 1991;42:451\u20135. ArticleCASPubMedGoogle Scholar Halldin C, Farde L, Barnett A, Sedvall G. Synthesis of carbon-11 labelled SCH 39166, a new selective dopamine D-1 receptor ligand, and preliminary PET investigations. Int J Rad Appl Instrum A. 1991;42:451\u20135. ArticleCASPubMedGoogle Scholar Halldin C, Foged C, Chou Y-H, Karlsson P, Swahn C-G, Johan S, Sedvall G, Farde L. Carbon-11-NNC 112: A Radioligand for PET Examination of Striatal and Neocortical D<sub>1</sub>-Dopamine Receptors. J Nucl Med. 1998;39:2061.CASPubMedGoogle Scholar Halldin C, Foged C, Chou Y-H, Karlsson P, Swahn C-G, Johan S, Sedvall G, Farde L. Carbon-11-NNC 112: A Radioligand for PET Examination of Striatal and Neocortical D<sub>1</sub>-Dopamine Receptors. J Nucl Med. 1998;39:2061. CASPubMedGoogle Scholar Halldin C, Foged C, Chou Y-H, Karlsson P, Swahn C-G, Johan S, Sedvall G, Farde L. Carbon-11-NNC 112: A Radioligand for PET Examination of Striatal and Neocortical D<sub>1</sub>-Dopamine Receptors. J Nucl Med. 1998;39:2061. CASPubMedGoogle Scholar Ekelund J, Slifstein M, Narendran R, Guillin O, Belani H, Guo N-N, Hwang Y, Hwang D-R, Abi-Dargham A, Laruelle M. In Vivo DA D1 Receptor Selectivity of NNC 112 and SCH 23390. Mol Imag Biol. 2007;9:117\u201325.ArticleGoogle Scholar Ekelund J, Slifstein M, Narendran R, Guillin O, Belani H, Guo N-N, Hwang Y, Hwang D-R, Abi-Dargham A, Laruelle M. In Vivo DA D1 Receptor Selectivity of NNC 112 and SCH 23390. Mol Imag Biol. 2007;9:117\u201325. ArticleGoogle Scholar Ekelund J, Slifstein M, Narendran R, Guillin O, Belani H, Guo N-N, Hwang Y, Hwang D-R, Abi-Dargham A, Laruelle M. In Vivo DA D1 Receptor Selectivity of NNC 112 and SCH 23390. Mol Imag Biol. 2007;9:117\u201325. ArticleGoogle Scholar Tamagnan G, Barret O, Alagille D, Carroll V, Madonia J, Constantinescu C, SanDiego C, Papin C, Morley T, Russell D, et al. T156. In vivo characterization of the first agonist dopamine D1 receptors PET imaging tracer [18F]MNI-968 in human. Schizophr Bull. 2018;44:1.ArticleGoogle Scholar Tamagnan G, Barret O, Alagille D, Carroll V, Madonia J, Constantinescu C, SanDiego C, Papin C, Morley T, Russell D, et al. T156. In vivo characterization of the first agonist dopamine D1 receptors PET imaging tracer [18F]MNI-968 in human. Schizophr Bull. 2018;44:1. ArticleGoogle Scholar Tamagnan G, Barret O, Alagille D, Carroll V, Madonia J, Constantinescu C, SanDiego C, Papin C, Morley T, Russell D, et al. T156. In vivo characterization of the first agonist dopamine D1 receptors PET imaging tracer [18F]MNI-968 in human. Schizophr Bull. 2018;44:1. ArticleGoogle Scholar Ray NJ, Miyasaki JM, Zurowski M, Ko JH, Cho SS, Pellecchia G, Antonelli F, Houle S, Lang AE, Strafella AP. Extrastriatal dopaminergic abnormalities of DA homeostasis in Parkinson\u2019s patients with medication-induced pathological gambling: a [11C] FLB-457 and PET study. Neurobiol Dis. 2012;48:519\u201325.ArticleCASPubMedPubMed CentralGoogle Scholar Ray NJ, Miyasaki JM, Zurowski M, Ko JH, Cho SS, Pellecchia G, Antonelli F, Houle S, Lang AE, Strafella AP. Extrastriatal dopaminergic abnormalities of DA homeostasis in Parkinson\u2019s patients with medication-induced pathological gambling: a [11C] FLB-457 and PET study. Neurobiol Dis. 2012;48:519\u201325. ArticleCASPubMedPubMed CentralGoogle Scholar Ray NJ, Miyasaki JM, Zurowski M, Ko JH, Cho SS, Pellecchia G, Antonelli F, Houle S, Lang AE, Strafella AP. Extrastriatal dopaminergic abnormalities of DA homeostasis in Parkinson\u2019s patients with medication-induced pathological gambling: a [11C] FLB-457 and PET study. Neurobiol Dis. 2012;48:519\u201325. ArticleCASPubMedPubMed CentralGoogle Scholar Nyberg S, Farde L, Eriksson L, Halldin C, Eriksson B. 5-HT2 and D2 dopamine receptor occupancy in the living human brain A PET study with risperidone. Psychopharmacology. 1993;110:265\u201372.ArticleCASPubMedGoogle Scholar Nyberg S, Farde L, Eriksson L, Halldin C, Eriksson B. 5-HT2 and D2 dopamine receptor occupancy in the living human brain A PET study with risperidone. Psychopharmacology. 1993;110:265\u201372. ArticleCASPubMedGoogle Scholar Nyberg S, Farde L, Eriksson L, Halldin C, Eriksson B. 5-HT2 and D2 dopamine receptor occupancy in the living human brain A PET study with risperidone. Psychopharmacology. 1993;110:265\u201372. ArticleCASPubMedGoogle Scholar Chefer SI, Kimes AS, Matochik JA, Horti AG, Kurian V, Shumway D, Domino EF, London ED, Mukhin AG. Estimation of D2-like receptor occupancy by dopamine in the putamen of hemiparkinsonian Monkeys. Neuropsychopharmacology. 2008;33:270\u20138.ArticleCASPubMedGoogle Scholar Chefer SI, Kimes AS, Matochik JA, Horti AG, Kurian V, Shumway D, Domino EF, London ED, Mukhin AG. Estimation of D2-like receptor occupancy by dopamine in the putamen of hemiparkinsonian Monkeys. Neuropsychopharmacology. 2008;33:270\u20138. ArticleCASPubMedGoogle Scholar Chefer SI, Kimes AS, Matochik JA, Horti AG, Kurian V, Shumway D, Domino EF, London ED, Mukhin AG. Estimation of D2-like receptor occupancy by dopamine in the putamen of hemiparkinsonian Monkeys. Neuropsychopharmacology. 2008;33:270\u20138. ArticleCASPubMedGoogle Scholar Sahin G, Thompson LH, Lavisse S, Ozgur M, Rbah-Vidal L, Doll\u00e9 F, Hantraye P, Kirik D. Differential dopamine receptor occupancy underlies L-DOPA-induced dyskinesia in a rat model of Parkinson\u2019s disease. PLoS ONE. 2014;9:e90759.ArticlePubMedPubMed CentralGoogle Scholar Sahin G, Thompson LH, Lavisse S, Ozgur M, Rbah-Vidal L, Doll\u00e9 F, Hantraye P, Kirik D. Differential dopamine receptor occupancy underlies L-DOPA-induced dyskinesia in a rat model of Parkinson\u2019s disease. PLoS ONE. 2014;9:e90759. ArticlePubMedPubMed CentralGoogle Scholar Sahin G, Thompson LH, Lavisse S, Ozgur M, Rbah-Vidal L, Doll\u00e9 F, Hantraye P, Kirik D. Differential dopamine receptor occupancy underlies L-DOPA-induced dyskinesia in a rat model of Parkinson\u2019s disease. PLoS ONE. 2014;9:e90759. ArticlePubMedPubMed CentralGoogle Scholar de la Fuente-Fern\u00e1ndez R, Sossi V, Huang Z, Furtado S, Lu JQ, Calne DB, Ruth TJ, Stoessl AJ. Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson\u2019s disease: implications for dyskinesias. Brain. 2004;127:2747\u201354.ArticlePubMedGoogle Scholar de la Fuente-Fern\u00e1ndez R, Sossi V, Huang Z, Furtado S, Lu JQ, Calne DB, Ruth TJ, Stoessl AJ. Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson\u2019s disease: implications for dyskinesias. Brain. 2004;127:2747\u201354. ArticlePubMedGoogle Scholar de la Fuente-Fern\u00e1ndez R, Sossi V, Huang Z, Furtado S, Lu JQ, Calne DB, Ruth TJ, Stoessl AJ. Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson\u2019s disease: implications for dyskinesias. Brain. 2004;127:2747\u201354. ArticlePubMedGoogle Scholar Del Bello F, Giannella M, Giorgioni G, Piergentili A, Quaglia W. Receptor Ligands as Helping Hands to L-DOPA in the Treatment of Parkinson\u2019s Disease. Biomolecules. 2019;9(4):142.ArticlePubMedPubMed CentralGoogle Scholar Del Bello F, Giannella M, Giorgioni G, Piergentili A, Quaglia W. Receptor Ligands as Helping Hands to L-DOPA in the Treatment of Parkinson\u2019s Disease. Biomolecules. 2019;9(4):142. ArticlePubMedPubMed CentralGoogle Scholar Del Bello F, Giannella M, Giorgioni G, Piergentili A, Quaglia W. Receptor Ligands as Helping Hands to L-DOPA in the Treatment of Parkinson\u2019s Disease. Biomolecules. 2019;9(4):142. ArticlePubMedPubMed CentralGoogle Scholar Clarke CE, Guttman M. Dopamine agonist monotherapy in Parkinson\u2019s disease. The Lancet. 2002;360:1767\u20139.ArticleCASGoogle Scholar Clarke CE, Guttman M. Dopamine agonist monotherapy in Parkinson\u2019s disease. The Lancet. 2002;360:1767\u20139. ArticleCASGoogle Scholar Clarke CE, Guttman M. Dopamine agonist monotherapy in Parkinson\u2019s disease. The Lancet. 2002;360:1767\u20139. ArticleCASGoogle Scholar Blandini F, Armentero MT. Dopamine receptor agonists for Parkinson\u2019s disease. Expert Opin Investig Drugs. 2014;23:387\u2013410.ArticleCASPubMedGoogle Scholar Blandini F, Armentero MT. Dopamine receptor agonists for Parkinson\u2019s disease. Expert Opin Investig Drugs. 2014;23:387\u2013410. ArticleCASPubMedGoogle Scholar Blandini F, Armentero MT. Dopamine receptor agonists for Parkinson\u2019s disease. Expert Opin Investig Drugs. 2014;23:387\u2013410. ArticleCASPubMedGoogle Scholar Davie CA. A review of Parkinson\u2019s disease. Br Med Bull. 2008;86:109\u201327.ArticleCASPubMedGoogle Scholar Davie CA. A review of Parkinson\u2019s disease. Br Med Bull. 2008;86:109\u201327. ArticleCASPubMedGoogle Scholar Davie CA. A review of Parkinson\u2019s disease. Br Med Bull. 2008;86:109\u201327. ArticleCASPubMedGoogle Scholar Abbott A. Levodopa: the story so far. Nature. 2010;466:S6\u20137.ArticleCASPubMedGoogle Scholar Abbott A. Levodopa: the story so far. Nature. 2010;466:S6\u20137. ArticleCASPubMedGoogle Scholar Abbott A. Levodopa: the story so far. Nature. 2010;466:S6\u20137. ArticleCASPubMedGoogle Scholar Guggenheim M. Dioxyphenylalanin, eine neue Aminos\u00e4ure aus Vicia faba. Biological Chemistry. 1913;88:276\u201384.Google Scholar Guggenheim M. Dioxyphenylalanin, eine neue Aminos\u00e4ure aus Vicia faba. Biological Chemistry. 1913;88:276\u201384. Google Scholar Guggenheim M. Dioxyphenylalanin, eine neue Aminos\u00e4ure aus Vicia faba. Biological Chemistry. 1913;88:276\u201384. Google Scholar Holtz P. Dopadecarboxylase. Naturwissenschaften. 1939;27:724\u20135.ArticleGoogle Scholar Holtz P. Dopadecarboxylase. Naturwissenschaften. 1939;27:724\u20135. ArticleGoogle Scholar Holtz P. Dopadecarboxylase. Naturwissenschaften. 1939;27:724\u20135. ArticleGoogle Scholar Hornykiewicz O. A brief history of levodopa. J Neurol. 2010;257:249\u201352.ArticleCASGoogle Scholar Hornykiewicz O. A brief history of levodopa. J Neurol. 2010;257:249\u201352. ArticleCASGoogle Scholar Hornykiewicz O. A brief history of levodopa. J Neurol. 2010;257:249\u201352. ArticleCASGoogle Scholar Neurology TL. Building on 50 years of levodopa therapy. Lancet Neurol. 2016;15:1.ArticleGoogle Scholar Neurology TL. Building on 50 years of levodopa therapy. Lancet Neurol. 2016;15:1. ArticleGoogle Scholar Neurology TL. Building on 50 years of levodopa therapy. Lancet Neurol. 2016;15:1. ArticleGoogle Scholar Senek M, Nielsen EI, Nyholm D. Levodopa-entacapone-carbidopa intestinal gel in Parkinson\u2019s disease: A randomized crossover study. Mov Disord. 2017;32:283\u20136.ArticleCASPubMedGoogle Scholar Senek M, Nielsen EI, Nyholm D. Levodopa-entacapone-carbidopa intestinal gel in Parkinson\u2019s disease: A randomized crossover study. Mov Disord. 2017;32:283\u20136. ArticleCASPubMedGoogle Scholar Senek M, Nielsen EI, Nyholm D. Levodopa-entacapone-carbidopa intestinal gel in Parkinson\u2019s disease: A randomized crossover study. Mov Disord. 2017;32:283\u20136. ArticleCASPubMedGoogle Scholar Antonini A. Levodopa in the treatment of Parkinson&rsquo;s disease: an old drug still going strong. Clin Interv Aging. 2010;5:229.ArticlePubMedPubMed CentralGoogle Scholar Antonini A. Levodopa in the treatment of Parkinson&rsquo;s disease: an old drug still going strong. Clin Interv Aging. 2010;5:229. ArticlePubMedPubMed CentralGoogle Scholar Antonini A. Levodopa in the treatment of Parkinson&rsquo;s disease: an old drug still going strong. Clin Interv Aging. 2010;5:229. ArticlePubMedPubMed CentralGoogle Scholar Tambasco N, Romoli M, Calabresi P. Levodopa in Parkinson\u2019s Disease: Current Status and Future Developments. Curr Neuropharmacol. 2018;16:1239\u201352.ArticleCASPubMedPubMed CentralGoogle Scholar Tambasco N, Romoli M, Calabresi P. Levodopa in Parkinson\u2019s Disease: Current Status and Future Developments. Curr Neuropharmacol. 2018;16:1239\u201352. ArticleCASPubMedPubMed CentralGoogle Scholar Tambasco N, Romoli M, Calabresi P. Levodopa in Parkinson\u2019s Disease: Current Status and Future Developments. Curr Neuropharmacol. 2018;16:1239\u201352. ArticleCASPubMedPubMed CentralGoogle Scholar Nutl JG, Fellman JH. Pharmacokinetics of Levodopa. Clin Neuropharmacol. 1984;7:35\u201350.ArticleGoogle Scholar Nutl JG, Fellman JH. Pharmacokinetics of Levodopa. Clin Neuropharmacol. 1984;7:35\u201350. ArticleGoogle Scholar Nutl JG, Fellman JH. Pharmacokinetics of Levodopa. Clin Neuropharmacol. 1984;7:35\u201350. ArticleGoogle Scholar Hauser RA. Levodopa: Past, Present, and Future. Eur Neurol. 2009;62:1\u20138.ArticleCASPubMedGoogle Scholar Hauser RA. Levodopa: Past, Present, and Future. Eur Neurol. 2009;62:1\u20138. ArticleCASPubMedGoogle Scholar Hauser RA. Levodopa: Past, Present, and Future. Eur Neurol. 2009;62:1\u20138. ArticleCASPubMedGoogle Scholar Cedarbaum JM. Clinical Pharmacokinetics of Anti-Parkinsonian Drugs. Clin Pharmacokinet. 1987;13:141\u201378.ArticleCASPubMedGoogle Scholar Cedarbaum JM. Clinical Pharmacokinetics of Anti-Parkinsonian Drugs. Clin Pharmacokinet. 1987;13:141\u201378. ArticleCASPubMedGoogle Scholar Cedarbaum JM. Clinical Pharmacokinetics of Anti-Parkinsonian Drugs. Clin Pharmacokinet. 1987;13:141\u201378. ArticleCASPubMedGoogle Scholar Salat D, Tolosa E. Levodopa in the Treatment of Parkinson\u2019s Disease: Current Status and New Developments. J Parkinson\u2019s dis. 2013;3:255\u201369.ArticleCASGoogle Scholar Salat D, Tolosa E. Levodopa in the Treatment of Parkinson\u2019s Disease: Current Status and New Developments. J Parkinson\u2019s dis. 2013;3:255\u201369. ArticleCASGoogle Scholar Salat D, Tolosa E. Levodopa in the Treatment of Parkinson\u2019s Disease: Current Status and New Developments. J Parkinson\u2019s dis. 2013;3:255\u201369. ArticleCASGoogle Scholar Lipp MM, Batycky R, Moore J, Leinonen M, Freed MI. Preclinical and clinical assessment of inhaled levodopa for OFF episodes in Parkinson\u2019s disease. Sci Transl Med. 2016;8:360ra136.ArticlePubMedGoogle Scholar Lipp MM, Batycky R, Moore J, Leinonen M, Freed MI. Preclinical and clinical assessment of inhaled levodopa for OFF episodes in Parkinson\u2019s disease. Sci Transl Med. 2016;8:360ra136. ArticlePubMedGoogle Scholar Lipp MM, Batycky R, Moore J, Leinonen M, Freed MI. Preclinical and clinical assessment of inhaled levodopa for OFF episodes in Parkinson\u2019s disease. Sci Transl Med. 2016;8:360ra136. ArticlePubMedGoogle Scholar Ellenbogen A, Stocchi F, Espay A, Poewe W, Oren S, Case R, Olanow CW. Impact of Subcutaneous Levodopa Infusion with ND0612 on Patient Reported Outcomes (4506). Neurology. 2020;94:4506.ArticleGoogle Scholar Ellenbogen A, Stocchi F, Espay A, Poewe W, Oren S, Case R, Olanow CW. Impact of Subcutaneous Levodopa Infusion with ND0612 on Patient Reported Outcomes (4506). Neurology. 2020;94:4506. ArticleGoogle Scholar Ellenbogen A, Stocchi F, Espay A, Poewe W, Oren S, Case R, Olanow CW. Impact of Subcutaneous Levodopa Infusion with ND0612 on Patient Reported Outcomes (4506). Neurology. 2020;94:4506. ArticleGoogle Scholar Birnberg T, Smania G, Bjornsson M, Jonsson N, Case R, Oren S, Adar L, Karlsson M. Pharmacokinetic analysis of levodopa and carbidopa following subcutaneous infusion: A population pharmacokinetics model (2019). Neurology. 2019;2021:96.Google Scholar Birnberg T, Smania G, Bjornsson M, Jonsson N, Case R, Oren S, Adar L, Karlsson M. Pharmacokinetic analysis of levodopa and carbidopa following subcutaneous infusion: A population pharmacokinetics model (2019). Neurology. 2019;2021:96. Google Scholar Birnberg T, Smania G, Bjornsson M, Jonsson N, Case R, Oren S, Adar L, Karlsson M. Pharmacokinetic analysis of levodopa and carbidopa following subcutaneous infusion: A population pharmacokinetics model (2019). Neurology. 2019;2021:96. Google Scholar Urso D, Chaudhuri KR, Qamar MA, Jenner P. Improving the Delivery of Levodopa in Parkinson\u2019s Disease: A Review of Approved and Emerging Therapies. CNS Drugs. 2020;34:1149\u201363.ArticleCASPubMedGoogle Scholar Urso D, Chaudhuri KR, Qamar MA, Jenner P. Improving the Delivery of Levodopa in Parkinson\u2019s Disease: A Review of Approved and Emerging Therapies. CNS Drugs. 2020;34:1149\u201363. ArticleCASPubMedGoogle Scholar Urso D, Chaudhuri KR, Qamar MA, Jenner P. Improving the Delivery of Levodopa in Parkinson\u2019s Disease: A Review of Approved and Emerging Therapies. CNS Drugs. 2020;34:1149\u201363. ArticleCASPubMedGoogle Scholar M\u00fcller T. Catechol-O-methyltransferase inhibitors in Parkinson\u2019s disease. Drugs. 2015;75:157\u201374.ArticlePubMedGoogle Scholar M\u00fcller T. Catechol-O-methyltransferase inhibitors in Parkinson\u2019s disease. Drugs. 2015;75:157\u201374. ArticlePubMedGoogle Scholar M\u00fcller T. Catechol-O-methyltransferase inhibitors in Parkinson\u2019s disease. Drugs. 2015;75:157\u201374. ArticlePubMedGoogle Scholar Ferreira JJ, Lees A, Rocha JF, Poewe W, Rascol O, Soares-da-Silva P. Opicapone as an adjunct to levodopa in patients with Parkinson\u2019s disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial. Lancet Neurol. 2016;15:154\u201365.ArticleCASPubMedGoogle Scholar Ferreira JJ, Lees A, Rocha JF, Poewe W, Rascol O, Soares-da-Silva P. Opicapone as an adjunct to levodopa in patients with Parkinson\u2019s disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial. Lancet Neurol. 2016;15:154\u201365. ArticleCASPubMedGoogle Scholar Ferreira JJ, Lees A, Rocha JF, Poewe W, Rascol O, Soares-da-Silva P. Opicapone as an adjunct to levodopa in patients with Parkinson\u2019s disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial. Lancet Neurol. 2016;15:154\u201365. ArticleCASPubMedGoogle Scholar Schapira AH. Monoamine oxidase B inhibitors for the treatment of Parkinson\u2019s disease: a review of symptomatic and potential disease-modifying effects. CNS Drugs. 2011;25:1061\u201371.ArticleCASPubMedGoogle Scholar Schapira AH. Monoamine oxidase B inhibitors for the treatment of Parkinson\u2019s disease: a review of symptomatic and potential disease-modifying effects. CNS Drugs. 2011;25:1061\u201371. ArticleCASPubMedGoogle Scholar Schapira AH. Monoamine oxidase B inhibitors for the treatment of Parkinson\u2019s disease: a review of symptomatic and potential disease-modifying effects. CNS Drugs. 2011;25:1061\u201371. ArticleCASPubMedGoogle Scholar Fox SH, Katzenschlager R, Lim S-Y, Ravina B, Seppi K, Coelho M, Poewe W, Rascol O, Goetz CG, Sampaio C. The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the motor symptoms of Parkinson\u2019s disease. Mov Disord. 2011;26:S2\u201341.ArticlePubMedGoogle Scholar Fox SH, Katzenschlager R, Lim S-Y, Ravina B, Seppi K, Coelho M, Poewe W, Rascol O, Goetz CG, Sampaio C. The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the motor symptoms of Parkinson\u2019s disease. Mov Disord. 2011;26:S2\u201341. ArticlePubMedGoogle Scholar Fox SH, Katzenschlager R, Lim S-Y, Ravina B, Seppi K, Coelho M, Poewe W, Rascol O, Goetz CG, Sampaio C. The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the motor symptoms of Parkinson\u2019s disease. Mov Disord. 2011;26:S2\u201341. ArticlePubMedGoogle Scholar Group PS. A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. Arch Neurol. 2002;59:1937\u201343.ArticleGoogle Scholar Group PS. A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. Arch Neurol. 2002;59:1937\u201343. ArticleGoogle Scholar Group PS. A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. Arch Neurol. 2002;59:1937\u201343. ArticleGoogle Scholar Schapira AH, Fox SH, Hauser RA, Jankovic J, Jost WH, Kenney C, Kulisevsky J, Pahwa R, Poewe W, Anand R. Assessment of Safety and Efficacy of Safinamide as a Levodopa Adjunct in Patients With Parkinson Disease and Motor Fluctuations: A Randomized Clinical Trial. JAMA Neurol. 2017;74:216\u201324.ArticlePubMedGoogle Scholar Schapira AH, Fox SH, Hauser RA, Jankovic J, Jost WH, Kenney C, Kulisevsky J, Pahwa R, Poewe W, Anand R. Assessment of Safety and Efficacy of Safinamide as a Levodopa Adjunct in Patients With Parkinson Disease and Motor Fluctuations: A Randomized Clinical Trial. JAMA Neurol. 2017;74:216\u201324. ArticlePubMedGoogle Scholar Schapira AH, Fox SH, Hauser RA, Jankovic J, Jost WH, Kenney C, Kulisevsky J, Pahwa R, Poewe W, Anand R. Assessment of Safety and Efficacy of Safinamide as a Levodopa Adjunct in Patients With Parkinson Disease and Motor Fluctuations: A Randomized Clinical Trial. JAMA Neurol. 2017;74:216\u201324. ArticlePubMedGoogle Scholar Ellis JM, Fell MJ. Current approaches to the treatment of Parkinson\u2019s Disease. Bioorg Med Chem Lett. 2017;27:4247\u201355.ArticleCASPubMedGoogle Scholar Ellis JM, Fell MJ. Current approaches to the treatment of Parkinson\u2019s Disease. Bioorg Med Chem Lett. 2017;27:4247\u201355. ArticleCASPubMedGoogle Scholar Ellis JM, Fell MJ. Current approaches to the treatment of Parkinson\u2019s Disease. Bioorg Med Chem Lett. 2017;27:4247\u201355. ArticleCASPubMedGoogle Scholar Bezard E, Brotchie JM, Gross CE. Pathophysiology of levodopa-induced dyskinesia: Potential for new therapies. Nat Rev Neurosci. 2001;2:577\u201388.ArticleCASPubMedGoogle Scholar Bezard E, Brotchie JM, Gross CE. Pathophysiology of levodopa-induced dyskinesia: Potential for new therapies. Nat Rev Neurosci. 2001;2:577\u201388. ArticleCASPubMedGoogle Scholar Bezard E, Brotchie JM, Gross CE. Pathophysiology of levodopa-induced dyskinesia: Potential for new therapies. Nat Rev Neurosci. 2001;2:577\u201388. ArticleCASPubMedGoogle Scholar Lee J, Zhu W-M, Stanic D, Finkelstein DI, Horne MH, Henderson J, Lawrence AJ, O\u2019Connor L, Tomas D, Drago J, Horne MK. Sprouting of dopamine terminals and altered dopamine release and uptake in Parkinsonian dyskinaesia. Brain. 2008;131:1574\u201387.ArticlePubMedGoogle Scholar Lee J, Zhu W-M, Stanic D, Finkelstein DI, Horne MH, Henderson J, Lawrence AJ, O\u2019Connor L, Tomas D, Drago J, Horne MK. Sprouting of dopamine terminals and altered dopamine release and uptake in Parkinsonian dyskinaesia. Brain. 2008;131:1574\u201387. ArticlePubMedGoogle Scholar Lee J, Zhu W-M, Stanic D, Finkelstein DI, Horne MH, Henderson J, Lawrence AJ, O\u2019Connor L, Tomas D, Drago J, Horne MK. Sprouting of dopamine terminals and altered dopamine release and uptake in Parkinsonian dyskinaesia. Brain. 2008;131:1574\u201387. ArticlePubMedGoogle Scholar Olanow CW, Obeso JA, Stocchi F. Continuous dopamine-receptor treatment of Parkinson\u2019s disease: scientific rationale and clinical implications. Lancet Neurol. 2006;5:677\u201387.ArticleCASPubMedGoogle Scholar Olanow CW, Obeso JA, Stocchi F. Continuous dopamine-receptor treatment of Parkinson\u2019s disease: scientific rationale and clinical implications. Lancet Neurol. 2006;5:677\u201387. ArticleCASPubMedGoogle Scholar Olanow CW, Obeso JA, Stocchi F. Continuous dopamine-receptor treatment of Parkinson\u2019s disease: scientific rationale and clinical implications. Lancet Neurol. 2006;5:677\u201387. ArticleCASPubMedGoogle Scholar Antonini A, Fung VS, Boyd JT, Slevin JT, Hall C, Chatamra K, Eaton S, Benesh JA. Effect of levodopa-carbidopa intestinal gel on dyskinesia in advanced Parkinson\u2019s disease patients. Mov Disord. 2016;31:530\u20137.ArticleCASPubMedPubMed CentralGoogle Scholar Antonini A, Fung VS, Boyd JT, Slevin JT, Hall C, Chatamra K, Eaton S, Benesh JA. Effect of levodopa-carbidopa intestinal gel on dyskinesia in advanced Parkinson\u2019s disease patients. Mov Disord. 2016;31:530\u20137. ArticleCASPubMedPubMed CentralGoogle Scholar Antonini A, Fung VS, Boyd JT, Slevin JT, Hall C, Chatamra K, Eaton S, Benesh JA. Effect of levodopa-carbidopa intestinal gel on dyskinesia in advanced Parkinson\u2019s disease patients. Mov Disord. 2016;31:530\u20137. ArticleCASPubMedPubMed CentralGoogle Scholar Poewe W, Antonini A. Novel formulations and modes of delivery of levodopa. Mov Disord. 2015;30:114\u201320.ArticleCASPubMedGoogle Scholar Poewe W, Antonini A. Novel formulations and modes of delivery of levodopa. Mov Disord. 2015;30:114\u201320. ArticleCASPubMedGoogle Scholar Poewe W, Antonini A. Novel formulations and modes of delivery of levodopa. Mov Disord. 2015;30:114\u201320. ArticleCASPubMedGoogle Scholar Firnau G, Nahmias C, Garnett S. The preparation of [18F]5-fluoro-DOPA with reactor-produced fluorine-18. Int J Appl Radiat Isot. 1973;24:182\u20134.ArticleCASPubMedGoogle Scholar Firnau G, Nahmias C, Garnett S. The preparation of [18F]5-fluoro-DOPA with reactor-produced fluorine-18. Int J Appl Radiat Isot. 1973;24:182\u20134. ArticleCASPubMedGoogle Scholar Firnau G, Nahmias C, Garnett S. The preparation of [18F]5-fluoro-DOPA with reactor-produced fluorine-18. Int J Appl Radiat Isot. 1973;24:182\u20134. ArticleCASPubMedGoogle Scholar Garnett S, Firnau G, Nahmias C, Chirakal R. Striatal dopamine metabolism in living monkeys examined by positron emission tomography. Brain Res. 1983;280:169\u201371.ArticleCASPubMedGoogle Scholar Garnett S, Firnau G, Nahmias C, Chirakal R. Striatal dopamine metabolism in living monkeys examined by positron emission tomography. Brain Res. 1983;280:169\u201371. ArticleCASPubMedGoogle Scholar Garnett S, Firnau G, Nahmias C, Chirakal R. Striatal dopamine metabolism in living monkeys examined by positron emission tomography. Brain Res. 1983;280:169\u201371. ArticleCASPubMedGoogle Scholar Nanni C, Fanti S, Rubello D. 18F-DOPA PET and PET/CT. J Nucl Med. 2007;48:1577\u20139.ArticlePubMedGoogle Scholar Nanni C, Fanti S, Rubello D. 18F-DOPA PET and PET/CT. J Nucl Med. 2007;48:1577\u20139. ArticlePubMedGoogle Scholar Nanni C, Fanti S, Rubello D. 18F-DOPA PET and PET/CT. J Nucl Med. 2007;48:1577\u20139. ArticlePubMedGoogle Scholar Ribeiro M-J, Vidailhet M, Loc\u2019h C, Dupel C, Nguyen JP, Ponchant M, Doll\u00e9 F, Peschanski M, Hantraye P, Cesaro P, et al. Dopaminergic Function and Dopamine Transporter Binding Assessed With Positron Emission Tomography in Parkinson Disease. Arch Neurol. 2002;59:580\u20136.ArticlePubMedGoogle Scholar Ribeiro M-J, Vidailhet M, Loc\u2019h C, Dupel C, Nguyen JP, Ponchant M, Doll\u00e9 F, Peschanski M, Hantraye P, Cesaro P, et al. Dopaminergic Function and Dopamine Transporter Binding Assessed With Positron Emission Tomography in Parkinson Disease. Arch Neurol. 2002;59:580\u20136. ArticlePubMedGoogle Scholar Ribeiro M-J, Vidailhet M, Loc\u2019h C, Dupel C, Nguyen JP, Ponchant M, Doll\u00e9 F, Peschanski M, Hantraye P, Cesaro P, et al. Dopaminergic Function and Dopamine Transporter Binding Assessed With Positron Emission Tomography in Parkinson Disease. Arch Neurol. 2002;59:580\u20136. ArticlePubMedGoogle Scholar Weeks RA, Brooks DJ. Positron emission tomography and central neurotransmitter systems in movement disorders. Fundam Clin Pharmacol. 1994;8:503\u201317.ArticleCASPubMedGoogle Scholar Weeks RA, Brooks DJ. Positron emission tomography and central neurotransmitter systems in movement disorders. Fundam Clin Pharmacol. 1994;8:503\u201317. ArticleCASPubMedGoogle Scholar Weeks RA, Brooks DJ. Positron emission tomography and central neurotransmitter systems in movement disorders. Fundam Clin Pharmacol. 1994;8:503\u201317. ArticleCASPubMedGoogle Scholar Garnett ES, Firnau G, Nahmias C. Dopamine visualized in the basal ganglia of living man. Nature. 1983;305:137\u20138.ArticleCASPubMedGoogle Scholar Garnett ES, Firnau G, Nahmias C. Dopamine visualized in the basal ganglia of living man. Nature. 1983;305:137\u20138. ArticleCASPubMedGoogle Scholar Garnett ES, Firnau G, Nahmias C. Dopamine visualized in the basal ganglia of living man. Nature. 1983;305:137\u20138. ArticleCASPubMedGoogle Scholar Piel M, Vernaleken I, Rosch F. Positron emission tomography in CNS drug discovery and drug monitoring. J Med Chem. 2014;57:9232\u201358.ArticleCASPubMedGoogle Scholar Piel M, Vernaleken I, Rosch F. Positron emission tomography in CNS drug discovery and drug monitoring. J Med Chem. 2014;57:9232\u201358. ArticleCASPubMedGoogle Scholar Piel M, Vernaleken I, Rosch F. Positron emission tomography in CNS drug discovery and drug monitoring. J Med Chem. 2014;57:9232\u201358. ArticleCASPubMedGoogle Scholar Dhawan V, Niethammer M, Lesser M, Pappas K, Hellman M, Fitzpatrick T, Quartarolo L, Bjelke D, Eidelberg D, Chlay T. Prospective FDOPA PET imaging study in human PD :our final step towards NDA approval. J Nucl Med. 2020;61:1565.Google Scholar Dhawan V, Niethammer M, Lesser M, Pappas K, Hellman M, Fitzpatrick T, Quartarolo L, Bjelke D, Eidelberg D, Chlay T. Prospective FDOPA PET imaging study in human PD :our final step towards NDA approval. J Nucl Med. 2020;61:1565. Google Scholar Dhawan V, Niethammer M, Lesser M, Pappas K, Hellman M, Fitzpatrick T, Quartarolo L, Bjelke D, Eidelberg D, Chlay T. Prospective FDOPA PET imaging study in human PD :our final step towards NDA approval. J Nucl Med. 2020;61:1565. Google Scholar Dannals RF, Neumeyer JL, Milius RA, Ravert HT, Wilson AA, Wagner HN Jr. Synthesis of a radiotracer for studying dopamine uptake sites in vivo using PET: 2\u03b2-carbomethoxy-3\u03b2-(4-fluorophenyl)-[N-11C-methyl]tropane ([11C]CFT or [11C]WIN-35,428). J Labelled Compd Radiopharm. 1993;33:147\u201352.ArticleCASGoogle Scholar Dannals RF, Neumeyer JL, Milius RA, Ravert HT, Wilson AA, Wagner HN Jr. Synthesis of a radiotracer for studying dopamine uptake sites in vivo using PET: 2\u03b2-carbomethoxy-3\u03b2-(4-fluorophenyl)-[N-11C-methyl]tropane ([11C]CFT or [11C]WIN-35,428). J Labelled Compd Radiopharm. 1993;33:147\u201352. ArticleCASGoogle Scholar Dannals RF, Neumeyer JL, Milius RA, Ravert HT, Wilson AA, Wagner HN Jr. Synthesis of a radiotracer for studying dopamine uptake sites in vivo using PET: 2\u03b2-carbomethoxy-3\u03b2-(4-fluorophenyl)-[N-11C-methyl]tropane ([11C]CFT or [11C]WIN-35,428). J Labelled Compd Radiopharm. 1993;33:147\u201352. ArticleCASGoogle Scholar Rinne JO, Bergman J, Ruottinen H, Haaparanta M, Eronen E, Oikonen V, Sonninen P, Solin O. Striatal uptake of a novel PET ligand, [18F]beta-CFT, is reduced in early Parkinson\u2019s disease. Synapse. 1999;31:119\u201324.ArticleCASPubMedGoogle Scholar Rinne JO, Bergman J, Ruottinen H, Haaparanta M, Eronen E, Oikonen V, Sonninen P, Solin O. Striatal uptake of a novel PET ligand, [18F]beta-CFT, is reduced in early Parkinson\u2019s disease. Synapse. 1999;31:119\u201324. ArticleCASPubMedGoogle Scholar Rinne JO, Bergman J, Ruottinen H, Haaparanta M, Eronen E, Oikonen V, Sonninen P, Solin O. Striatal uptake of a novel PET ligand, [18F]beta-CFT, is reduced in early Parkinson\u2019s disease. Synapse. 1999;31:119\u201324. ArticleCASPubMedGoogle Scholar Appel L, Jonasson M, Danfors T, Nyholm D, Askmark H, Lubberink M, S\u00f6rensen J. Use of 11C-PE2I PET in differential diagnosis of parkinsonian disorders. J Nucl Med. 2015;56:234\u201342.ArticlePubMedGoogle Scholar Appel L, Jonasson M, Danfors T, Nyholm D, Askmark H, Lubberink M, S\u00f6rensen J. Use of 11C-PE2I PET in differential diagnosis of parkinsonian disorders. J Nucl Med. 2015;56:234\u201342. ArticlePubMedGoogle Scholar Appel L, Jonasson M, Danfors T, Nyholm D, Askmark H, Lubberink M, S\u00f6rensen J. Use of 11C-PE2I PET in differential diagnosis of parkinsonian disorders. J Nucl Med. 2015;56:234\u201342. ArticlePubMedGoogle Scholar Fischman AJ, Bonab AA, Babich JW, Livni E, Alpert NM, Meltzer PC, Madras BK. [(11)C, (127)I] Altropane: a highly selective ligand for PET imaging of dopamine transporter sites. Synapse. 2001;39:332\u201342.ArticleCASPubMedGoogle Scholar Fischman AJ, Bonab AA, Babich JW, Livni E, Alpert NM, Meltzer PC, Madras BK. [(11)C, (127)I] Altropane: a highly selective ligand for PET imaging of dopamine transporter sites. Synapse. 2001;39:332\u201342. ArticleCASPubMedGoogle Scholar Fischman AJ, Bonab AA, Babich JW, Livni E, Alpert NM, Meltzer PC, Madras BK. [(11)C, (127)I] Altropane: a highly selective ligand for PET imaging of dopamine transporter sites. Synapse. 2001;39:332\u201342. ArticleCASPubMedGoogle Scholar Seifert KD, Wiener JI. The impact of DaTscan on the diagnosis and management of movement disorders: A retrospective study. Am J Neurodegener Dis. 2013;2:29\u201334.PubMedPubMed CentralGoogle Scholar Seifert KD, Wiener JI. The impact of DaTscan on the diagnosis and management of movement disorders: A retrospective study. Am J Neurodegener Dis. 2013;2:29\u201334. PubMedPubMed CentralGoogle Scholar Seifert KD, Wiener JI. The impact of DaTscan on the diagnosis and management of movement disorders: A retrospective study. Am J Neurodegener Dis. 2013;2:29\u201334. PubMedPubMed CentralGoogle Scholar Frost JJ, Rosier AJ, Reich SG, Smith JS, Ehlers MD, Snyder SH, Ravert HT, Dannals RF. Positron emission tomographic imaging of the dopamine transporter with 11C-WIN 35,428 reveals marked declines in mild Parkinson\u2019s disease. Ann Neurol. 1993;34:423\u201331.ArticleCASPubMedGoogle Scholar Frost JJ, Rosier AJ, Reich SG, Smith JS, Ehlers MD, Snyder SH, Ravert HT, Dannals RF. Positron emission tomographic imaging of the dopamine transporter with 11C-WIN 35,428 reveals marked declines in mild Parkinson\u2019s disease. Ann Neurol. 1993;34:423\u201331. ArticleCASPubMedGoogle Scholar Frost JJ, Rosier AJ, Reich SG, Smith JS, Ehlers MD, Snyder SH, Ravert HT, Dannals RF. Positron emission tomographic imaging of the dopamine transporter with 11C-WIN 35,428 reveals marked declines in mild Parkinson\u2019s disease. Ann Neurol. 1993;34:423\u201331. ArticleCASPubMedGoogle Scholar Piccini PP. Dopamine transporter: Basic aspects and neuroimaging. Mov Disord. 2003;18:S3\u20138.ArticlePubMedGoogle Scholar Piccini PP. Dopamine transporter: Basic aspects and neuroimaging. Mov Disord. 2003;18:S3\u20138. ArticlePubMedGoogle Scholar Piccini PP. Dopamine transporter: Basic aspects and neuroimaging. Mov Disord. 2003;18:S3\u20138. ArticlePubMedGoogle Scholar Brooks DJ. Molecular imaging of dopamine transporters. Ageing Res Rev. 2016;30:114\u201321.ArticleCASPubMedGoogle Scholar Brooks DJ. Molecular imaging of dopamine transporters. Ageing Res Rev. 2016;30:114\u201321. ArticleCASPubMedGoogle Scholar Brooks DJ. Molecular imaging of dopamine transporters. Ageing Res Rev. 2016;30:114\u201321. ArticleCASPubMedGoogle Scholar Peter D, Liu Y, Sternini C, De Giorgio R, Brecha N, Edwards R. Differential expression of two vesicular monoamine transporters. J Neurosci. 1995;15:6179\u201388.ArticleCASPubMedPubMed CentralGoogle Scholar Peter D, Liu Y, Sternini C, De Giorgio R, Brecha N, Edwards R. Differential expression of two vesicular monoamine transporters. J Neurosci. 1995;15:6179\u201388. ArticleCASPubMedPubMed CentralGoogle Scholar Peter D, Liu Y, Sternini C, De Giorgio R, Brecha N, Edwards R. Differential expression of two vesicular monoamine transporters. J Neurosci. 1995;15:6179\u201388. ArticleCASPubMedPubMed CentralGoogle Scholar Vander Borght TM, Sima AAF, Kilbourn MR, Desmond TJ, Kuhl DE, Frey KA. [3H]methoxytetrabenazine: A high specific activity ligand for estimating monoaminergic neuronal integrity. Neuroscience. 1995;68:955\u201362.ArticleCASPubMedGoogle Scholar Vander Borght TM, Sima AAF, Kilbourn MR, Desmond TJ, Kuhl DE, Frey KA. [3H]methoxytetrabenazine: A high specific activity ligand for estimating monoaminergic neuronal integrity. Neuroscience. 1995;68:955\u201362. ArticleCASPubMedGoogle Scholar Vander Borght TM, Sima AAF, Kilbourn MR, Desmond TJ, Kuhl DE, Frey KA. [3H]methoxytetrabenazine: A high specific activity ligand for estimating monoaminergic neuronal integrity. Neuroscience. 1995;68:955\u201362. ArticleCASPubMedGoogle Scholar Frey KA, Koeppe RA, Kilbourn MR, Vander Borght TM, Albin RL, Gilman S, Kuhl DE. Presynaptic monoaminergic vesicles in Parkinson\u2019s disease and normal aging. Ann Neurol. 1996;40:873\u201384.ArticleCASPubMedGoogle Scholar Frey KA, Koeppe RA, Kilbourn MR, Vander Borght TM, Albin RL, Gilman S, Kuhl DE. Presynaptic monoaminergic vesicles in Parkinson\u2019s disease and normal aging. Ann Neurol. 1996;40:873\u201384. ArticleCASPubMedGoogle Scholar Frey KA, Koeppe RA, Kilbourn MR, Vander Borght TM, Albin RL, Gilman S, Kuhl DE. Presynaptic monoaminergic vesicles in Parkinson\u2019s disease and normal aging. Ann Neurol. 1996;40:873\u201384. ArticleCASPubMedGoogle Scholar Okamura N, Villemagne VL, Drago J, Pejoska S, Dhamija RK, Mulligan RS, Ellis JR, Ackermann U, O\u2019Keefe G, Jones G, et al. In vivo measurement of vesicular monoamine transporter type 2 density in Parkinson disease with (18)F-AV-133. J Nucl Med. 2010;51:223\u20138.ArticlePubMedGoogle Scholar Okamura N, Villemagne VL, Drago J, Pejoska S, Dhamija RK, Mulligan RS, Ellis JR, Ackermann U, O\u2019Keefe G, Jones G, et al. In vivo measurement of vesicular monoamine transporter type 2 density in Parkinson disease with (18)F-AV-133. J Nucl Med. 2010;51:223\u20138. ArticlePubMedGoogle Scholar Okamura N, Villemagne VL, Drago J, Pejoska S, Dhamija RK, Mulligan RS, Ellis JR, Ackermann U, O\u2019Keefe G, Jones G, et al. In vivo measurement of vesicular monoamine transporter type 2 density in Parkinson disease with (18)F-AV-133. J Nucl Med. 2010;51:223\u20138. ArticlePubMedGoogle Scholar Hsiao IT, Weng YH, Hsieh CJ, Lin WY, Wey SP, Kung MP, Yen TC, Lu CS, Lin KJ. Correlation of Parkinson disease severity and 18F-DTBZ positron emission tomography. JAMA Neurol. 2014;71:758\u201366.ArticlePubMedGoogle Scholar Hsiao IT, Weng YH, Hsieh CJ, Lin WY, Wey SP, Kung MP, Yen TC, Lu CS, Lin KJ. Correlation of Parkinson disease severity and 18F-DTBZ positron emission tomography. JAMA Neurol. 2014;71:758\u201366. ArticlePubMedGoogle Scholar Hsiao IT, Weng YH, Hsieh CJ, Lin WY, Wey SP, Kung MP, Yen TC, Lu CS, Lin KJ. Correlation of Parkinson disease severity and 18F-DTBZ positron emission tomography. JAMA Neurol. 2014;71:758\u201366. ArticlePubMedGoogle Scholar Chaudhuri KR, Healy DG, Schapira AH. Non-motor symptoms of Parkinson\u2019s disease: diagnosis and management. Lancet Neurol. 2006;5:235\u201345.ArticlePubMedGoogle Scholar Chaudhuri KR, Healy DG, Schapira AH. Non-motor symptoms of Parkinson\u2019s disease: diagnosis and management. Lancet Neurol. 2006;5:235\u201345. ArticlePubMedGoogle Scholar Chaudhuri KR, Healy DG, Schapira AH. Non-motor symptoms of Parkinson\u2019s disease: diagnosis and management. Lancet Neurol. 2006;5:235\u201345. ArticlePubMedGoogle Scholar Politis M, Wu K, Loane C, Kiferle L, Molloy S, Brooks DJ, Piccini P. Staging of serotonergic dysfunction in Parkinson\u2019s disease: an in vivo 11C-DASB PET study. Neurobiol Dis. 2010;40:216\u201321.ArticleCASPubMedGoogle Scholar Politis M, Wu K, Loane C, Kiferle L, Molloy S, Brooks DJ, Piccini P. Staging of serotonergic dysfunction in Parkinson\u2019s disease: an in vivo 11C-DASB PET study. Neurobiol Dis. 2010;40:216\u201321. ArticleCASPubMedGoogle Scholar Politis M, Wu K, Loane C, Kiferle L, Molloy S, Brooks DJ, Piccini P. Staging of serotonergic dysfunction in Parkinson\u2019s disease: an in vivo 11C-DASB PET study. Neurobiol Dis. 2010;40:216\u201321. ArticleCASPubMedGoogle Scholar Doder M, Rabiner EA, Turjanski N, Lees AJ, Brooks DJ. study CWP: Tremor in Parkinson\u2019s disease and serotonergic dysfunction: an 11C-WAY 100635 PET study. Neurology. 2003;60:601\u20135.ArticleCASPubMedGoogle Scholar Doder M, Rabiner EA, Turjanski N, Lees AJ, Brooks DJ. study CWP: Tremor in Parkinson\u2019s disease and serotonergic dysfunction: an 11C-WAY 100635 PET study. Neurology. 2003;60:601\u20135. ArticleCASPubMedGoogle Scholar Doder M, Rabiner EA, Turjanski N, Lees AJ, Brooks DJ. study CWP: Tremor in Parkinson\u2019s disease and serotonergic dysfunction: an 11C-WAY 100635 PET study. Neurology. 2003;60:601\u20135. ArticleCASPubMedGoogle Scholar Fu H, Rong J, Chen Z, Zhou J, Collier T, Liang SH. Positron Emission Tomography (PET) Imaging Tracers for Serotonin Receptors. J Med Chem. 2022;65:10755\u2013808.ArticleCASPubMedGoogle Scholar Fu H, Rong J, Chen Z, Zhou J, Collier T, Liang SH. Positron Emission Tomography (PET) Imaging Tracers for Serotonin Receptors. J Med Chem. 2022;65:10755\u2013808. ArticleCASPubMedGoogle Scholar Fu H, Rong J, Chen Z, Zhou J, Collier T, Liang SH. Positron Emission Tomography (PET) Imaging Tracers for Serotonin Receptors. J Med Chem. 2022;65:10755\u2013808. ArticleCASPubMedGoogle Scholar Wilson H, Dervenoulas G, Pagano G, Koros C, Yousaf T, Picillo M, Polychronis S, Simitsi A, Giordano B, Chappell Z, et al. Serotonergic pathology and disease burden in the premotor and motor phase of A53T alpha-synuclein parkinsonism: a cross-sectional study. Lancet Neurol. 2019;18:748\u201359.ArticleCASPubMedGoogle Scholar Wilson H, Dervenoulas G, Pagano G, Koros C, Yousaf T, Picillo M, Polychronis S, Simitsi A, Giordano B, Chappell Z, et al. Serotonergic pathology and disease burden in the premotor and motor phase of A53T alpha-synuclein parkinsonism: a cross-sectional study. Lancet Neurol. 2019;18:748\u201359. ArticleCASPubMedGoogle Scholar Wilson H, Dervenoulas G, Pagano G, Koros C, Yousaf T, Picillo M, Polychronis S, Simitsi A, Giordano B, Chappell Z, et al. Serotonergic pathology and disease burden in the premotor and motor phase of A53T alpha-synuclein parkinsonism: a cross-sectional study. Lancet Neurol. 2019;18:748\u201359. ArticleCASPubMedGoogle Scholar Sahli ZT, Tarazi FI. Pimavanserin: novel pharmacotherapy for Parkinson\u2019s disease psychosis. Expert Opin Drug Discov. 2018;13:103\u201310.ArticleCASPubMedGoogle Scholar Sahli ZT, Tarazi FI. Pimavanserin: novel pharmacotherapy for Parkinson\u2019s disease psychosis. Expert Opin Drug Discov. 2018;13:103\u201310. ArticleCASPubMedGoogle Scholar Sahli ZT, Tarazi FI. Pimavanserin: novel pharmacotherapy for Parkinson\u2019s disease psychosis. Expert Opin Drug Discov. 2018;13:103\u201310. ArticleCASPubMedGoogle Scholar Johnson KA, Conn PJ, Niswender CM. Glutamate receptors as therapeutic targets for Parkinson\u2019s disease. CNS Neurol Disord: Drug Targets. 2009;8:475\u201391.ArticleCASPubMedGoogle Scholar Johnson KA, Conn PJ, Niswender CM. Glutamate receptors as therapeutic targets for Parkinson\u2019s disease. CNS Neurol Disord: Drug Targets. 2009;8:475\u201391. ArticleCASPubMedGoogle Scholar Johnson KA, Conn PJ, Niswender CM. Glutamate receptors as therapeutic targets for Parkinson\u2019s disease. CNS Neurol Disord: Drug Targets. 2009;8:475\u201391. ArticleCASPubMedGoogle Scholar Crupi R, Impellizzeri D, Cuzzocrea S. Role of Metabotropic Glutamate Receptors in Neurological Disorders. Front Mol Neurosci. 2019;12:20.ArticleCASPubMedPubMed CentralGoogle Scholar Crupi R, Impellizzeri D, Cuzzocrea S. Role of Metabotropic Glutamate Receptors in Neurological Disorders. Front Mol Neurosci. 2019;12:20. ArticleCASPubMedPubMed CentralGoogle Scholar Crupi R, Impellizzeri D, Cuzzocrea S. Role of Metabotropic Glutamate Receptors in Neurological Disorders. Front Mol Neurosci. 2019;12:20. ArticleCASPubMedPubMed CentralGoogle Scholar Karcz-Kubicha M, Lorenz B, Danysz W. GlycineB antagonists and partial agonists in rodent models of Parkinson\u2019s disease\u2013comparison with uncompetitive N-methyl-D-aspartate receptor antagonist. Neuropharmacology. 1999;38:109\u201319.ArticleCASPubMedGoogle Scholar Karcz-Kubicha M, Lorenz B, Danysz W. GlycineB antagonists and partial agonists in rodent models of Parkinson\u2019s disease\u2013comparison with uncompetitive N-methyl-D-aspartate receptor antagonist. Neuropharmacology. 1999;38:109\u201319. ArticleCASPubMedGoogle Scholar Karcz-Kubicha M, Lorenz B, Danysz W. GlycineB antagonists and partial agonists in rodent models of Parkinson\u2019s disease\u2013comparison with uncompetitive N-methyl-D-aspartate receptor antagonist. Neuropharmacology. 1999;38:109\u201319. ArticleCASPubMedGoogle Scholar Ossowska K. The role of excitatory amino acids in experimental models of Parkinson\u2019s disease. J Neural Transm Park Dis Dement Sect. 1994;8:39\u201371.ArticleCASPubMedGoogle Scholar Ossowska K. The role of excitatory amino acids in experimental models of Parkinson\u2019s disease. J Neural Transm Park Dis Dement Sect. 1994;8:39\u201371. ArticleCASPubMedGoogle Scholar Ossowska K. The role of excitatory amino acids in experimental models of Parkinson\u2019s disease. J Neural Transm Park Dis Dement Sect. 1994;8:39\u201371. ArticleCASPubMedGoogle Scholar Marino MJ, Valenti O, Conn PJ. Glutamate receptors and Parkinson\u2019s disease: opportunities for intervention. Drugs Aging. 2003;20:377\u201397.ArticleCASPubMedGoogle Scholar Marino MJ, Valenti O, Conn PJ. Glutamate receptors and Parkinson\u2019s disease: opportunities for intervention. Drugs Aging. 2003;20:377\u201397. ArticleCASPubMedGoogle Scholar Marino MJ, Valenti O, Conn PJ. Glutamate receptors and Parkinson\u2019s disease: opportunities for intervention. Drugs Aging. 2003;20:377\u201397. ArticleCASPubMedGoogle Scholar Marin C, Papa S, Engber TM, Bonastre M, Tolosa E, Chase TN. MK-801 prevents levodopa-induced motor response alterations in parkinsonian rats. Brain Res. 1996;736:202\u20135.ArticleCASPubMedGoogle Scholar Marin C, Papa S, Engber TM, Bonastre M, Tolosa E, Chase TN. MK-801 prevents levodopa-induced motor response alterations in parkinsonian rats. Brain Res. 1996;736:202\u20135. ArticleCASPubMedGoogle Scholar Marin C, Papa S, Engber TM, Bonastre M, Tolosa E, Chase TN. MK-801 prevents levodopa-induced motor response alterations in parkinsonian rats. Brain Res. 1996;736:202\u20135. ArticleCASPubMedGoogle Scholar Sawada H, Oeda T, Kuno S, Nomoto M, Yamamoto K, Yamamoto M, Hisanaga K, Kawamura T, Amantadine Study G. Amantadine for dyskinesias in Parkinson\u2019s disease: a randomized controlled trial. PLoS ONE. 2010;5:e15298.ArticleCASPubMedPubMed CentralGoogle Scholar Sawada H, Oeda T, Kuno S, Nomoto M, Yamamoto K, Yamamoto M, Hisanaga K, Kawamura T, Amantadine Study G. Amantadine for dyskinesias in Parkinson\u2019s disease: a randomized controlled trial. PLoS ONE. 2010;5:e15298. ArticleCASPubMedPubMed CentralGoogle Scholar Sawada H, Oeda T, Kuno S, Nomoto M, Yamamoto K, Yamamoto M, Hisanaga K, Kawamura T, Amantadine Study G. Amantadine for dyskinesias in Parkinson\u2019s disease: a randomized controlled trial. PLoS ONE. 2010;5:e15298. ArticleCASPubMedPubMed CentralGoogle Scholar Paoletti P, Neyton J. NMDA receptor subunits: function and pharmacology. Curr Opin Pharmacol. 2007;7:39\u201347.ArticleCASPubMedGoogle Scholar Paoletti P, Neyton J. NMDA receptor subunits: function and pharmacology. Curr Opin Pharmacol. 2007;7:39\u201347. ArticleCASPubMedGoogle Scholar Paoletti P, Neyton J. NMDA receptor subunits: function and pharmacology. Curr Opin Pharmacol. 2007;7:39\u201347. ArticleCASPubMedGoogle Scholar Nash JE, Fox SH, Henry B, Hill MP, Peggs D, McGuire S, Maneuf Y, Hille C, Brotchie JM, Crossman AR. Antiparkinsonian actions of ifenprodil in the MPTP-lesioned marmoset model of Parkinson\u2019s disease. Exp Neurol. 2000;165:136\u201342.ArticleCASPubMedGoogle Scholar Nash JE, Fox SH, Henry B, Hill MP, Peggs D, McGuire S, Maneuf Y, Hille C, Brotchie JM, Crossman AR. Antiparkinsonian actions of ifenprodil in the MPTP-lesioned marmoset model of Parkinson\u2019s disease. Exp Neurol. 2000;165:136\u201342. ArticleCASPubMedGoogle Scholar Nash JE, Fox SH, Henry B, Hill MP, Peggs D, McGuire S, Maneuf Y, Hille C, Brotchie JM, Crossman AR. Antiparkinsonian actions of ifenprodil in the MPTP-lesioned marmoset model of Parkinson\u2019s disease. Exp Neurol. 2000;165:136\u201342. ArticleCASPubMedGoogle Scholar Steece-Collier K, Chambers LK, Jaw-Tsai SS, Menniti FS, Greenamyre JT. Antiparkinsonian actions of CP-101,606, an antagonist of NR2B subunit-containing N-methyl-d-aspartate receptors. Exp Neurol. 2000;163:239\u201343.ArticleCASPubMedGoogle Scholar Steece-Collier K, Chambers LK, Jaw-Tsai SS, Menniti FS, Greenamyre JT. Antiparkinsonian actions of CP-101,606, an antagonist of NR2B subunit-containing N-methyl-d-aspartate receptors. Exp Neurol. 2000;163:239\u201343. ArticleCASPubMedGoogle Scholar Steece-Collier K, Chambers LK, Jaw-Tsai SS, Menniti FS, Greenamyre JT. Antiparkinsonian actions of CP-101,606, an antagonist of NR2B subunit-containing N-methyl-d-aspartate receptors. Exp Neurol. 2000;163:239\u201343. ArticleCASPubMedGoogle Scholar Smart K, Zheng MQ, Ahmed H, Fang H, Xu Y, Cai L, Holden D, Kapinos M, Haider A, Felchner Z, et al. Comparison of three novel radiotracers for GluN2B-containing NMDA receptors in non-human primates: (R)-[(11)C]NR2B-Me, (R)-[(18)F]of-Me-NB1, and (S)-[(18)F]of-NB1. J Cereb Blood Flow Metab. 2022;42:1398\u2013409.ArticleCASPubMedPubMed CentralGoogle Scholar Smart K, Zheng MQ, Ahmed H, Fang H, Xu Y, Cai L, Holden D, Kapinos M, Haider A, Felchner Z, et al. Comparison of three novel radiotracers for GluN2B-containing NMDA receptors in non-human primates: (R)-[(11)C]NR2B-Me, (R)-[(18)F]of-Me-NB1, and (S)-[(18)F]of-NB1. J Cereb Blood Flow Metab. 2022;42:1398\u2013409. ArticleCASPubMedPubMed CentralGoogle Scholar Smart K, Zheng MQ, Ahmed H, Fang H, Xu Y, Cai L, Holden D, Kapinos M, Haider A, Felchner Z, et al. Comparison of three novel radiotracers for GluN2B-containing NMDA receptors in non-human primates: (R)-[(11)C]NR2B-Me, (R)-[(18)F]of-Me-NB1, and (S)-[(18)F]of-NB1. J Cereb Blood Flow Metab. 2022;42:1398\u2013409. ArticleCASPubMedPubMed CentralGoogle Scholar Ahmed H, Zheng MQ, Smart K, Fang H, Zhang L, Emery PR, Gao H, Ropchan J, Haider A, Tamagnan G, et al. Evaluation of (rac)-, (R)- and (S)-(18)F-OF-NB1 for imaging GluN2B subunit-containing N-methyl-D-aspartate receptors in non-human primates. J Nucl Med. 2022;63(12):1912\u20138.ArticleCASPubMedPubMed CentralGoogle Scholar Ahmed H, Zheng MQ, Smart K, Fang H, Zhang L, Emery PR, Gao H, Ropchan J, Haider A, Tamagnan G, et al. Evaluation of (rac)-, (R)- and (S)-(18)F-OF-NB1 for imaging GluN2B subunit-containing N-methyl-D-aspartate receptors in non-human primates. J Nucl Med. 2022;63(12):1912\u20138. ArticleCASPubMedPubMed CentralGoogle Scholar Ahmed H, Zheng MQ, Smart K, Fang H, Zhang L, Emery PR, Gao H, Ropchan J, Haider A, Tamagnan G, et al. Evaluation of (rac)-, (R)- and (S)-(18)F-OF-NB1 for imaging GluN2B subunit-containing N-methyl-D-aspartate receptors in non-human primates. J Nucl Med. 2022;63(12):1912\u20138. ArticleCASPubMedPubMed CentralGoogle Scholar Zheng M, Ahmed H, Smart K, Xu Y, Holden D, Kapinos M, Felchner Z, Haider A, Tamagnan G, Carson RE, et al. Characterization in nonhuman primates of (R)-[(18)F]OF-Me-NB1 and (S)-[(18)F]OF-Me-NB1 for imaging the GluN2B subunits of the NMDA receptor. Eur J Nucl Med Mol Imaging. 2022;49:2153\u201362.ArticleCASPubMedPubMed CentralGoogle Scholar Zheng M, Ahmed H, Smart K, Xu Y, Holden D, Kapinos M, Felchner Z, Haider A, Tamagnan G, Carson RE, et al. Characterization in nonhuman primates of (R)-[(18)F]OF-Me-NB1 and (S)-[(18)F]OF-Me-NB1 for imaging the GluN2B subunits of the NMDA receptor. Eur J Nucl Med Mol Imaging. 2022;49:2153\u201362. ArticleCASPubMedPubMed CentralGoogle Scholar Zheng M, Ahmed H, Smart K, Xu Y, Holden D, Kapinos M, Felchner Z, Haider A, Tamagnan G, Carson RE, et al. Characterization in nonhuman primates of (R)-[(18)F]OF-Me-NB1 and (S)-[(18)F]OF-Me-NB1 for imaging the GluN2B subunits of the NMDA receptor. Eur J Nucl Med Mol Imaging. 2022;49:2153\u201362. ArticleCASPubMedPubMed CentralGoogle Scholar Rischka L, Vraka C, Pichler V, Rasul S, Nics L, Gryglewski G, Handschuh P, Murga\u0161 M, Godbersen GM, Silberbauer LR, et al. First-in-Humans Brain PET Imaging of the GluN2B-Containing N-methyl-d-aspartate Receptor with (R)-(11)C-Me-NB1. J Nucl Med. 2022;63:936\u201341.ArticleCASPubMedPubMed CentralGoogle Scholar Rischka L, Vraka C, Pichler V, Rasul S, Nics L, Gryglewski G, Handschuh P, Murga\u0161 M, Godbersen GM, Silberbauer LR, et al. First-in-Humans Brain PET Imaging of the GluN2B-Containing N-methyl-d-aspartate Receptor with (R)-(11)C-Me-NB1. J Nucl Med. 2022;63:936\u201341. ArticleCASPubMedPubMed CentralGoogle Scholar Rischka L, Vraka C, Pichler V, Rasul S, Nics L, Gryglewski G, Handschuh P, Murga\u0161 M, Godbersen GM, Silberbauer LR, et al. First-in-Humans Brain PET Imaging of the GluN2B-Containing N-methyl-d-aspartate Receptor with (R)-(11)C-Me-NB1. J Nucl Med. 2022;63:936\u201341. ArticleCASPubMedPubMed CentralGoogle Scholar Ahmed H, Wallimann R, Haider A, Hosseini V, Gruber S, Robledo M, Nguyen TAN, Herde AM, Iten I, Keller C, et al. Preclinical Development of (18)F-OF-NB1 for Imaging GluN2B-Containing N-Methyl-d-Aspartate Receptors and Its Utility as a Biomarker for Amyotrophic Lateral Sclerosis. J Nucl Med. 2021;62:259\u201365.ArticleCASPubMedGoogle Scholar Ahmed H, Wallimann R, Haider A, Hosseini V, Gruber S, Robledo M, Nguyen TAN, Herde AM, Iten I, Keller C, et al. Preclinical Development of (18)F-OF-NB1 for Imaging GluN2B-Containing N-Methyl-d-Aspartate Receptors and Its Utility as a Biomarker for Amyotrophic Lateral Sclerosis. J Nucl Med. 2021;62:259\u201365. ArticleCASPubMedGoogle Scholar Ahmed H, Wallimann R, Haider A, Hosseini V, Gruber S, Robledo M, Nguyen TAN, Herde AM, Iten I, Keller C, et al. Preclinical Development of (18)F-OF-NB1 for Imaging GluN2B-Containing N-Methyl-d-Aspartate Receptors and Its Utility as a Biomarker for Amyotrophic Lateral Sclerosis. J Nucl Med. 2021;62:259\u201365. ArticleCASPubMedGoogle Scholar Ahmed H, Haider A, Varisco J, Stankovi\u0107 M, Wallimann R, Gruber S, Iten I, H\u00e4ne S, M\u00fcller Herde A, Keller C, et al. Structure-Affinity Relationships of 2,3,4,5-Tetrahydro-1H-3-benzazepine and 6,7,8,9-Tetrahydro-5H-benzo[7]annulen-7-amine Analogues and the Discovery of a Radiofluorinated 2,3,4,5-Tetrahydro-1H-3-benzazepine Congener for Imaging GluN2B Subunit-Containing N-Methyl-d-aspartate Receptors. J Med Chem. 2019;62:9450\u201370.ArticleCASPubMedGoogle Scholar Ahmed H, Haider A, Varisco J, Stankovi\u0107 M, Wallimann R, Gruber S, Iten I, H\u00e4ne S, M\u00fcller Herde A, Keller C, et al. Structure-Affinity Relationships of 2,3,4,5-Tetrahydro-1H-3-benzazepine and 6,7,8,9-Tetrahydro-5H-benzo[7]annulen-7-amine Analogues and the Discovery of a Radiofluorinated 2,3,4,5-Tetrahydro-1H-3-benzazepine Congener for Imaging GluN2B Subunit-Containing N-Methyl-d-aspartate Receptors. J Med Chem. 2019;62:9450\u201370. ArticleCASPubMedGoogle Scholar Ahmed H, Haider A, Varisco J, Stankovi\u0107 M, Wallimann R, Gruber S, Iten I, H\u00e4ne S, M\u00fcller Herde A, Keller C, et al. Structure-Affinity Relationships of 2,3,4,5-Tetrahydro-1H-3-benzazepine and 6,7,8,9-Tetrahydro-5H-benzo[7]annulen-7-amine Analogues and the Discovery of a Radiofluorinated 2,3,4,5-Tetrahydro-1H-3-benzazepine Congener for Imaging GluN2B Subunit-Containing N-Methyl-d-aspartate Receptors. J Med Chem. 2019;62:9450\u201370. ArticleCASPubMedGoogle Scholar Haider A, Iten I, Ahmed H, M\u00fcller Herder A, Gruber S, Kr\u00e4mer SD, Keller C, Schibli R, W\u00fcnsch B, Mu L, Ametamey SM. Identification and Preclinical Evaluation of a Radiofluorinated Benzazepine Derivative for Imaging the GluN2B Subunit of the Ionotropic NMDA Receptor. J Nucl Med. 2018;60:259\u201366.ArticlePubMedGoogle Scholar Haider A, Iten I, Ahmed H, M\u00fcller Herder A, Gruber S, Kr\u00e4mer SD, Keller C, Schibli R, W\u00fcnsch B, Mu L, Ametamey SM. Identification and Preclinical Evaluation of a Radiofluorinated Benzazepine Derivative for Imaging the GluN2B Subunit of the Ionotropic NMDA Receptor. J Nucl Med. 2018;60:259\u201366. ArticlePubMedGoogle Scholar Haider A, Iten I, Ahmed H, M\u00fcller Herder A, Gruber S, Kr\u00e4mer SD, Keller C, Schibli R, W\u00fcnsch B, Mu L, Ametamey SM. Identification and Preclinical Evaluation of a Radiofluorinated Benzazepine Derivative for Imaging the GluN2B Subunit of the Ionotropic NMDA Receptor. J Nucl Med. 2018;60:259\u201366. ArticlePubMedGoogle Scholar Szermerski M, B\u00f6rgel F, Schepmann D, Haider A, Betzel T, Ametamey SM, W\u00fcnsch B. Fluorinated GluN2B Receptor Antagonists with a 3-Benzazepine Scaffold Designed for PET Studies. ChemMedChem. 2018;13:1058\u201368.ArticleCASPubMedGoogle Scholar Szermerski M, B\u00f6rgel F, Schepmann D, Haider A, Betzel T, Ametamey SM, W\u00fcnsch B. Fluorinated GluN2B Receptor Antagonists with a 3-Benzazepine Scaffold Designed for PET Studies. ChemMedChem. 2018;13:1058\u201368. ArticleCASPubMedGoogle Scholar Szermerski M, B\u00f6rgel F, Schepmann D, Haider A, Betzel T, Ametamey SM, W\u00fcnsch B. Fluorinated GluN2B Receptor Antagonists with a 3-Benzazepine Scaffold Designed for PET Studies. ChemMedChem. 2018;13:1058\u201368. ArticleCASPubMedGoogle Scholar Kr\u00e4mer SD, Betzel T, Mu L, Haider A, Herde AM, Boninsegni AK, Keller C, Szermerski M, Schibli R, W\u00fcnsch B, Ametamey SM. Evaluation of (11)C-Me-NB1 as a Potential PET Radioligand for Measuring GluN2B-Containing NMDA Receptors, Drug Occupancy, and Receptor Cross Talk. J Nucl Med. 2018;59:698\u2013703.ArticlePubMedGoogle Scholar Kr\u00e4mer SD, Betzel T, Mu L, Haider A, Herde AM, Boninsegni AK, Keller C, Szermerski M, Schibli R, W\u00fcnsch B, Ametamey SM. Evaluation of (11)C-Me-NB1 as a Potential PET Radioligand for Measuring GluN2B-Containing NMDA Receptors, Drug Occupancy, and Receptor Cross Talk. J Nucl Med. 2018;59:698\u2013703. ArticlePubMedGoogle Scholar Kr\u00e4mer SD, Betzel T, Mu L, Haider A, Herde AM, Boninsegni AK, Keller C, Szermerski M, Schibli R, W\u00fcnsch B, Ametamey SM. Evaluation of (11)C-Me-NB1 as a Potential PET Radioligand for Measuring GluN2B-Containing NMDA Receptors, Drug Occupancy, and Receptor Cross Talk. J Nucl Med. 2018;59:698\u2013703. ArticlePubMedGoogle Scholar Goldstein DS, Holmes C, Cannon RO, Eisenhofer G, Kopin IJ. Sympathetic Cardioneuropathy in Dysautonomias. N Engl J Med. 1997;336:696\u2013702.ArticleCASPubMedGoogle Scholar Goldstein DS, Holmes C, Cannon RO, Eisenhofer G, Kopin IJ. Sympathetic Cardioneuropathy in Dysautonomias. N Engl J Med. 1997;336:696\u2013702. ArticleCASPubMedGoogle Scholar Goldstein DS, Holmes C, Cannon RO, Eisenhofer G, Kopin IJ. Sympathetic Cardioneuropathy in Dysautonomias. N Engl J Med. 1997;336:696\u2013702. ArticleCASPubMedGoogle Scholar Sakakibara R, Tateno F, Kishi M, Tsuyusaki Y, Terada H, Inaoka T. MIBG myocardial scintigraphy in pre-motor Parkinson\u2019s disease: A review. Parkinsonism Relat Disord. 2014;20:267\u201373.ArticlePubMedGoogle Scholar Sakakibara R, Tateno F, Kishi M, Tsuyusaki Y, Terada H, Inaoka T. MIBG myocardial scintigraphy in pre-motor Parkinson\u2019s disease: A review. Parkinsonism Relat Disord. 2014;20:267\u201373. ArticlePubMedGoogle Scholar Sakakibara R, Tateno F, Kishi M, Tsuyusaki Y, Terada H, Inaoka T. MIBG myocardial scintigraphy in pre-motor Parkinson\u2019s disease: A review. Parkinsonism Relat Disord. 2014;20:267\u201373. ArticlePubMedGoogle Scholar De Pablo-Fernandez E, Tur C, Revesz T, Lees AJ, Holton JL, Warner TT. Association of Autonomic Dysfunction With Disease Progression and Survival in Parkinson Disease. JAMA Neurol. 2017;74:970\u20136.ArticlePubMedPubMed CentralGoogle Scholar De Pablo-Fernandez E, Tur C, Revesz T, Lees AJ, Holton JL, Warner TT. Association of Autonomic Dysfunction With Disease Progression and Survival in Parkinson Disease. JAMA Neurol. 2017;74:970\u20136. ArticlePubMedPubMed CentralGoogle Scholar De Pablo-Fernandez E, Tur C, Revesz T, Lees AJ, Holton JL, Warner TT. Association of Autonomic Dysfunction With Disease Progression and Survival in Parkinson Disease. JAMA Neurol. 2017;74:970\u20136. ArticlePubMedPubMed CentralGoogle Scholar De Pablo-Fernandez E, Warner TT. Autonomic Dysfunction in Parkinson\u2019s Disease: The Hidden Game Changer? Mov Disord. 2018;33:1028.ArticlePubMedGoogle Scholar De Pablo-Fernandez E, Warner TT. Autonomic Dysfunction in Parkinson\u2019s Disease: The Hidden Game Changer? Mov Disord. 2018;33:1028. ArticlePubMedGoogle Scholar De Pablo-Fernandez E, Warner TT. Autonomic Dysfunction in Parkinson\u2019s Disease: The Hidden Game Changer? Mov Disord. 2018;33:1028. ArticlePubMedGoogle Scholar Hauser RA, Heritier S, Rowse GJ, Hewitt LA, Isaacson SH. Droxidopa and Reduced Falls in a Trial of Parkinson Disease Patients With Neurogenic Orthostatic Hypotension. Clin Neuropharmacol. 2016;39:220\u20136.ArticleCASPubMedPubMed CentralGoogle Scholar Hauser RA, Heritier S, Rowse GJ, Hewitt LA, Isaacson SH. Droxidopa and Reduced Falls in a Trial of Parkinson Disease Patients With Neurogenic Orthostatic Hypotension. Clin Neuropharmacol. 2016;39:220\u20136. ArticleCASPubMedPubMed CentralGoogle Scholar Hauser RA, Heritier S, Rowse GJ, Hewitt LA, Isaacson SH. Droxidopa and Reduced Falls in a Trial of Parkinson Disease Patients With Neurogenic Orthostatic Hypotension. Clin Neuropharmacol. 2016;39:220\u20136. ArticleCASPubMedPubMed CentralGoogle Scholar Braune S, Reinhardt M, Schnitzer R, Riedel A, L\u00fccking CH. Cardiac uptake of [123I]MIBG separates Parkinson\u2019s disease from multiple system atrophy. Neurology. 1999;53:1020\u20135.ArticleCASPubMedGoogle Scholar Braune S, Reinhardt M, Schnitzer R, Riedel A, L\u00fccking CH. Cardiac uptake of [123I]MIBG separates Parkinson\u2019s disease from multiple system atrophy. Neurology. 1999;53:1020\u20135. ArticleCASPubMedGoogle Scholar Braune S, Reinhardt M, Schnitzer R, Riedel A, L\u00fccking CH. Cardiac uptake of [123I]MIBG separates Parkinson\u2019s disease from multiple system atrophy. Neurology. 1999;53:1020\u20135. ArticleCASPubMedGoogle Scholar Rascol O, Schelosky L. 123I-metaiodobenzylguanidine scintigraphy in Parkinson\u2019s disease and related disorders. Mov Disord. 2009;24(Suppl 2):S732-741.PubMedGoogle Scholar Rascol O, Schelosky L. 123I-metaiodobenzylguanidine scintigraphy in Parkinson\u2019s disease and related disorders. Mov Disord. 2009;24(Suppl 2):S732-741. PubMedGoogle Scholar Rascol O, Schelosky L. 123I-metaiodobenzylguanidine scintigraphy in Parkinson\u2019s disease and related disorders. Mov Disord. 2009;24(Suppl 2):S732-741. PubMedGoogle Scholar Download references **Acknowledgements** Figures were created withwww.biorender.com. **Funding** We gratefully acknowledge the financial support provided, in part, by NIH grants (MH120197, MH128705, AG063290, AG070060, AG073428, AG074218, AG075444, AG078058, AG079956 and AG080262), Emory Radiology Chair Fund and Emory School of Medicine Endowed Directorship to S.H.L, and the Swiss National Science Foundation AQ7 (Grant number 191836) to A.H. **Author information** **Authors and Affiliations** Department of Radiology, Division of Nuclear Medicine and Molecular Imaging Massachusetts General Hospital and Harvard Medical School, 55 Fruit Street, Boston, MA, 02114, USAAchi Haider & Steven H. Liang Department of Radiology, Division of Nuclear Medicine and Molecular Imaging Massachusetts General Hospital and Harvard Medical School, 55 Fruit Street, Boston, MA, 02114, USA Achi Haider & Steven H. Liang Department of Radiology, Division of Nuclear Medicine and Molecular Imaging Massachusetts General Hospital and Harvard Medical School, 55 Fruit Street, Boston, MA, 02114, USA Achi Haider & Steven H. Liang Department of Radiology and Imaging Sciences, Emory University, 101 Woodruff Circle, Atlanta, GA, 30322, USAAchi Haider & Steven H. Liang Department of Radiology and Imaging Sciences, Emory University, 101 Woodruff Circle, Atlanta, GA, 30322, USA Achi Haider & Steven H. Liang Department of Radiology and Imaging Sciences, Emory University, 101 Woodruff Circle, Atlanta, GA, 30322, USA Achi Haider & Steven H. Liang Biochemistry Department, Faculty of Pharmacy and Biotechnology, German University in Cairo, Main Entrance of Al-Tagamoa Al-Khames, Cairo, 11835, EgyptNehal H. Elghazawy & Alyaa Dawoud Biochemistry Department, Faculty of Pharmacy and Biotechnology, German University in Cairo, Main Entrance of Al-Tagamoa Al-Khames, Cairo, 11835, Egypt Nehal H. Elghazawy & Alyaa Dawoud Biochemistry Department, Faculty of Pharmacy and Biotechnology, German University in Cairo, Main Entrance of Al-Tagamoa Al-Khames, Cairo, 11835, Egypt Nehal H. Elghazawy & Alyaa Dawoud Molecular Genetics Research Team (MGRT), Pharmaceutical Biology Department, Faculty of Pharmacy and Biotechnology, German University in Cairo, Main Entrance of Al-Tagamoa Al-Khames, Cairo, 11835, EgyptNehal H. Elghazawy & Alyaa Dawoud Molecular Genetics Research Team (MGRT), Pharmaceutical Biology Department, Faculty of Pharmacy and Biotechnology, German University in Cairo, Main Entrance of Al-Tagamoa Al-Khames, Cairo, 11835, Egypt Nehal H. Elghazawy & Alyaa Dawoud Molecular Genetics Research Team (MGRT), Pharmaceutical Biology Department, Faculty of Pharmacy and Biotechnology, German University in Cairo, Main Entrance of Al-Tagamoa Al-Khames, Cairo, 11835, Egypt Nehal H. Elghazawy & Alyaa Dawoud Department of Nuclear Medicine, University Hospital Zurich, Raemistrasse 100, 8091, Zurich, SwitzerlandCatherine Gebhard Department of Nuclear Medicine, University Hospital Zurich, Raemistrasse 100, 8091, Zurich, Switzerland Catherine Gebhard Department of Nuclear Medicine, University Hospital Zurich, Raemistrasse 100, 8091, Zurich, Switzerland Catherine Gebhard Center for Molecular Cardiology, University of Zurich, Schlieren, SwitzerlandCatherine Gebhard Center for Molecular Cardiology, University of Zurich, Schlieren, Switzerland Catherine Gebhard Center for Molecular Cardiology, University of Zurich, Schlieren, Switzerland Catherine Gebhard Department of Neurology/School of Medicine, Yerkes National Primate Research Center, Emory University, Atlanta, GA, USAThomas Wichmann Department of Neurology/School of Medicine, Yerkes National Primate Research Center, Emory University, Atlanta, GA, USA Thomas Wichmann Department of Neurology/School of Medicine, Yerkes National Primate Research Center, Emory University, Atlanta, GA, USA Thomas Wichmann Institute of Pharmacy, Department of Medicinal Chemistry, Martin-Luther-University Halle-Wittenberg, W.-Langenbeck-Str. 4, 06120, Halle, GermanyWolfgang Sippl Institute of Pharmacy, Department of Medicinal Chemistry, Martin-Luther-University Halle-Wittenberg, W.-Langenbeck-Str. 4, 06120, Halle, Germany Wolfgang Sippl Institute of Pharmacy, Department of Medicinal Chemistry, Martin-Luther-University Halle-Wittenberg, W.-Langenbeck-Str. 4, 06120, Halle, Germany Wolfgang Sippl Neuroscience and Rare Diseases Discovery and Translational Area, Roche Innovation Center Basel, F. Hoffmann-La Roche, Grenzacherstrasse 124, 4070, Basel, SwitzerlandMarius Hoener Neuroscience and Rare Diseases Discovery and Translational Area, Roche Innovation Center Basel, F. Hoffmann-La Roche, Grenzacherstrasse 124, 4070, Basel, Switzerland Marius Hoener Neuroscience and Rare Diseases Discovery and Translational Area, Roche Innovation Center Basel, F. Hoffmann-La Roche, Grenzacherstrasse 124, 4070, Basel, Switzerland Marius Hoener Karolinska Institutet, MBB, Molecular Neurobiology, Stockholm, SwedenErnest Arenas Karolinska Institutet, MBB, Molecular Neurobiology, Stockholm, Sweden Ernest Arenas Karolinska Institutet, MBB, Molecular Neurobiology, Stockholm, Sweden Ernest Arenas Achi HaiderView author publicationsYou can also search for this author inPubMedGoogle Scholar You can also search for this author inPubMedGoogle Scholar You can also search for this author inPubMedGoogle Scholar Nehal H. ElghazawyView author publicationsYou can also search for this author inPubMedGoogle Scholar You can also search for this author inPubMedGoogle Scholar You can also search for this author inPubMedGoogle Scholar Alyaa DawoudView author publicationsYou can also search for this author inPubMedGoogle Scholar You can also search for this author inPubMedGoogle Scholar You can also search for this author inPubMedGoogle Scholar Catherine GebhardView author publicationsYou can also search for this author inPubMedGoogle Scholar You can also search for this author inPubMedGoogle Scholar You can also search for this author inPubMedGoogle Scholar Thomas WichmannView author publicationsYou can also search for this author inPubMedGoogle Scholar You can also search for this author inPubMedGoogle Scholar You can also search for this author inPubMedGoogle Scholar Wolfgang SipplView author publicationsYou can also search for this author inPubMedGoogle Scholar You can also search for this author inPubMedGoogle Scholar You can also search for this author inPubMedGoogle Scholar Marius HoenerView author publicationsYou can also search for this author inPubMedGoogle Scholar You can also search for this author inPubMedGoogle Scholar You can also search for this author inPubMedGoogle Scholar Ernest ArenasView author publicationsYou can also search for this author inPubMedGoogle Scholar You can also search for this author inPubMedGoogle Scholar You can also search for this author inPubMedGoogle Scholar Steven H. LiangView author publicationsYou can also search for this author inPubMedGoogle Scholar You can also search for this author inPubMedGoogle Scholar You can also search for this author inPubMedGoogle Scholar **Contributions** All authors read and approved the final manuscript. **Corresponding authors** Correspondence toAchi HaiderorSteven H. Liang. **Ethics declarations** **Ethics approval and consent to participate** Not applicable. **Consent for publication** Not applicable. **Competing interests** The authors declare no competing interests. **Additional information** **Publisher's Note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. **Rights and permissions** Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visithttp://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. Reprints and permissions **About this article** **Cite this article** Haider, A., Elghazawy, N.H., Dawoud, A.et al.Translational molecular imaging and drug development in Parkinson\u2019s disease.Mol Neurodegeneration18, 11 (2023). https://doi.org/10.1186/s13024-023-00600-z Download citation Received:10 October 2022 Received:10 October 2022 Received:10 October 2022 Accepted:23 January 2023 Accepted:23 January 2023 Accepted:23 January 2023 Published:10 February 2023 Published:10 February 2023 Published:10 February 2023 DOI:https://doi.org/10.1186/s13024-023-00600-z DOI:https://doi.org/10.1186/s13024-023-00600-z DOI:https://doi.org/10.1186/s13024-023-00600-z **Share this article** Anyone you share the following link with will be able to read this content: Sorry, a shareable link is not currently available for this article. Provided by the Springer Nature SharedIt content-sharing initiative **Keywords** Translational molecular imaging Parkinson\u2019s disease Drug development Dopamine \u03b1-Synuclein Mitochondrial dysfunction Neuroinflammation Neurodegeneration Advertisement ISSN: 1750-1326 Submission enquiries:madelyn.marciano@springernature.com General enquiries:journalsubmissions@springernature.com Read more on our blogs Receive BMC newsletters Manage article alerts Language editing for authors Scientific editing for authors Policies Accessibility Press center Support and Contact Leave feedback Careers **Follow BMC** BMC Twitter page BMC Facebook page BMC Weibo page By using this website, you agree to ourTerms and Conditions,Your US state privacy rights,Privacy statementandCookiespolicy.Your privacy choices/Manage cookieswe use in the preference centre. \u00a9 2025 BioMed Central Ltd unless otherwise stated. Part ofSpringer Nature."}